Antibodies to mucin 17 and uses thereof

Abstract

The present invention relates to antibodies that bind to human salmucin 17 (MUC17). Furthermore, the present invention relates to detection systems comprising such antibodies. The antibodies or detection systems can be used to detect or quantify MUC17, diagnose MUC17-associated diseases, stratify patients, monitor disease progression, and assess treatment response.

Description

[Technical Field]

[0001] The present invention relates to antibodies that bind to mucin 17 (MUC17). Furthermore, the present invention relates to detection systems comprising such antibodies. The antibodies or detection systems can be used to detect or quantify MUC17, diagnose MUC17-associated diseases, stratify patients, monitor disease progression, and assess therapeutic response. [Background technology]

[0002] Mucins have been identified as interesting markers for inflammatory and cancerous diseases. Mucins are high-molecular-weight glycoproteins characterized by high levels of O-glycosylation at serine and threonine residues within tandem repeat domains (Johansson and Hansson, Nat. Rev. Immunology 2016). There are at least 20 mucin family members, including secreted and transmembrane proteins expressed by epithelial cells in various tissues (Corfield, Biochim. Biophys. Acta 2013). The primary function of mucins is in the structure and regulation of the mucosal layer, which forms a protective barrier between epithelial cells and the environment (Hollingsworth and Swanson, Nat. Rev. Cancer 2004; Hattrup and Gendler, Annu. Rev. Physiol. 2008). Transmembrane mucins also play roles in cellular signaling, including regulating proliferation and apoptosis, and in tumorigenesis (Hollingsworth and Swanson, Nat. Rev. Cancer 2004). Among mucins, mucin 17 (MUC17) was the first transmembrane mucin identified by its homology to MUC3 (Gum et al., Biochem. Biophys. Res. Comm. 2002).

[0003] Analysis of the complete coding sequence of MUC17 revealed that it has a central region of 61 tandem repeats, an epidermal growth factor (EGF) domain, a sea urchin sperm protein, enterokinase, and agrin (SEA) domain, and a large extracellular domain composed of a second EGF domain. The SEA domain contains a putative cleavage site conserved in other mucins (Moniaux et al., J. Biol. Chem. 2006). MUC17 is a single-pass transmembrane protein with an intracellular 80-amino acid cytoplasmic tail (Moniaux et al., J. Biol. Chem. 2006). In healthy adults, MUC17 expression is restricted to the apical surface of enterocytes lining the intestinal tract or mature absorptive epithelial cells (Moniaux et al., J. Biol. Chem. 2006; Johanasson and Hansson, Nat. Rev. Immunology 2016). MUC17 is also expressed by the stomach and pancreas (Moniaux et al., J. Biol. Chem. 2006; Moehle et al., J. Mol. Med. 2006). The biological function of MUC17 is thought to be maintaining the integrity of the intestinal mucosal barrier, including through mucosal repair (Luu et al., Int. J. Biochem. Cell Biol. 2010; Resta-Lenert et al., Am. J. Physiology 2011; Johanasson and Hansson, Nat. Rev. Immunology 2016).

[0004] MUC17 is aberrantly expressed in some cancers. MUC17 mRNA has been shown to be expressed in one pancreatic cancer cell line and three colon cancer cell lines (Gum et al. 2002). Immunohistochemistry studies have confirmed MUC17 protein expression in pancreatic cancer (Moniaux et al. 2006). However, MUC17 protein expression has been shown to be reduced in colon cancer (Senapati et al., J. Clin. Pathol. 2010). Nevertheless, the expression pattern of MUC17 makes it a potential target for the treatment of various forms of malignancies. Clinical trials using anti-MUC17 antibody constructs have been initiated to test their suitability for treating gastrointestinal and gastroesophageal junction cancers (clinicaltrials.gov; NCT04117958). [Prior art documents] [Non-patent literature]

[0005] [Non-Patent Document 1] Johansson and Hansson, Nat. Rev. Immunology 2016 [Non-patent document 2] Corfield,Biochim.Biophys.Acta 2013 [Non-patent document 3] Hollingsworth and Swanson, Nat. Rev. Cancer 2004 [Non-patent document 4] Hattrup and Gendler,Annu.Rev.Physiol.2008 [Non-Patent Document 5] Gum et al.,Biochem.Biophys.Res.Comm.2002 [Non-patent document 6] Moniaux et al.,J.Biol.Chem.2006 [Non-Patent Document 7] Johanasson and Hansson, Nat. Rev. Immunology 2016 [Non-patent document 8] Moehle et al., J. Mol. Med. 2006 [Non-Patent Document 9] Luu et al.,Int.J.Biochem.Cell Biol.2010 [Non-Patent Document 10] Resta-Lenert et al.,Am.J.Physiology 2011 [Non-Patent Document 11] Senapati et al.,J.Clin.Pathol.2010 Summary of the Invention [Problem to be solved by the invention]

[0006] In view of the conflicting implications in the literature for MUC17 as a potential target for such pathologies, it is an object of the present invention to clearly identify specific conditions associated with MUC17 upregulation and to provide binders (e.g., antibodies) that selectively bind to MUC17 for use as diagnostic tools in MUC17-associated conditions, preferably for use in detecting / diagnosing said specific conditions prior to, concurrently with, and subsequent to therapeutic intervention, and / or in monitoring the disease status. Monitoring helps determine the success of a given treatment and allows the treating physician to determine whether the treatment is effective, insufficient, or needs to be modified.

[0007] Ideally, the diagnostic antibody binds to a region that is identified or targeted by a therapeutic antibody construct. Because tumor antigens can present themselves in various splice forms or have mutations that affect the three-dimensional structure of the target, it is desirable to confirm that the target of the therapeutic antibody is present in a given patient and that such patient is approved for such treatment. If the target region of the tumor antigen is not present in a given patient, treatment with a selectively binding therapeutic antibody construct may not be promising, given potential adverse events associated with the treatment. Furthermore, patients may not be subjected to inappropriate, potentially disadvantageous, exhausting, and cost-intensive treatments, but rather may be treated with alternative treatments that show a greater likelihood of effectiveness. It should be noted that patients receiving immunotherapy are usually very unhealthy. Often, such patients are refractory to first-line treatments or have metastases that have not experienced recurrence and / or do not respond to initial treatment. It is undesirable to treat patients without a clear diagnostic basis for which treatment with an immunotherapeutic compound is rational and medically justified. [Means for solving the problem]

[0008] Thus, the present invention provides antibodies that bind to MUC17, which can be used in diagnostic methods of tissue samples obtained from individuals, particularly patients suspected of having neoplastic diseases, such as gastrointestinal cancer, pancreatic cancer, etc., that are associated with and / or distinguishable by aberrating MUC17 expression.

[0009] The antibodies may also serve as a diagnostic tool in the detection of MUC17 in laboratory animals, for example, in previously sacrificed cancer-bearing animals.

[0010] Furthermore, the present invention provides polynucleotides encoding the antibody constructs, vectors containing the polynucleotides, and host cells expressing the constructs, as well as diagnostic compositions comprising these, and kits comprising the antibodies of the invention as diagnostic tools, together with additional components including at least one of, but not limited to, secondary antibodies, enzymes, buffers, instructions for use, tools for calibration, controls, etc.

[0011] Embodiments of the invention In a first embodiment, the present invention relates to an antibody that binds to human MUC17 as set forth in SEQ ID NO: 1, wherein said antibody binds to cell surface-associated MUC17 protein.

[0012] In a second embodiment, the invention relates to an antibody that binds to human MUC17 as set forth in SEQ ID NO: 1, wherein said antibody binds to a cell surface-associated MUC17 protein, and said antibody comprises a variable heavy chain comprising a CDR3 region as set forth in SEQ ID NO: 4.

[0013] In a third embodiment, the invention relates to an antibody according to embodiments 1 and 2, wherein said antibody further comprises heavy chain CDR1 and CDR2 regions as set forth in SEQ ID NOs: 2 and 3, and / or light chain CDR1, CDR2, and / or CDR3 regions as set forth in SEQ ID NOs: 6, 7, and 8.

[0014] In a fourth embodiment, the invention relates to an antibody according to any one of the previous embodiments, wherein the monoclonal antibody comprises a VH region and / or a VL region constituted by the sequences shown in SEQ ID NOs: 5 and 9.

[0015] In a fifth embodiment, the invention relates to an antibody according to any one of the previous embodiments, wherein the antibody is a monoclonal antibody.

[0016] In a sixth embodiment, the invention relates to an antibody according to any one of the preceding embodiments, wherein the antibody specifically binds to human and cynomolgus MUC17 in immunohistochemistry assays, to MUC17-expressing cells in fluorescence-activated cell sorting assays, and to fixed and permeabilized MUC17-expressing cells, and optionally the antibody does not bind to secreted forms of huMUC17.

[0017] In a seventh embodiment, the invention relates to an antibody according to any one of the previous embodiments, wherein the antibody comprises a VH region comprised in SEQ ID NO: 5 and a VL region according to SEQ ID NO: 9.

[0018] In an eighth embodiment, the invention relates to an antibody according to any one of the previous embodiments, which is an IgG antibody, an IgD antibody, an IgE antibody, an IgM antibody, or an IgA antibody, preferably an IgG antibody, such as an IgG1 antibody, an IgG2 antibody, an IgG3 antibody, or an IgG4 antibody.

[0019] Within the above embodiments, it is further envisaged that the present invention provides an antibody construct, wherein a first domain of the antibody construct binds to an epitope within MUC17 corresponding to amino acid sequences 4171 to 4296 according to Uniprot Q685J3 numbering.

[0020] Within the above embodiments, it is also envisaged that the present invention provides an antibody construct, wherein a first domain of the antibody construct binds to an epitope within MUC17 corresponding to amino acid sequences 4184 to 4291 according to Uniprot Q685J3 numbering.

[0021] Within the above embodiments, it is further envisaged that the present invention provides an antibody construct, wherein a first domain of the antibody construct binds to an epitope within MUC17 corresponding to amino acid sequences 4131 to 4243 according to Uniprot Q685J3 numbering.

[0022] Within the above embodiments, it is also envisaged in the context of the present invention to provide an antibody construct, wherein a first domain of the antibody construct binds to an epitope within MUC17 corresponding to amino acid sequences 4244 to 4389 according to Uniprot Q685J3 numbering.

[0023] Within the above embodiments, it is further envisioned that the present invention provides an antibody construct, wherein a first domain of the antibody construct binds to an epitope in MUC17 corresponding to amino acids 4131 to 4243 according to uniprot Q685J3 numbering, but does not bind to an epitope in MUC17 corresponding to amino acids 4244 to 4389 according to uniprot Q685J3 numbering.

[0024] Within the above embodiments, it is also contemplated that the present invention provides an antibody construct, wherein a first domain of the antibody construct binds to an epitope in MUC17 corresponding to amino acids 4171-4390 according to uniprot Q685J3 numbering, or amino acids 4184-4390 according to uniprot Q685J3 numbering, but does not bind to an epitope in MUC17 corresponding to amino acids 4341-4390 according to uniprot Q685J3 numbering, or an epitope in MUC17 corresponding to amino acids 4291-4390 according to uniprot Q685J3 numbering.

[0025] In a ninth embodiment, the present invention relates to a polynucleotide encoding an antibody as defined in any one of the previous embodiments.

[0026] In a tenth embodiment, the present invention relates to a vector comprising a polynucleotide as defined in embodiment 9.

[0027] In an eleventh embodiment, the present invention relates to a host cell transformed or transfected with a polynucleotide as defined in the tenth embodiment or with a vector as defined in the ninth embodiment.

[0028] In a twelfth embodiment, the present invention relates to a process for producing an antibody defined in any one of embodiments 1 to 8, said process comprising culturing a host cell defined in embodiment 10 under conditions permissive for expression of said antibody, and recovering the produced antibody from the culture.

[0029] In a thirteenth embodiment, the present invention relates to a hybridoma producing an antibody according to any one of the preceding embodiments 1 to 8.

[0030] In a fourteenth embodiment, the present invention relates to a composition comprising an antibody as defined in any one of embodiments 1 to 8, or a composition produced according to the process of the twelfth embodiment.

[0031] In a fifteenth embodiment, the present invention relates to a detection system comprising an antibody as defined in any one of embodiments 1 to 8 or an antibody produced according to the process of embodiment 12.

[0032] In a sixteenth embodiment, the present invention relates to the use of an antibody as defined in any one of embodiments 1 to 8, or an antibody produced according to the process of embodiment 12, or the use of the detection system of embodiment 15 in a diagnostic method.

[0033] In a seventeenth embodiment, the present invention relates to an antibody as defined in any one of embodiments 1 to 8, or an antibody produced according to the process of embodiment 12, the composition of embodiment 14, or the detection system of embodiment 15, used in a method for detecting neoplastic growth.

[0034] In an eighteenth embodiment, the present invention relates to an antibody or detection system according to embodiment 17 for use in a method for detecting neoplastic growth, comprising determining the amount of expression of MUC17 in a sample from a patient suspected of having cancer, in a negative control sample, and optionally in a positive control sample.

[0035] In a nineteenth embodiment, the present invention relates to an antibody or detection system according to any one of embodiments 17 and 18 for use in a method of detecting neoplastic growth, comprising determining the amount of expression of MUC17 in a sample from a patient suspected of having cancer and in a negative control sample, and further comprising comparing the expression levels of MUC17 between the samples, wherein optionally the expression levels in the negative control and / or positive control may be derived from stored data in at least one negative control sample and / or at least one positive control sample obtained in the method of detecting neoplastic growth, comprising determining the amount of expression of MUC17, and optionally further wherein the expression levels in the negative control and / or positive control sample may be derived from stored data comprising the average expression levels of a plurality of negative control samples and / or a plurality of positive control samples obtained in the method of detecting neoplastic growth, comprising determining the amount of expression of MUC17.

[0036] In a twentieth embodiment, the invention relates to an antibody or detection system according to any one of embodiments 17 and 19 for use in a method for detecting neoplastic growth, comprising determining the amount of expression of MUC17 in a sample, wherein the sample is a solid tissue sample or a liquid tissue sample.

[0037] In a twenty-first embodiment, the present invention provides a method for detecting and / or quantifying MUC17 expression in a sample, comprising: (a) using the antibody defined in or produced according to any one of the preceding embodiments, or using the detection system of embodiment 15, to determine the expression level of MUC17 in a sample; (b) determining the expression level of MUC17 in step (a); (c) a predefined value for MUC17 expression level; (d) the expression level of MUC17 determined in a control sample; or (e) the expression level of MUC17 determined in a sample obtained from the same source or subject at a previous time point. and comparing the

[0038] In a twenty-second embodiment, the present invention provides a method for diagnosing a neoplastic disease associated with MUC17 expression level or increased MUC17 expression level, comprising: (a) using the antibody as defined in or produced according to any one of the embodiments, or using the detection system of embodiment 15, to determine the expression level of MUC17 in a sample; (b) determining the expression level of MUC17 in step (a); (c) a predefined cutoff value for MUC17 expression that indicates the absence of such a disease; or (d) MUC17 expression levels determined in negative control samples representing the absence of such neoplastic disease. and a process of comparing Including, wherein a higher level of MUC17 expression determined in step (a) compared to the predefined cutoff value in (i) or the level of MUC17 expression determined in a negative control sample in (ii) indicates the presence of a disease associated with increased MUC17 expression or MUC17 expression.

[0039] In a twenty-third embodiment, the present invention provides a method for monitoring the progression of a disease associated with MUC17 expression or increased MUC17 expression, or monitoring the response to treatment of a disease associated with MUC17 expression or increased MUC17 expression, comprising: (a) using the antibody defined in any one of the preceding embodiments, or using the detection system of embodiment 15, to determine the expression level of MUC17 at a first time point in a sample obtained from a subject diagnosed with such a disease; (b) using the antibody of any one of the preceding embodiments, or the detection system of embodiment 15, to determine the expression level of MUC17 in a sample obtained from the subject at a second time point or after treatment; (c) comparing the amount of MUC17 expression determined in step (a) with the amount of MUC17 expression determined in step (b); Including, wherein a higher level of MUC17 expression determined in step (a) compared to the level of MUC17 expression determined in step (b) indicates that the disease is progressing, and / or a lower level of MUC17 expression determined in step (a) compared to the level of MUC17 expression determined in step (b) indicates that the disease is in remission or that the disease is responding to the treatment.

[0040] In a 24th embodiment, the present invention relates to the use or product for use of any one of embodiments 16 to 20, or the method of any one of embodiments 21 to 23, wherein the sample is a biological sample, preferably a human biological sample, such as a tissue sample, or a sample comprising cultured cells.

[0041] In a 25th embodiment, the present invention relates to the use or product for use of any one of embodiments 16 to 20, or the method of any one of embodiments 21 to 24, wherein the sample is obtained from a human subject, preferably a human subject suspected of having or having a disease associated with MUC17 expression or increased MUC17 expression, or a subject undergoing treatment for a disease associated with MUC17 expression or increased MUC17 expression.

[0042] In a 26th embodiment, the present invention relates to the use or product for use of any one of embodiments 16 to 20, or the method of any one of embodiments 21 to 25, wherein the disease is selected from the group comprising esophageal cancer, gastric cancer, gastroesophageal cancer (including gastroesophageal junction cancer (GJC)), gastrointestinal cancer, and pancreatic cancer.

[0043] In a twenty-seventh embodiment, the present invention relates to the use of any of the products defined herein above for the detection of MUC17 expression by immunohistochemistry (IHC), which comprises the step of preparing a sample of tissue (including a liquid biopsy, e.g., from an individual or animal, or cells obtained from cell culture). The sample material is typically provided on a support, e.g., a carrier such as a glass or plastic slide. The tissue may be fixed using a fixation medium known in the art, e.g., paraffin, ethanol, or acetone, or any other suitable medium that ensures fixation of the tissue or cells on the support. The sample is then prepared, e.g., deparaffinized, and incubated with a medium that allows the antibodies described herein to access their target of interest, MUC17, herein. The tissue is then incubated with a medium containing an amount of the antibodies disclosed herein sufficient to allow the antibodies to bind to MUC17 present in the tissue sample. After a commonly known and suitable amount of time, incubation of the tissue with the antibody is typically stopped by washing the support and tissue in a medium, e.g., PBS. Both the incubation and washing steps may be carried out at room temperature, although higher or lower temperatures, e.g., 2-50°C, are possible. The incubation temperature usually depends on the duration of the incubation. For example, it is possible to stain tissue overnight at 4°C, but it is equally possible to shorten the incubation time to just a few minutes at higher temperatures, e.g., about 30-40°C, e.g., 37°C. To check the influence of the incubation medium, fixation medium, incubation time, and temperature, tests are usually performed with a positive control material known to express the target (herein MUC17) and with a negative control sample known not to express MUC17. Negative controls can also (or optionally additionally) be performed using the antibody products of the invention and blocking epitopes corresponding to those specifically / selectively recognized or bound by the antibodies described herein.In a titration assay, a blocking epitope is added to positive control material. In this way, the concentration of the epitope that prevents the antibody of the present invention from specifically and / or selectively detecting MUC17 can be determined. In this way, the positive control (in the presence of the blocking epitope) no longer serves as a positive control, because the amount of antibody-bound MUC17 is blocked by a sufficient amount of the blocking epitope to saturate the antibody. Determining the exact amount of blocking epitope and antibody to perform appropriate positive and negative controls is a matter known to those skilled in the art of immunocytochemistry and, particularly, immunohistochemistry. If appropriate controls are available, test material that can be characterized by pathologically enhanced / distributed MUC17 expression, such as material obtained from a patient suspected of suffering from a disease, e.g., cancer, can be analyzed. As discussed further below, the antibody may bear a detectable label or may be recognized by another binder bearing such a label. The terms for this technique are known to those skilled in the art as direct immunocytological / immunohistochemical detection and indirect immunocytological / immunohistochemical detection. Once the tissue samples and controls have been subjected to the required incubation and washing steps, the tissue is prepared for analysis, for example, using an immunofluorescence-based detection system. The intensity and number of detectable labels can be determined and compared with positive and negative controls and / or known reference values. Based on this, a scientist can draw a conclusion as to whether the sample is positive for MUC17 expression. [Brief explanation of the drawings]

[0044] [Figure 1A]Figures 1A-1C show that MUC17 is highly expressed in gastric cancer via immunohistochemistry. Immunohistochemistry using the antibodies described herein reveals multifocal, diffuse MUC17 staining (brown staining) in human metastatic gastric cancer tissue sections (Figures 1A-1B), whereas MUC17 expression is restricted to the apical membrane in normal human gastrointestinal tract, i.e., enterocytes (Figure 1C). [Figure 1B] Figures 1A-1C show that MUC17 is highly expressed in gastric cancer via immunohistochemistry. Immunohistochemistry using the antibodies described herein reveals multifocal, diffuse MUC17 staining (brown staining) in human metastatic gastric cancer tissue sections (Figures 1A-1B), whereas MUC17 expression is restricted to the apical membrane in normal human gastrointestinal tract, i.e., enterocytes (Figure 1C). [Figure 1C] Figures 1A-1C show that MUC17 is highly expressed in gastric cancer via immunohistochemistry. Immunohistochemistry using the antibodies described herein reveals multifocal, diffuse MUC17 staining (brown staining) in human metastatic gastric cancer tissue sections (Figures 1A-1B), whereas MUC17 expression is restricted to the apical membrane in normal human gastrointestinal tract, i.e., enterocytes (Figure 1C). DETAILED DESCRIPTION OF THE INVENTION

[0045] definition Thus, in one aspect, the present invention provides an antibody (or a portion or derivative thereof) that binds to MUC17. Hereinafter, whenever the term "antibody" (i.e., an antibody that binds to MUC17) is used, the term is meant to encompass "antibody fragments," as defined herein below. Furthermore, the definition and specification of "antibodies of the invention (e.g., monoclonal antibodies that bind to MUC17)" provided below also apply to any antibodies that are chemically or enzymatically modified, for example, antibodies bearing labels such as fluorescent, radioactive, luminescent, or colorgenic labels, or enzymes capable of emitting a detectable signal. "Detectable signal" means that the intensity of the label of the MUC17 antibody can be measured using methods known in the art.

[0046] An "antibody" (sometimes known as an immunoglobulin) is a protein that immunospecifically binds to a target. Antibodies recognize unique targets, called antigens, through their variable regions. An "antibody" can be of any immunoglobulin isotype (e.g., IgG (e.g., IgG1, IgG2, IgG3, and IgG4 subtypes), IgA (e.g., IgA1 and IgA2 subtypes), IgM, and IgE). The term "antibody" can include, for example, monoclonal antibodies, chimeric antibodies, recombinant antibodies, deimmunized antibodies, affinity matured antibodies, humanized antibodies, and human antibodies, as well as antibodies from other species (e.g., rodent, rabbit, mouse, rat, hamster, goat, etc.). An antibody can be derived from only a single source or can be "chimeric," i.e., different portions of the antibody (e.g., CDRs, framework regions, variable regions, constant regions) can be derived from two different antibodies. The definition of "antibody" according to the present invention includes full-length antibodies, and also includes camelid antibodies and other immunoglobulins produced by biotechnological or protein engineering methods or processes. Antibodies may also be produced in hybridomas.

[0047] An intact IgG antibody will generally comprise two full-length heavy chains and two full-length light chains. The "light chain" comprises a variable region ("VL") having one domain and a constant region ("CL") having one domain. The variable region of the light chain is at the amino-terminus of the polypeptide. Light chains include kappa and lambda chains. The "heavy chain" comprises a variable region ("VH") having one domain and a constant region ("CH") having three domains in the case of an intact IgG antibody: CH1, CH2, and CH3. VH is at the amino-terminus of the polypeptide, the CH domain is at the carboxyl-terminus, and CH3 is closest to the carboxy-terminus of the polypeptide.

[0048] In classical full-length antibodies or immunoglobulins, each light (L) chain is linked to a heavy (H) chain by one covalent disulfide bond, while the two H chains are linked to each other by one or more disulfide bonds, depending on the H chain isotype. The heavy chain constant (CH) domain closest to VH is usually referred to as CH1. The constant ("C") domains are not directly involved in antigen binding but exhibit various effector functions, such as antibody-dependent, cell-mediated cytotoxicity (ADCC) and complement activation (complement-dependent cytotoxicity, CDC). The Fc region of an antibody is the "tail" region of a classical antibody that interacts with cell surface receptors called Fc receptors and certain proteins of the complement system. In IgG, IgA, and IgD antibody isotypes, the Fc region is composed of two identical protein fragments derived from the second and third constant domains (CH2 and CH3) of the antibody's two heavy chains. The Fc region of IgM and IgE contains three heavy chain constant domains (CH2, CH3, and CH4) within each polypeptide chain. The Fc region also contains a portion of the so-called "hinge" region held together by one or more disulfides and non-covalent interactions. The Fc region of naturally occurring IgG has highly conserved N-glycosylation sites. Glycosylation of the Fc fragment is essential for Fc receptor-mediated activity.

[0049] It is contemplated that the monoclonal antibody of the present invention may be an IgG antibody, an IgD antibody, an IgE antibody, an IgM antibody, or an IgA antibody. According to one embodiment, the monoclonal antibody is an IgG antibody, for example, an IgG1 antibody, an IgG2 antibody, an IgG3 antibody, or an IgG4 antibody. The isotype and subclass of the antibody may be rat, mouse, hamster, or other (e.g., mouse IgG, mouse IgG1, or other).

[0050] In the context of the present invention, the term "variable" refers to that portion of an antibody or immunoglobulin domain that exhibits variability in its sequence and is responsible for determining the specificity and binding affinity of a particular antibody (i.e., the "variable region"). Typically, a heavy chain variable region (VH) and a light chain variable region (VL) pair together to form a single antigen-binding site. The variability is not uniformly distributed throughout the variable regions of an antibody, but is concentrated within subdomains of each of the heavy and light chain variable regions. These subdomains are called "hypervariable regions" or "complementarity-determining regions" (CDRs). The more conserved (i.e., less hypervariable) portions of the variable regions are called "framework" (FR) regions, which provide a scaffold for the six CDRs that form the antigen-binding surface in three-dimensional space. The heavy and light chain variable regions of naturally occurring antibodies each contain four FR regions (FR1, FR2, FR3, and FR4) that largely adopt a β-sheet configuration. Together with the CDRs, the FR regions form the following sequence in the variable heavy or variable light chain: FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4. The hypervariable regions in each chain are held together in close proximity by framework regions and, usually with the hypervariable regions from the other chain, contribute to the formation of the antigen-binding site (see Kabat et al., Sequences of Proteins of Immunological Interest. Bethesda, National Institutes of Health. 1991).

[0051] The term "CDR" and its plural "CDRs" refer to complementarity-determining regions, three of which (CDR-L1, CDR-L2, and CDR-L3) constitute the binding properties of the light chain variable region, and three of which (CDR-H1, CDR-H2, and CDR-H3) constitute the binding properties of the heavy chain variable region. CDRs contain most of the residues of an antibody (or binding domain) responsible for specific interactions with an antigen and therefore contribute to the functional activity of an antibody molecule; CDRs are the primary determinants of antigen specificity. The precise definition of the boundaries and lengths of CDRs follows various classification and numbering systems. Thus, CDRs may be referred to by Kabat, Chothia, contact, or any other boundary definition, including the numbering systems described herein. Although the boundaries differ, each of these systems has some overlap in the portions that constitute the so-called "hypervariable regions" within the variable sequences. Thus, CDR definitions according to these systems may differ in length and boundary regions with respect to the adjacent framework regions. See, for example, Kabat (an approach based on interspecies sequence variability), Chothia (an approach based on crystallographic studies of antigen-antibody complexes), and / or MacCallum (Kabat et al., supra; Chothia et al., J. MoI. Biol., 1987, 196:901-917; and MacCallum et al., J. MoI. Biol., 1996, 262:732). Yet another standard for characterizing antigen-binding sites is the AbM definition used by Oxford Molecular's AbM antibody modeling software. See, for example, Protein Sequence and Structure Analysis of Antibody Variable Domains. In: Antibody Engineering Lab Manual (Eds.: Duebel, S. and Kontermann, R., Springer-Verlag, Heidelberg). Two residue identification techniques can be combined to define hybrid CDRs, as long as they define overlapping but not identical regions. However, numbering according to the so-called Kabat system is preferred.

[0052] Typically, CDRs form loop structures that can be classified as canonical structures. The term "canonical structure" refers to the main chain conformation adopted by the antigen-binding (CDR) loop. Comparative structural studies have found that five of the six antigen-binding loops have only a limited repertoire of available conformations. Each canonical structure can be characterized by the torsion angle of the polypeptide backbone. Thus, corresponding loops between antibodies can have very similar three-dimensional structures despite high amino acid sequence variability in most parts of the loop (Chothia and Lesk, J. MoI. Biol., 1987, 196:901; Chothia et al., Nature, 1989, 342:877; Martin and Thornton, J. MoI. Biol., 1996, 263:800). Furthermore, there is a relationship between the loop structure adopted and the surrounding amino acid sequence. The conformation of a particular canonical class is determined by the length of the loop and the amino acid residues present at key positions within the loop and within the conserved framework (i.e., outside the loop), and therefore assignment to a particular canonical class can be made based on the presence of these key amino acid residues.

[0053] The term "canonical structure" can also include considerations regarding the linear sequence of an antibody, for example, as classified by Kabat (Kabat et al., supra). The Kabat numbering scheme is a widely adopted standard for numbering the amino acid residues of antibody variable regions in a consistent manner and, as noted elsewhere herein, is the preferred scheme used in the present invention. Additional structural considerations can also be used to determine the canonical structure of an antibody. For example, differences not fully reflected by the Kabat numbering can be accounted for by the numbering system of Chothia et al. and / or can be revealed by other techniques, such as crystallography and two- or three-dimensional computer modeling. Thus, a given antibody sequence can be placed into a canonical class, which, among other things, can enable identification of appropriate class sequences (e.g., based on the desire to include various canonical structures in a library). The Kabat numbering of antibody amino acid sequences and the structural considerations described by Chothia et al. (supra), as well as their significance in interpreting canonical aspects of antibody structure, are explained in the literature. The subunit structures and three-dimensional configurations of various classes of immunoglobulins are well known in the art. For a review of antibody structure, see Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory, eds. Harlow et al., 1988.

[0054] The CDR3 of the light chain and, in particular, the CDR3 of the heavy chain may constitute the most important determinant for antigen binding within the light chain variable region and the heavy chain variable region. In some antibodies or binding domains, the heavy chain CDR3 appears to constitute the main contact area between the antigen and the antibody. An in vitro selection scheme that varies only the CDR3 can be used to change the binding characteristics of the antibody / binding domain or to determine which residues contribute to antigen binding. Therefore, the CDR3 is typically the greatest source of molecular diversity within the antibody binding site. For example, the CDR-H3 can be as few as 2 amino acid residues or more than 26 amino acids.

[0055] After assembly and somatic mutation, antibody gene sequences are highly diverse, and the diverse genes are estimated to encode 10 distinct antibody molecules (Immunoglobulin Genes, 2nd ed., eds. Jonio et al., Academic Press, San Diego, CA, 1995). Thus, the immune system provides a repertoire of immunoglobulins. The term "repertoire" refers to at least one nucleotide sequence derived in whole or in part from at least one sequence encoding at least one immunoglobulin. The sequences can be generated by in vivo rearrangement of heavy chain V, D, and J segments and light chain V and J segments. Alternatively, the sequences can be generated by cells in response to, for example, in vitro stimuli that cause rearrangement. Alternatively, some or all of the sequences can be obtained by DNA splicing, nucleotide synthesis, mutagenesis, and other methods (see, e.g., U.S. Pat. No. 5,565,332). A repertoire may contain only one sequence, or may contain multiple sequences, including those in a genetically diverse collection.

[0056] The antibodies of the present invention are intended to be monoclonal. As used herein, an antibody or binding domain designated "monoclonal" (mAb) is obtained from a population of substantially homogeneous antibodies or binding domains, i.e., the individual antibodies or binding domains within the population are identical (particularly with respect to amino acid sequence) except for possible naturally occurring mutations and / or post-translational modifications (e.g., isomerization, amidation), which may be present in minor amounts. Monoclonal antibodies or binding domains are highly specific, directed against a single epitope within an antigen, in contrast to polyclonal antibody preparations, which typically include different antibodies directed against different determinants (or epitopes). In addition to their specificity, monoclonal antibodies are advantageous in that they are synthesized by hybridoma culture and, therefore, are uncontaminated by other immunoglobulins. The modifier "monoclonal" indicates the character of the antibody or binding domain as being obtained from a substantially homogeneous population of antibodies or binding domains, and should not be construed as requiring production of the antibody by any particular method.

[0057] For the preparation of monoclonal antibodies, any technique that provides antibodies produced by continuous cell line cultures can be used. For example, the monoclonal antibodies or binding domains to be used can be made by the hybridoma method first described by Koehler et al., Nature, 256:495 (1975), or can be made by recombinant DNA methods (see, e.g., U.S. Pat. No. 4,816,567). Additional techniques for producing human monoclonal antibodies include the trioma technique, the human B-cell hybridoma technique (Kozbor, Immunology Today 4 (1983), 72), and the EBV-hybridoma technique (Cole et al., Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, Inc. (1985), 77-96).

[0058] The hybridomas can then be screened using standard methods, such as enzyme-linked immunosorbent assay (ELISA) and surface plasmon resonance (BIACORE™) analysis, to identify one or more hybridomas that produce an antibody or binding domain that immunospecifically binds to a particular antigen. Any form of related antigen can be used as an immunogen, including, for example, recombinant antigens, naturally occurring forms, chimeric antigens, any variants or fragments of the antigen, and antigenic peptides thereof. Surface plasmon resonance, as employed in the BIAcore™ system, can be used to enhance the efficiency of phage antibodies or binding domains that bind to epitopes of the target antigen (Schier, Human Antibodies Hybridomas 7 (1996), 97-105; Malmborg, J. Immunol. Methods 183 (1995), 7-13).

[0059] Another exemplary method for generating antibodies or binding domains includes screening protein expression libraries, such as phage display or ribosome display libraries. Phage display is described, for example, in U.S. Patent No. 5,223,409 to Ladner et al.; Smith (1985) Science 228:1315-1317; Clackson et al., Nature, 352:624-628 (1991); and Marks et al., J. Mol. Biol., 222:581-597 (1991).

[0060] In addition to using display libraries, relevant antigens can be used to immunize non-human animals, such as rodents (such as mice, hamsters, rabbits, or rats). In one embodiment, the non-human animals contain at least a portion of a human immunoglobulin gene. For example, mouse strains deficient in mouse antibody production can be engineered with large fragments of the human Ig (immunoglobulin) locus. Using hybridoma technology, antigen-specific monoclonal antibodies derived from genes with the desired specificity can be produced and selected. See, e.g., Xenomouse™, Green et al. (1994) Nature Genetics 7:13-21, U.S. Patent Application Publication No. 2003-0070185, WO 96 / 34096, and WO 96 / 33735.

[0061] Monoclonal antibodies can also be obtained from non-human animals and then modified, e.g., humanized, deimmunized, chimerized, etc., using recombinant DNA techniques known in the art. Examples of modified antibodies, constructs, or binding domains include humanized variants of non-human antibodies, "affinity matured" antibody constructs or binding domains (see, e.g., Hawkins et al. J. Mol. Biol. 254, 889-896 (1992) and Lowman et al., Biochemistry 30, 10832-10837 (1991)), and antibody variants or mutants with altered effector function (see, e.g., U.S. Pat. No. 5,648,260; Kontermann and Duebel (2010), supra; and Little (2009), supra).

[0062] In immunology, affinity maturation is the process by which B cells produce antibodies with increasing affinity for antigens during an immune response. Repeated exposure to the same antigen leads the host to produce antibodies with successively increasing affinities. Similar to natural prototypes, in vitro affinity maturation is based on the principle of mutation and selection. In vitro affinity maturation has been successfully used to optimize antibodies, antibody fragments, antibody variants, or binding domains. Random mutations within the CDRs are introduced using radiation, chemical mutagens, or error-prone PCR. In addition, genetic diversity can be increased by chain shuffling. Two or three rounds of mutation and selection using display methods such as phage display typically yield antibodies, antibody fragments, antibody variants, or binding domains with affinities in the low nanomolar range.

[0063] Amino acid sequence modification(s) of the antibodies described herein are also contemplated. For example, it may be desirable to improve the binding affinity and / or other biological properties of the antibody. Amino acid sequence variants of the antibodies are prepared by peptide synthesis or by introducing appropriate nucleotide changes into the nucleic acid molecule encoding the antibody. All amino acid sequence modifications described below should result in an antibody that retains the desired biological activity (binding to MUC17) of the unmodified parent molecule.

[0064] The term "amino acid" or "amino acid residue" typically refers to an amino acid having an art-recognized definition, such as an amino acid selected from the group consisting of alanine (Ala or A); arginine (Arg or R); asparagine (Asn or N); aspartic acid (Asp or D); cysteine ​​(Cys or C); glutamine (Gln or Q); glutamic acid (Gln or E); glycine (Gln or G); histidine (His or H); isoleucine (Ile or I); leucine (Leu or L); lysine (Lys or K); methionine (Met or M); phenylalanine (Phe or F); proline (Pro or P); serine (Ser or S); threonine (Thr or T); tryptophan (Trp or W); tyrosine (Tyr or Y); and valine (Val or V), although modified, synthetic, or rare amino acids may be used if desired. There are essentially four distinct amino acid classes determined by their different side chains: (1) Non-polar and neutral (uncharged): Ala, Gly, Ile, Leu, Met, Phe, Pro, Val (2) Polar and neutral (uncharged): Asn, Cys (slightly polar), Gln, Ser, Thr, Trp (slightly polar), Tyr (3) Acidic and polar (negatively charged): Asp and Glu (4) Basic and polar (positively charged): Arg, His, Lys.

[0065] Hydrophobic amino acids can be divided according to whether they have aliphatic or aromatic side chains. Phe and Trp (very hydrophobic), and Tyr and His (less hydrophobic), are classified as aromatic amino acids. Strictly speaking, aliphatic means that the side chain contains only hydrogen and carbon atoms. By this strict definition, amino acids with aliphatic side chains are alanine, isoleucine, leucine (also norleucine), proline, and valine. Alanine's very short side chain means that it is not particularly hydrophobic, and proline has a unique geometry that gives it a special role in proteins. It is often convenient to consider methionine in the same category as isoleucine, leucine, and valine, but methionine also contains a sulfur atom. A unifying theme is that these amino acids contain primarily unreactive and flexible side chains. The amino acids alanine, cysteine, glycine, proline, serine, and threonine are often grouped together because they are all small. Gly and Pro can influence chain orientation.

[0066] Amino acid modifications include, for example, deletion of residues from, insertion of residues into, and / or substitution of residues within the amino acid sequence of the monoclonal antibody or binding domain. Any combination of deletion, insertion, and / or substitution can be made to arrive at the final monoclonal antibody or binding domain, provided that the final antibody possesses the desired properties, e.g., the biological activity of the unmodified parent molecule (e.g., binding to MUC17). Amino acid changes can also alter post-translational processes of the antibody, such as changing the number or location of glycosylation sites.

[0067] For example, in each of the CDRs, 1, 2, 3, 4, 5, or 6 amino acids may be inserted, deleted, and / or substituted (depending, of course, on the length of each), while in each of the FRs, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, or 25 amino acids may be inserted, deleted, and / or substituted. Amino acid sequence insertions also include N- and / or C-terminal additions of amino acids ranging in length from 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 residues to polypeptides containing more than 10, e.g., 100 or more residues, as well as intrasequence insertions of single or multiple amino acid residues.

[0068] The most interesting sites for amino acid modifications, particularly amino acid substitutions, include the hypervariable regions of the heavy and / or light chains, particularly the individual CDRs, although alterations of the FRs in the heavy and / or light chains are also contemplated herein. Substitutions may be conservative, as described herein. Preferably, depending on the length of the CDRs or framework regions (FRs), 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acids may be substituted in the CDRs, while 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, or 25 amino acids may be substituted in the FRs. For example, if a CDR sequence contains six amino acids, it is contemplated that one, two, or three of these amino acids may be substituted. Similarly, if a CDR sequence contains 15 amino acids, it is contemplated that one, two, three, four, five, or six of these amino acids may be substituted.

[0069] A useful method for identifying specific residues or regions within a monoclonal antibody or binding domain that are preferred locations for mutagenesis is called "alanine scanning mutagenesis," and is described, for example, in Cunningham BC and Wells JA (Science. 1989 Jun 2;244(4908):1081-5). Here, residues or groups of residues within an antibody are identified (e.g., charged residues such as Arg, His, Lys, Asp, and Glu) and substituted with neutral or nonpolar amino acids (most preferably alanine or polyalanine), thereby affecting the interaction of each amino acid with the epitope of the target protein. Alanine scanning is a technique used to determine the contribution of specific residues to the stability or function of a given protein. Alanine is used because of its non-bulky, chemically inert methyl functional group, which still mimics the secondary structure preferences of many amino acids other than alanine. Occasionally, bulky amino acids such as valine or leucine can be used when it is necessary to preserve the size of the mutated residue. This technique can also be useful for determining whether the side chains of specific residues play an important role in biological activity. Alanine scanning is typically accomplished by site-directed mutagenesis or randomly by PCR library generation. Additionally, computational methods have been developed to estimate thermodynamic parameters based on theoretical alanine substitutions. Data can be examined by IR / NMR spectroscopy, mathematical methods, bioassays, etc.

[0070] Amino acid positions demonstrating functional sensitivity to the substitution (as determined by, e.g., alanine scanning) can then be refined by introducing further or other variants at or for the substitution sites. Thus, while the sites or regions for introducing amino acid sequence variation are predetermined, the nature of the mutation per se need not be predetermined. For example, to analyze or optimize the performance of a mutation at a given site, alanine scanning or random mutagenesis may be performed at the target codon or region, and the expressed monoclonal antibodies / variants are screened for the optimal combination of desired activity. Techniques for making substitution mutations at predetermined sites within DNA having a known sequence are well known, such as M13 primer mutagenesis and PCR mutagenesis. Mutants are screened using, e.g., antigen (e.g., MUC17) binding activity assays as described herein.

[0071] Generally, if amino acids are substituted in one or more or all of the CDRs of the heavy and / or light chain / variable region, it is expected that the resulting "substituted" sequence will be at least 60% or 65%, more preferably 70% or 75%, even more preferably 80% or 85%, and particularly preferably 90% or 95% identical / homologous / similar to the "original" or "parent" CDR sequence. This means that the degree of identity / homology / similarity between the original and substituted sequences depends on the length of the CDR. For example, a CDR having a total of five amino acids and containing one amino acid substitution is 80% identical to the "original" or "parent" CDR sequence, while a CDR having a total of 10 amino acids and containing one amino acid substitution is 90% identical to the "original" or "parent" CDR sequence. Thus, the substituted CDRs of the monoclonal antibodies of the present invention may have varying degrees of identity with their original sequences; for example, CDRL1 may be 80% homologous, while CDRL3 may be 90% homologous. The same considerations apply to the framework regions and the VH and VL regions as a whole.

[0072] A "variant CDR" is a CDR that has particular sequence homology, similarity, or identity to a parent CDR of the invention and shares a biological function with the parent CDR, for example, but not limited to, at least 60%, 65%, 70%, 75%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% of the specificity and / or activity of the parent CDR. Generally, the amino acid homology, similarity, or identity between the individual variant CDRs is at least 60% relative to the parent sequences set forth herein; more typically, the homology, similarity, or identity is at least 65% or 70%, preferably at least 75% or 80%, more preferably at least 85%, 90%, 91%, 92%, 93%, 94%, and most preferably 95%, 96%, 97%, 98%, 99%, and even higher, such as nearly 100%. The same applies to "variant VH" and "variant VL". According to one embodiment, the sequence variation within a "variant VH" and / or a "variant VL" does not extend to the CDRs. Therefore, the present invention relates to antibodies or derivatives or fragments as defined herein comprising VH and VL sequences that have a particular sequence homology / identity / similarity (see above) to the particular sequences defined herein ("parental" VH and VL), wherein the CDR sequences are 100% identical to the particular CDR sequences ("parental" CDRs) defined herein.

[0073] Preferred substitutions (or replacements) are conservative. However, any substitution (including a non-conservative substitution or one or more from the "exemplary substitutions" listed in Table 1 below) is contemplated, as long as the monoclonal antibody () retains the ability to bind to MUC17 and / or the CDR, FR, VH and / or VL sequences have a degree of identity to the original or parent sequence of at least 60% or 65%, more preferably at least 70% or 75%, even more preferably at least 80% or 85%, and particularly preferably at least 90% or 95%.

[0074] A conservative substitution (also called a conservative mutation or conservative substitution) is an amino acid substitution that changes a given amino acid to a different amino acid with similar biochemical properties (e.g., charge, hydrophobicity, size). Conservative substitutions in proteins often have a smaller effect on protein function than non-conservative substitutions. Conservative substitutions are shown in Table 1. Exemplary conservative substitutions are indicated as "exemplary substitutions." If such a substitution results in a change in biological activity, more substantial changes can be introduced as further described herein with respect to amino acid classes, and the products can be screened for desired properties.

[0075] [Table 1]

[0076] Substantial modifications in the biological properties of the antibodies of the invention are achieved by selecting substitutions that differ significantly in their effect on (a) the structure of the polypeptide backbone in the region of the substitution, e.g., as a sheet or helical conformation, (b) the charge or hydrophobicity of the molecule at the target site, or (c) maintaining side-chain bulk. Non-conservative substitutions will usually involve the exchange of a member of one of the above-defined amino acid classes (e.g., polar, neutral, acidic, basic, aliphatic, aromatic, small, etc.) for another class. Any cysteine ​​residue not involved in maintaining the proper conformation of the antibody may be substituted, generally with serine, to improve the oxidative stability of the antibody.

[0077] Sequence identity, homology, and / or similarity of amino acid sequences can be determined using standard techniques known in the art, including, but not limited to, the local sequence identity algorithm of Smith and Waterman, 1981, Adv. Appl. Math. 2:482, preferably using default settings; the sequence identity alignment algorithm of Needleman and Wunsch (J Mol Biol. 1970 Mar;48(3):443-53); the similarity search method of Pearson and Lipman (Proc Natl Acad Sci USA. 1988 Apr;85(8):2444-8); computerized implementations of these algorithms (GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group, 575 Science Dr., Madison, Wis.); Devereux et al. (Nucleic Acids Res. 1984 Jan 11;12(1 Pt 1):387-95) or by visual inspection. Percent identity is expected to be calculated by FastDB based on the following parameters: mismatch penalty of 1; gap penalty of 1; gap size penalty of 0.33; and joining penalty of 30. See also, "Current Methods in Sequence Comparison and Analysis," Macromolecules Sequencing and Synthesis, Selected Methods and Applications, pp. 127-149 (1988), Alan R. Liss, Inc.

[0078] One example of a useful algorithm is PILEUP. PILEUP generates a multiple sequence alignment from a group of related sequences using progressive pairwise alignments. It can also plot a tree showing the clustering relationships used to generate the alignment. PILEUP uses a simplified version of the progressive alignment method of Feng and Doolittle (J Mol Evol. 1987;25(4):351-60); the method is similar to that described by Higgins and Sharp (Comput Appl Biosci. 1989 Apr;5(2):151-3). Useful PILEUP parameters include a default gap weight of 3.00, a default gap length weight of 0.10, and weighted end gaps.

[0079] Another example of a useful algorithm is the BLAST algorithm described in Altschul et al. (J Mol Biol. 1990 Oct 5;215(3):403-10.); Altschul et al., (Nucleic Acids Res. 1997 Sep 1;25(17):3389-402); and Karlin and Altschul (Proc Natl Acad Sci USA. 1993 Jun 15;90(12):5873-7). A particularly useful BLAST program is the WU-Blast-2 program, which was obtained from Altschul et al. (Methods Enzymol. 1996;266:460-80). WU-Blast-2 uses several search parameters, most of which are set to the default values. Adjustable parameters are set to the following values: overlap span=1, overlap fraction=0.125, word threshold (T)=II. The HSP S and HSP S2 parameters are dynamic values ​​that are established by the program itself depending on the composition of the particular sequence and the composition of the particular database in which the sequence of interest will be searched; however, the values ​​can be adjusted to increase sensitivity.

[0080] An additional useful algorithm is Gapped BLAST, as reported by Altschul et al. (Nucleic Acids Res. 1997 Sep 1;25(17):3389-402). Gapped BLAST uses BLOSUM-62 substitution scores; the threshold T parameter is set to 9; the two-hit method of triggering ungapped extension imposes a cost of 10+k on gap length k; Xu is set to 16, and Xg is set to 40 for the database search stage and 67 for the output stage of the algorithm. Gapped alignments are triggered by scores corresponding to approximately 22 bits.

[0081] Consistent with this, the term "percent (%) nucleic acid sequence identity / homology / similarity" with respect to nucleic acid sequences encoding the monoclonal antibodies identified herein is defined as the percentage of nucleotide residues in a candidate sequence that are identical with nucleotide residues in the coding sequence of the antibody. One method for determining homology between two sequences by aligning them uses the BLASTN module of WU-Blast2 with default parameters, with overlap span and overlap fraction set to 1 and 0.125, respectively. Generally, the nucleic acid sequence homology, similarity, or identity between the nucleotide sequence encoding each variant CDR and the nucleotide sequences set forth herein is at least 60%, and more typically the homology, similarity, or identity is at least 65%, 70%, 75%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%, and as high as nearly 100%. Again, the same applies to nucleic acid sequences encoding a "variant VH" and / or a "variant VL."

[0082] The term "antibody derivative" according to the present invention may also include fragments of full-length antibodies, such as VH, VHH, VL, (s)dAb, Fv, light chain (VL-CL), Fd (VH-CH1), heavy chain, Fab, Fab', F(ab')2, or "rIgG" (a "half antibody" consisting of a heavy and light chain). Antibody fragments may be produced by enzymatic or chemical cleavage of intact antibodies. Antibody fragments according to the present invention may also include modified fragments of antibodies, also called antibody variants or antibody derivatives. Examples include, but are not limited to, scFv, di-scFv or bi(s)-scFv, scFv-Fc, scFv-zipper, scFab, Fab2, Fab3, diabodies, single chain diabodies, tandem diabodies (Tandab's), tandem di-scFv, tandem tri-scFv, "minibodies" (exemplified by structures such as (VH-VL-CH3)2, (scFv-CH3)2, ((scFv)2-CH3+CH3), ((scFv)2-CH3), or (scFv-CH3-scFv)2), multibodies such as triabodies or tetrabodies, and single domain antibodies, e.g., nanobodies or single variable domain antibodies comprising only one variable region, which may be VHH, VH, or VL, that specifically bind to an antigen or target independent of other variable regions or domains. Further possible formats of antibody fragments according to the invention are crossbodies, maxibodies, hetero-Fc constructs, mono-Fc constructs, and scFc constructs. Examples of these formats are described herein below. Furthermore, the definition of the term "antibody" includes molecules consisting of only one polypeptide chain as well as molecules consisting of two, three, four, or more polypeptide chains, which chains may be identical (homodimers, homotrimers, or homo-oligomers) or different (heterodimers, heterotrimers, or hetero-oligomers).Examples of the above-identified antibodies and their fragments, variants, derivatives, and binding domains derived therefrom are described, inter alia, in Harlow and Lane, Antibodies: A laboratory manual, CSHL Press (1988); Kontermann and Duebel, Antibody Engineering, Springer, 2nd ed. 2010; and Little, Recombinant Antibodies for Immunotherapy, Cambridge University Press 2009.

[0083] The term "binding domain" or "domain that binds to" in the context of the present invention characterizes a domain of an antibody that specifically binds to / interacts specifically with / recognizes an epitope on a target or antigen (herein MUC17). The structure and function of a binding domain are based on the structure and / or function of an antibody (e.g., a full-length immunoglobulin molecule). Thus, a "binding domain" or "domain that binds to" may comprise the minimal structural requirements of an antibody that enable immunospecific target binding. The minimal structural requirements of a binding domain may be defined, for example, by the presence of at least three light chain CDRs (i.e., CDR1, CDR2, and CDR3 of the VL region) and / or three heavy chain CDRs (i.e., CDR1, CDR2, and CDR3 of the VH region), preferably all six CDRs. A "domain that binds to" (or "binding domain") may typically comprise an antibody light chain variable region (VL) and an antibody heavy chain variable region (VH); however, it need not comprise both and may comprise only VH or VL. Fd fragments, for example, often retain some antigen-binding function of an intact antigen-binding domain.

[0084] Examples of formats for a "domain that binds to" (or "binding domain") include full-length antibodies, fragments of full-length antibodies (such as VH, VHH, VL), (s)dAb, Fv, light chain (VL-CL), Fd (VH-CH1), heavy chain, Fab, Fab', F(ab')2, or "rIgG" ("half antibody"), antibody variants, or derivatives, such as scFv, di-scFv or bi(s)-scFv, scFv-Fc, scFv-zipper, scFab, Fab2, Fab3, diabodies, single chain diabodies, tandem diabodies ( These include, but are not limited to, Tandbody's), tandem di-scFvs, tandem tri-scFvs, "minibodies" (selected from formats such as (VH-VL-CH3)2, (scFv-CH3)2, ((scFv)2-CH3+CH3), ((scFv)2-CH3), or (scFv-CH3-scFv)2), multibodies, e.g., triabodies or tetrabodies, and single domain antibodies such as nanobodies or single variable domain antibodies that comprise only one variable region, which may be VHH, VH, or VL. Further examples of formats for a "domain that binds to" (or "binding domain") include: (1) an antibody fragment or antibody variant (e.g., Fab) comprising a VL, VH, CL, and CH1; (2) an antibody fragment or antibody variant (e.g., F(ab')2) comprising two linked Fab fragments; (3) an antibody fragment or antibody variant (e.g., Fd) comprising a VH and CH1; (4) an antibody fragment or antibody variant (e.g., a light chain) comprising a VL and CL; (5) an antibody fragment or antibody variant (e.g., an Fv) comprising a VL and a VH; (5) a dAb fragment having a VH domain (Ward et al., (1989) Nature 341:544-546); (6) an antibody variant comprising at least three isolated CDRs of the heavy and / or light chain; and (7) a single-chain Fv (scFv).Exemplary antibody embodiments according to the invention are described, for example, in WO 00 / 006605, WO 2005 / 040220, WO 2008 / 119567, WO 2010 / 037838, WO 2013 / 026837, WO 2013 / 026833, U.S. Patent Application Publication No. 2014 / 0308285, U.S. Patent Application Publication No. 2014 / 0302037, WO 2014 / 144722, WO 2014 / 151910, and WO 2015 / 048272.

[0085] In an scFv, the VH and VL regions are arranged in the order VH-VL or VL-VH (from N-terminus to C-terminus). It is envisioned that the VH and VL regions are linked via a linker, preferably a peptide linker. According to one embodiment, the VH region is located at the N-terminus of the linker, and the VL region is located at the C-terminus of the linker. It is further possible that two scFv domains of an antibody are linked via a linker, preferably a peptide linker. An scFv can, for example, comprise domains in the order (from N-terminus to C-terminus) first domain-linker-second domain. The reverse order (second domain-linker-first domain) is also possible.

[0086] The linker is preferably a peptide linker, more preferably a short-chain peptide linker. According to the present invention, a "peptide linker" comprises an amino acid sequence that connects the amino acid sequence of one domain of an antibody to another (variable and / or binding) domain (e.g., variable domain or binding domain). An essential technical feature of such a peptide linker is that it does not contain any polymerization activity. Suitable peptide linkers include those described in U.S. Pat. Nos. 4,751,180 and 4,935,233 or WO 88 / 09344. In the present context, a "short" linker has 2 to 50 amino acids, preferably 3 to 35, 4 to 30, 5 to 25, 6 to 20, or 6 to 17 amino acids. The linker between the two variable regions of one binding domain may be different in length (e.g., longer) than the linker between the two binding domains. For example, the linker between the two variable regions of one binding domain may be 7 to 15 amino acids long, preferably 9 to 13 amino acids long, and the linker between two binding domains may be 3 to 10 amino acids long, preferably 4 to 8 amino acids long. It is further contemplated that the peptide linker is a glycine / serine linker. The majority of amino acids in the glycine / serine linker are selected from glycine and serine.

[0087] According to one embodiment of the present invention, the antibody of the present invention that binds to MUC17 can be a "single-chain antibody construct." The two domains of the Fv fragment, VL and VH, are encoded by separate genes, but they can be joined by an artificial linker (as described earlier in this specification) that allows them to be produced as a single protein chain using recombinant methods, in which the VL and VH regions pair to form a monovalent molecule (see, e.g., Huston et al. (1988) Proc. Natl. Acad. Sci USA 85:5879-5883). These antibody fragments are obtained using conventional techniques known to those skilled in the art, and the fragments are evaluated for function in the same manner as full-length antibodies or IgGs. Thus, single-chain variable fragments (scFvs) are typically fusion proteins of the variable regions of the heavy (VH) and light (VL) chains of immunoglobulins, linked by a short linker peptide. The linker is usually glycine-rich for flexibility and serine- or threonine-rich for solubility, and can connect the N-terminus of the VH to the C-terminus of the VL, or vice versa. The protein retains the specificity of the original immunoglobulin despite the removal of the constant regions and the introduction of the linker.

[0088] Antibodies called "single-domain antibodies" contain a single (monomeric) antibody variable region that can selectively bind to a specific antigen, independent of other variable regions. The first single-domain antibodies were engineered from heavy-chain antibodies found in camels and are called VHH fragments. Cartilaginous fish also possess heavy-chain antibodies (IgNARs), from which single-domain antibodies called VNAR fragments can be derived. An alternative approach is to split the dimeric variable region from a common immunoglobulin into monomers, yielding VH or VL as single-domain Abs. Currently, most research on single-domain antibodies is based on heavy-chain variable regions, but nanobodies derived from light chains have also been shown to specifically bind to target epitopes. Examples of single-domain antibodies are called sdAbs, nanobodies, or single variable domain antibodies. Thus, a (single-domain mAb)2 is a monoclonal antibody composed of (at least) two single-domain monoclonal antibodies, each individually selected from the group including VH, VL, VHH, and VNAR. The linker is preferably in the form of a peptide linker. Similarly, an "scFv-single domain mAb" is a monoclonal antibody composed of at least one single domain antibody as described above and one scFv molecule as described above. Again, the linker is preferably in the form of a peptide linker.

[0089] According to one embodiment, the antibody that binds to MUC17 is in the form of one or more polypeptides or in the form of a protein. In addition to the proteinaceous portion, such a polypeptide or protein may include a non-proteinaceous portion (e.g., a chemical linker or chemical cross-linking agent, such as glutaraldehyde).

[0090] Peptides are short chains of amino acid monomers linked by covalent peptide (amide) bonds. Therefore, peptides are classified within the broad chemical class of biological oligomers and polymers. The amino acids that are part of a peptide or polypeptide chain are referred to as "residues" and can be numbered consecutively. All peptides, except cyclic peptides, have an N-terminal residue at one end and a C-terminal residue at the other end. Oligopeptides consist of only a small number of amino acids (usually 2-20). Polypeptides are longer, continuous, unbranched peptide chains. Peptides are distinguished from proteins based on size and, as an arbitrary standard, can be understood to contain approximately 50 amino acids or less. Proteins usually consist of one or more polypeptides arranged in a biologically functional manner. While aspects of the laboratory techniques used for peptides versus polypeptides and proteins (e.g., details of electrophoresis, chromatography, etc.) differ, the size boundary that distinguishes peptides from polypeptides and proteins is not absolute. Thus, in the context of the present invention, the terms "peptide," "polypeptide," and "protein" may be used interchangeably, with the term "polypeptide" being preferred in many cases. The terms "peptide," "polypeptide," and "protein" also refer to naturally occurring modified peptides / polypeptides / proteins, where the modification has been achieved by post-translational modifications such as glycosylation, acetylation, and phosphorylation. A "peptide," "polypeptide," or "protein," as referred to herein, may also be chemically modified. Such modifications are well known in the art and are described herein below.

[0091] The terms "bind (specifically or immunospecifically) to," "recognize (specifically or immunospecifically) to," or "react (specifically or immunospecifically) with," according to the present invention, mean that an antibody or binding domain interacts or immunospecifically interacts with a given epitope on a target molecule (antigen), here MUC17. This interaction or binding occurs more frequently, more rapidly, with longer duration, with higher affinity, or some combination of the above, to an epitope on a specific target compared to alternative substances (non-target molecules). However, due to sequence similarity between homologous proteins in different species, an antibody or binding domain that immunospecifically binds to its target (such as a human target) may cross-react with a homologous target molecule from a different species (e.g., from a non-human primate, e.g., cynomolgus monkey). Thus, the term "specific / immunospecific binding" can include binding of an antibody or binding domain to an epitope in multiple species or to structurally related epitopes.

[0092] In the context of the present invention, the term "epitope" refers to a portion or region of an antigen that is recognized / immunospecifically recognized by a binding domain, antibody, or derivative thereof. Because "epitopes" are antigenic, the term epitope is sometimes also referred to as "antigenic structure" or "antigenic determinant." The portion of a binding domain or antibody that binds to an epitope is called a paratope. Specific binding is believed to be achieved by a specific motif in the amino acid sequence of the binding domain, antibody, and / or antigen. Thus, binding is achieved as a result of its primary, secondary, and / or tertiary structure, as well as potential secondary modifications of said structure. If the paratope specifically interacts with its antigenic determinant, the site may simply bind to the antigen. In some cases, alternatively or additionally, a signal may be elicited by the specific interaction, for example, due to the induction of a conformational change in the antigen, oligomerization of the antigen, etc.

[0093] Epitopes of protein antigens are classified into two categories, conformational epitopes and linear epitopes, based on their structure and interaction with the paratope. Conformational epitopes are composed of discontinuous sections of the antigen's amino acid sequence. The epitope interacts with the paratope based on the antigen's three-dimensional surface features and shape or tertiary structure (folding). Methods for determining the conformation of an epitope include, but are not limited to, X-ray crystallography, two-dimensional nuclear magnetic resonance (2D-NMR) spectroscopy, and site-directed spin labeling and electron paramagnetic resonance (EPR) spectroscopy. In contrast, linear epitopes interact with the paratope based on their primary structure. Linear epitopes are formed by a contiguous sequence of amino acids from the antigen, typically containing at least three or at least four, more commonly at least five, at least six, or at least seven, e.g., about 8 to about 10, amino acids in a unique sequence.

[0094] A method for MUC17 epitope mapping is described below. A predefined region (usually a contiguous stretch of amino acids) within the extracellular domain of human MUC17 protein is exchanged / substituted with the corresponding region of MUC17 from another species (e.g., mouse; however, other species are also contemplated as long as the antibody does not cross-react with that species). This human MUC17 / mouse (or other species) MUC17 chimera can be expressed on the surface of host cells (e.g., CHO cells). Antibody binding can be tested via FACS analysis. If antibody binding to the chimeric molecule is completely abolished or significantly reduced binding is observed, it can be concluded that the region of human MUC17 removed from the chimeric molecule is involved in immunospecific epitope-paratope recognition. The reduction in binding is preferably at least 10%, 20%, 30%, 40%, or 50% compared to binding to human (wild-type) MUC17; more preferably at least 60%, 70%, or 80%, and most preferably 90%, 95%, or even 100% (here, binding to human MUC17 is defined as 100%). Additionally, the epitope mapping analysis described above can be modified by introducing one or more point mutations into the sequence of MUC17. Such point mutations can reflect, for example, differences between human MUC17 and mouse (or other species) MUC17.

[0095] A further method for determining the contribution of specific residues of a target antigen to recognition by an antibody or binding domain is alanine scanning, in which each residue to be analyzed is substituted with alanine, e.g., via site-directed mutagenesis (see, e.g., Morrison KL & Weiss GA. Curr Opin Chem Biol. 2001 Jun;5(3):302-7). Alanine is used because of its non-bulky, chemically inert methyl functional group, which still mimics the secondary structural features of many amino acids other than alanine. Occasionally, bulky amino acids such as valine or leucine can be used when it is desired to preserve the size of the mutated residue.

[0096] The interaction of a monoclonal antibody with an epitope on a target antigen implies that the variable region exhibits recognizable or high affinity for the epitope / target antigen (herein, MUC17) and generally does not exhibit high affinity for proteins or antigens other than the target antigen (notwithstanding cross-reactivity with homologous targets, e.g., from other species, as discussed above). "High affinity" includes binding with an affinity (dissociation constant, KD) of about ≦10 M. Preferably, binding is considered specific when the binding affinity is about ≦10 M, ≦10 M, ≦10 M, or ≦10 M. Thus, it is contemplated that the monoclonal antibodies of the present invention have an affinity (KD) for MUC17 of about ≦10 M, ≦10 M, ≦10 M, or ≦10 M. These values ​​are preferably measured by a surface plasmon resonance assay, such as a Biacore assay.

[0097] Whether an antibody (immuno)specifically reacts with or (immuno)specifically binds to a target can be easily tested, for example, by comparing the affinity of the antibody for a desired target protein or antigen with the affinity of the antibody for a non-target protein or antigen (herein, a protein other than MUC17). Preferably, the antibody of the present invention binds poorly to proteins or antigens other than MUC17, unless any additional binding domains directed against additional targets have been intentionally introduced into the antibody of the present invention. The term "poorly binds" means that the monoclonal antibody of the present invention does not bind to proteins or antigens other than MUC17. Thus, the antibody exhibits a reactivity of ≦30%, preferably ≦20%, more preferably ≦10%, and particularly preferably ≦9%, ≦8%, ≦7%, ≦6%, ≦5%, ≦4%, ≦3%, ≦2%, or ≦1% with proteins or antigens other than MUC17 (where binding to MUC17 is considered 100%). "Reactivity" can be expressed, for example, as an affinity value (see above). It is contemplated that the monoclonal antibodies (or derivatives, binding domains, etc.) of the present invention bind or poorly bind to, do not interact with, do not recognize, do not immunospecifically bind to, or do not interact with human BAFF-R and / or human TACI.

[0098] The antibody of the present invention may be an "in vitro generated antibody" and / or a "recombinant antibody". In the context of the present invention, the term "in vitro generated" refers to an antibody / antibody construct according to the above definition, in which all or part of the variable region (e.g., at least one CDR) is generated by non-immune cell selection on a protein chip (e.g., in vitro phage display), or by any other method in which candidate amino acid sequences can be tested for their ability to bind to an antigen. The term therefore preferably excludes sequences generated solely by genome rearrangement in an animal's immune cells. It is envisioned that antibodies can be produced or obtained by phage display or library screening methods, or by grafting CDR sequences from existing antibodies into a scaffold. A "recombinant antibody" is an antibody generated or produced (among other things) using recombinant DNA technology or genetic engineering.

[0099] A preferred type of amino acid substitution variation of the antibodies of the invention involves substituting one or more residues within the hypervariable regions of the parent antibody structure. Generally, the resulting variants selected for further development will have improved biological properties relative to the parent antibody structure from which they were generated. A convenient method for generating such substitution variants involves affinity maturation using phage display. Briefly, several sites (e.g., 6-7 sites) in the hypervariable regions are mutated to generate all possible amino acid substitutions at each site. The variants thus generated are displayed in a monovalent manner from filamentous phage particles as fusions to the M13 gene III product packaged within each particle. The phage-displayed variants are then screened for biological activity (e.g., binding affinity) as disclosed herein. Alanine scanning mutagenesis can also be performed to identify candidate hypervariable region sites (modification candidates) that significantly contribute to antigen binding. Alternatively, or additionally, it may be beneficial to analyze a crystal structure of the antibody or binding domain in complex with an antigen to identify contact points between the antibody binding domain and its specific antigen. Such contact and adjacent residues are candidates for substitution according to the techniques detailed herein. Once such variants are generated, the panel of variants can be subjected to screening as described herein, and antibodies, antigen-binding fragments thereof, or binding domains with superior properties in one or more relevant assays can be selected for further development.

[0100] According to one embodiment, the antibody is of murine origin. The term "antibody" includes antibodies and binding domains, each having antibody-derived regions (e.g., variable regions or domains and constant regions or domains) that substantially correspond to germline immunoglobulin sequences known in the art. Binding domains of the invention may contain amino acid residues not encoded by germline immunoglobulin sequences (e.g., mutations introduced by random or site-directed mutagenesis in vitro or by somatic mutation in vivo), for example, within the CDRs, particularly CDR3. Antibody binding domains may have at least one, two, three, four, five, or more positions substituted with amino acid residues not encoded by germline immunoglobulin sequences. The definitions of antibody and binding domain used herein also contemplate complete antibodies and binding domains, including only non-artificial and / or genetically modified sequences of antibodies.

[0101] The antibodies of the present invention are contemplated as "isolated" or "substantially pure" antibodies. "Isolated" or "substantially pure," when used to describe antibodies described herein, refers to an antibody that has been identified, separated, and / or recovered from components of its production environment. Preferably, the antibody is free or substantially free from association with all other components from its production environment. Contaminating components of the production environment (e.g., arising from recombinant, transfected cells) may include, for example, substances that may interfere with the diagnostic use of the antibody, such as enzymes, hormones, and other proteinaceous or non-proteinaceous compounds. It is understood that an isolated or substantially pure antibody may constitute 5% to 99.9% by weight of the total protein / polypeptide content in a given sample, depending on the circumstances. The desired antibody may be produced at significantly higher concentrations using inducible or high-expression promoters. The definition encompasses the production of antibodies in a wide variety of organisms and / or host cells known in the art. In certain embodiments, antibodies are purified (1) sufficiently to obtain at least 15 residues of N-terminal or internal amino acid sequence by use of a spinning cup sequenator, or (2) to homogeneity by SDS-PAGE under non-reducing or reducing conditions using Coomassie blue, or preferably silver staining. Ordinarily, however, isolated antibody will be prepared by at least one purification step.

[0102] According to one embodiment of the present invention, the monoclonal antibody or binding domain comprises a VH region comprising VH-CDR1 as set forth in SEQ ID NO: 2, VH-CDR2 as set forth in SEQ ID NO: 3, and VH-CDR3 as set forth in SEQ ID NO: 4, and a VL region comprising VL-CDR1 as set forth in SEQ ID NO: 6, VL-CDR2 as set forth in SEQ ID NO: 7, and VL-CDR3 as set forth in SEQ ID NO: 8.

[0103] It is further envisioned that the antibodies of the invention bind to the same epitope of MUC17 as the antibodies of a), b), or c), above, or compete for binding to MUC17 with the antibodies of a), b), or c), above.

[0104] Whether an antibody or binding domain binds to the same epitope of MUC17 (or the extracellular domain of MUC17) as another given antibody or binding domain can be determined by various analyses, such as epitope mapping using chimeric or mutant MUC17 molecules, as described in WO 2013 / 072406. Other methods for determining epitopes are described herein, such as alanine scanning (see, e.g., Morrison KL & Weiss GA. Curr Opin Chem Biol. 2001 Jun;5(3):302-7), in which each residue in the target amino acid sequence to be analyzed is replaced with alanine, e.g., via site-directed mutagenesis. Alanine is used because of its non-bulky, chemically inert methyl functional group, which still mimics the secondary structural features of many amino acids other than alanine. Occasionally, bulky amino acids such as valine or leucine can be used when it is desired to preserve the size of the mutated residue. This method, in which systematic mutations of amino acids are introduced into the sequence of a target protein and antibody binding to each mutant protein is tested to identify the amino acids that contain the epitope, is also called "site-directed mutagenesis." Other methods available for mapping antibody epitopes on target antigens are high-throughput shotgun mutagenesis epitope mapping, cross-linking coupled mass spectrometry, X-ray cocrystallography, cryo-electron microscopy, and hydrogen-deuterium exchange.

[0105] Whether an antibody competes with another given antibody for binding to an antigen (e.g., MUC17) can be measured by a competitive assay, such as a competitive ELISA. Avidin-conjugated microparticles (beads) can also be used. Similar to an avidin-coated ELISA plate, each of these beads can be used as a substrate for reacting with biotinylated proteins, on which the assay can be performed. The antigen is coated onto the beads, followed by pre-coating with the first antibody. A second antibody is added, and any additional binding is determined. Readings are performed via flow cytometry. Cell-based competitive assays can be used, using either cells that naturally express MUC17 or cells stably or transiently transfected with MUC17. The term "compete for binding," in this context, means that there is at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% competition between two test antibodies, as determined by any one of the assays disclosed above.

[0106] According to one embodiment of the invention, the antibody comprises: a) the VH region contained in SEQ ID NO: 5; b) the VL region shown in SEQ ID NO: 9; or a monoclonal antibody of the present invention, c) binds to the same MUC17 epitope as the antibody in c) or competes with the antibody in c) for binding to MUC17; d) binds to the same MUC17 epitope as the antibody of d) or competes with the antibody of d) for binding to MUC17; or e) binds to the same MUC17 epitope as the antibody of e) or competes with the antibody of e) for binding to MUC17.

[0107] It is envisioned that the monoclonal antibody of the invention (or "first monoclonal antibody") and / or second monoclonal antibody as defined herein binds to MUC17 in a sample. According to one embodiment, the sample may be a biological sample. According to one embodiment, the sample is a human sample, e.g., a human biological sample. The biological sample may be a (human) serum sample, plasma sample, blood sample, bone marrow sample, or tissue sample. The sample may also be a supernatant obtained from a cell culture of (human) bone marrow mononuclear cells or (human) peripheral blood mononuclear cells. The sample may be obtained from a subject (e.g., a human subject) suspected of having or having (diagnosed with) MUC17 or a disease associated with increased MUC17, or a subject undergoing treatment for MUC17 or a disease associated with increased MUC17.

[0108] "Blood" is the bodily fluid of humans and other animals that delivers essential substances (e.g., nutrients and oxygen) to cells and carries metabolic waste products away from them. In vertebrates, blood is composed of blood cells suspended in plasma. Blood plasma or "plasma" is the liquid component of blood in which several types of blood cells are suspended. Plasma is mostly water and contains dissolved proteins (e.g., serum albumin, globulins, fibrinogen, etc.), glucose, clotting factors, electrolytes, hormones, carbon dioxide, and oxygen. Serum is plasma without clotting factors. Therefore, serum contains all plasma proteins not used in clotting. "Bone marrow" is a semisolid tissue that can be found within the spongy or cancellous portion of bone. "Tissue" refers to a level of cellular organization between cells and complete organs. A tissue is an assembly of similar cells of the same origin and their extracellular matrix that perform a specific function together. Organs are then formed by functionally grouping multiple tissues together.

[0109] Covalent modifications of the antibodies of the present invention are also included within the scope of the present invention and are generally, although not necessarily, carried out post-translationally. For example, some types of covalent modifications of antibodies are introduced into the molecule by reacting specific amino acid residues of the antibody with organic derivatizing agents capable of reacting with selected side chains or with the N- or C-terminal residues. Derivatization with bifunctional agents is useful for crosslinking the antibodies of the present invention to water-insoluble support matrices or surfaces for use in various methods, particularly detection methods. Glutaminyl and asparaginyl residues are frequently deamidated to the corresponding glutamyl and aspartyl residues, respectively. Alternatively, these residues are deamidated under mildly acidic conditions. Both forms of these residues are included within the scope of the present invention. Other modifications include hydroxylation of proline and lysine, phosphorylation of the hydroxyl group of seryl or threonyl residues, methylation of the α-amino groups of lysine, arginine, and histidine side chains (TECreighton, Proteins: Structure and Molecular Properties, W.H. Freeman & Co., San Francisco, 1983, pp. 79-86), acetylation of the N-terminal amine, and amidation of any C-terminal carboxyl group.

[0110] According to the present invention, the monoclonal antibody is conjugated to a detectable label. In some embodiments, covalent modification of the monoclonal antibody of the present invention includes the addition of one or more labels (e.g., detectable labels). The label or labeling group can be conjugated to the antibody via a spacer arm of various lengths to reduce potential steric hindrance. Various protein labeling methods are known in the art and can be used to practice the present invention. The term "label" or "labeling group" refers to any detectable label. Generally, labels are divided into various classes depending on the assay in which they will be detected, including, but not limited to, the following examples: a) Radioisotopes or radionuclides (e.g., 3 H, 14 C. 15 N, 35S, 89 Zr, 90 Y, 99 Tc, 111 In, 125 I, 131 Isotopic labels which can be radioactive isotopes or heavy isotopes such as I) b) Magnetic labels (e.g., magnetic particles) c) redox-active moieties d) optical dyes (including but not limited to chromophores, fluorophores, and fluorophores), such as fluorescent groups (e.g., FITC, rhodamine, lanthanide fluorophores), chemiluminescent groups, and fluorophores, which can be either "small molecule" fluorophores or proteinaceous fluorophores; e) Enzymes (e.g., horseradish peroxidase, β-galactosidase, luciferase, alkaline phosphatase) f) Biotinylation group g) A predetermined polypeptide epitope recognized by a secondary reporter (eg, a leucine zipper pair sequence, a binding site for a secondary antibody, a metal binding domain, an epitope tag, etc.).

[0111] "Fluorescent label" refers to any molecule that can be detected through its inherent fluorescent properties. Suitable fluorescent labels include, but are not limited to, fluorescein, rhodamine, tetramethylrhodamine, eosin, erythrosine, coumarin, methylcoumarin, pyrene, malachite green, stilbene, Lucifer Yellow, Cascade Blue J, Texas Red, IAEDANS, EDANS, BODIPY FL, LC Red 640, Cy 5, Cy 5.5, LC Red 705, Oregon Green, Alexa-Fluor dyes (Alexa Fluor 350, Alexa Fluor 430, Alexa Fluor 488, Alexa Fluor 546, Alexa Fluor 568, Alexa Fluor 594, Alexa Fluor 633, Alexa Fluor 660, Alexa Fluor 680), Cascade Blue, Cascade Yellow, and R-phycoerythrin (PE) (Molecular Suitable optical dyes, including fluorophores, are described in Molecular Probes Handbook by Richard P. Haugland.

[0112] Suitable proteinaceous fluorescent labels include green fluorescent proteins, e.g., GFPs of Renilla, Ptilosarcus, or Aequorea species (Chalfie et al., 1994, Science 263:802-805), EGFP (Clontech Laboratories, Inc., Genbank® Accession No. U55762), blue fluorescent proteins (BFP, Quantum Biotechnologies, Inc. 1801 de Maisonneuve Blvd. West, 8th Floor, Montreal, Quebec, Canada H3H 1J9; Stauber, 1998, Biotechniques 24:462-471; Heim et al., 1996, Curr. Biol. 6:178-182), enhanced yellow fluorescent proteins (EYFP, Clontech Laboratories, Inc.), luciferase (Ichiki et al., 1994, Science 263:802-805), and the like. al., 1993, J. Immunol. 150:5408-5417), β-galactosidase (Nolan et al. al., 1988, Proc. Natl. Acad. Sci. USA 85:2603-2607), and Renilla (WO 92 / 15673, WO 95 / 07463, WO 98 / 14605, WO 98 / 26277, WO 99 / 49019, U.S. Pat. Nos. 5,292,658; 5,418,155; 5,683,888; 5,741,668; 5,777,079; 5,804,387; 5,874,304; 5,876,995; and 5,925,558).

[0113] The antibodies of the present invention may also contain additional domains, e.g., useful for isolating the molecule. Domains useful for isolating the antibody may be selected from peptide motifs or secondarily introduced moieties that can be captured by isolation methods, e.g., isolation columns. Non-limiting examples of such additional domains include peptide motifs known as Myc tags, HAT tags, HA tags, TAP tags, GST tags, chitin-binding domains (CBD tags), maltose-binding protein (MBP tags), Flag tags, Strep tags, and variants thereof (e.g., Strep II tags), and His tags. All antibodies disclosed herein characterized by identified CDRs may contain a His tag domain, commonly known as a repeat of consecutive His residues (e.g., five His residues or six His residues (hexahistidine)) within the amino acid sequence of the molecule. The His tag may be located, for example, at the N-terminus or C-terminus of the antibody. In one embodiment, a hexahistidine tag is linked to the C-terminus of an antibody according to the present invention via a peptide bond.

[0114] The present invention further provides polynucleotides / nucleic acid molecules encoding the antibodies of the present invention. Nucleic acid molecules are biopolymers composed of nucleotides. Polynucleotides are biopolymers composed of 13 or more nucleotide monomers covalently linked in a chain. DNA (e.g., cDNA) and RNA (e.g., mRNA) are examples of polynucleotides / nucleic acid molecules with distinct biological functions. Nucleotides are organic molecules that function as monomers or subunits of nucleic acid molecules such as DNA or RNA. Nucleic acid molecules or polynucleotides of the present invention can be double-stranded or single-stranded, linear or circular. It is contemplated that the nucleic acid molecules or polynucleotides are contained within a vector. It is further contemplated that such vectors are contained within a host cell. The host cell is capable of expressing the antibody, for example, after transformation or transfection with the vector or polynucleotide / nucleic acid molecule of the present invention. For this purpose, the polynucleotide or nucleic acid molecule is operably linked to a regulatory sequence.

[0115] The genetic code is a set of rules by which information encoded in genetic material (nucleic acids) is translated into proteins. Biological decoding in living cells is carried out by ribosomes, which use tRNA molecules to transport amino acids and read mRNA three nucleotides at a time, linking the amino acids in the order specified by the mRNA. The code defines how a sequence of triplet nucleotides, called a codon, specifies which amino acid will be added next during protein synthesis. With some exceptions, each three-nucleotide codon in a nucleic acid sequence specifies one amino acid. Because most genes are coded with the exact same code, this particular code is often referred to as the canonical or standard genetic code.

[0116] Codon degeneracy is the redundancy of the genetic code, manifested as a multiplicity of three-base-pair codon combinations that specify an amino acid. Degeneracy arises because there are more codons than there are codable amino acids. Codons encoding an amino acid can differ in any of their three positions; however, most often, this difference is in the second or third position. For example, the codons GAA and GAG both specify glutamic acid and exhibit redundancy, but neither specifies any other amino acid, so there is no ambiguity. The genetic code of various organisms can be biased toward using one of several codons that encode the same amino acid over others, meaning that one will be found more frequently than expected by chance. For example, leucine is specified by six distinct codons, some of which are rarely used. Codon usage tables detailing genomic codon usage for most organisms are available. In recombinant genetic technology, this effect is often exploited by performing a technique called codon optimization, in which polynucleotides are designed using codons preferred by the respective host cells (e.g., cells of human or hamster origin, Escherichia coli cells, or Saccharomyces cerevisiae cells) to, for example, increase protein expression. It is therefore envisioned that the polynucleotide / nucleic acid molecules of the present disclosure are codon-optimized. Nevertheless, polynucleotide / nucleic acid molecules encoding the antibodies of the present invention may be designed using any codons that encode a desired amino acid.

[0117] According to one embodiment, the polynucleotide / nucleic acid molecule of the present invention encoding the antibody of the present invention is in the form of one single molecule or in the form of two or more separate molecules. If the antibody of the present invention is single-chain, the polynucleotide / nucleic acid molecule encoding such a construct will most likely also be in the form of one single molecule. However, it is also envisaged that different components of the antibody (e.g., heavy and light chains) are located on separate polypeptide chains, in which case the polynucleotide / nucleic acid molecule will most likely be in the form of two (or more) separate molecules.

[0118] The same applies to vectors comprising polynucleotide / nucleic acid molecules of the invention. If the antibody of the invention is a single-chain antibody, then one vector may comprise a polynucleotide encoding the antibody at one single location (as one single open reading frame, ORF). Alternatively, one vector may comprise two or more polynucleotide / nucleic acid molecules at separate locations (with individual ORFs), each encoding a different component of the antibody (e.g., heavy and light chains). It is envisioned that vectors comprising polynucleotide / nucleic acid molecules of the invention may be in the form of one single vector or two or more separate vectors. In one embodiment, and for the purpose of expressing an antibody in a host cell, the host cell of the invention should comprise the antibody-encoding polynucleotide / nucleic acid molecule or vector comprising such polynucleotide / nucleic acid molecule in its entirety, meaning that all components of the antibody (whether encoded as one single molecule or in separate molecules / locations) will post-translationally assemble to form together a biologically active antibody of the invention.

[0119] The present invention also provides vectors comprising the polynucleotides / nucleic acid molecules of the present invention. A vector is typically a nucleic acid molecule used as a vehicle to transfer (exogenous) genetic material into cells for replication and / or expression. The term "vector" includes, but is not limited to, plasmids, viruses, cosmids, and artificial chromosomes. Some vectors are specifically designed for cloning (cloning vectors), while others are designed for protein expression (expression vectors). So-called transcription vectors are primarily used to amplify the insert. DNA manipulations are typically performed on E. coli vectors, which contain elements necessary for maintenance in E. coli. However, vectors can also have elements that allow them to be maintained in other organisms, such as yeast, plant, or mammalian cells; these vectors are referred to as shuttle vectors. Insertion of a vector into a target or host cell is typically referred to as transformation for bacterial cells and transfection for eukaryotic cells, while insertion of a viral vector is often referred to as transduction.

[0120] Generally, engineered vectors contain an origin of replication, a multiple cloning site, and a selectable marker. The vector itself is a nucleotide sequence (generally a DNA sequence) that generally contains an insert (transgene) and a larger sequence that serves as the "backbone" of the vector. While the genetic code determines the polypeptide sequence of a given coding region, other genomic regions can influence when and where this polypeptide is produced. Thus, in addition to the transgene insert and backbone, modern vectors can include the following additional features: promoters, genetic markers, antibiotic resistance, reporter genes, targeting sequences, protein purification tags. Vectors called expression vectors (expression constructs) are specifically intended for the expression of a transgene in target cells and generally contain regulatory sequences.

[0121] The term "control sequence" refers to DNA sequences necessary for the expression of an operably linked coding sequence in a host organism. Control sequences suitable for prokaryotes include, for example, a promoter, optionally an operator sequence, and a ribosome binding site. Eukaryotic cells are known to utilize promoters, polyadenylation signals, Kozak sequences, and enhancers.

[0122] A nucleic acid is "operably linked" when it is placed into a functional relationship with another nucleic acid sequence. For example, DNA for a presequence or secretory leader is operably linked to DNA for a polypeptide if it is expressed as a preprotein that participates in the secretion of the polypeptide; a promoter or enhancer is operably linked to a coding sequence if it affects the transcription of the sequence; or a ribosome binding site is operably linked to a coding sequence if it is positioned so as to facilitate translation. Generally, "operably linked" means that the nucleotide sequences being linked are contiguous, and, in the case of a secretory leader, contiguous and in reading phase. Enhancers, however, need not be contiguous. Linking is accomplished by ligation at convenient restriction sites. If such sites do not exist, synthetic oligonucleotide adaptors or linkers are used in accord with conventional practice.

[0123] "Transfection" is the process of intentionally introducing nucleic acid molecules or polynucleotides (including vectors) into target cells. The term is primarily used for non-viral methods in eukaryotic cells. Transduction is often used to describe viral-mediated transfer of nucleic acid molecules or polynucleotides. Transfection of animal cells typically involves creating transient pores or "holes" in the cell membrane to allow uptake of material. Transfection can be performed using biological particles (e.g., viral transfection, also referred to as viral transduction), chemical-based methods (e.g., using calcium phosphate, lipofection, Fugene, cationic polymers, nanoparticles), or physical treatments (e.g., electroporation, microinjection, gene guns, cell squeezing, magnetofection, hydrostatic pressure, impalefection, sonication, optical transfection, heat shock).

[0124] The term "transformation" is used to describe the non-viral transfer of nucleic acid molecules or polynucleotides (including vectors) into bacteria and into non-animal eukaryotic cells, including plant cells. Transformation is therefore the genetic modification of bacteria or non-animal eukaryotic cells resulting from the direct uptake of exogenous genetic material (nucleic acid molecules) from its surroundings through the cell membrane and subsequent integration. Transformation can be carried out by artificial means. For transformation to occur, the cells or bacteria must be in a state of competence, which can occur as a time-limited response to environmental conditions such as starvation and cell density, and can also be artificially induced.

[0125] The present invention further provides host cells transformed or transfected with a polynucleotide / nucleic acid molecule of the present invention or a vector of the present invention. As used herein, the term "host cell" or "recipient cell" is intended to include any individual cell or cell culture that can be or has been a recipient of a vector, exogenous nucleic acid molecule, and / or polynucleotide encoding an antibody of the present invention; and / or the antibody itself. Introduction of the respective material into a cell can be accomplished by transformation, transfection, and the like (see above). The term "host cell" is also intended to include the progeny or potential progeny of a single cell. Because certain modifications may occur in successive generations due to spontaneous, accidental, or deliberate mutation, or due to environmental influences, such progeny may not, in fact, be completely identical (morphologically or in genomic or total DNA complement) to the parent cell, but still be within the scope of the term as used herein. Suitable host cells include prokaryotic or eukaryotic cells, and include, but are not limited to, bacteria (e.g., E. coli), yeast cells, fungal cells, plant cells, and animal cells (e.g., insect cells, and mammalian cells, such as hamster, mouse, rat, macaque, or human cells).

[0126] In addition to prokaryotes, eukaryotic microbes such as filamentous fungi or yeast are suitable cloning or expression hosts for the antibodies of the invention. Saccharomyces cerevisiae, or common baker's yeast, is the most commonly used among lower eukaryotic host microorganisms. However, several other genera, species, and strains are commonly available and useful herein, such as: Schizosaccharomyces pombe, Kluyveromyces genus hosts, e.g., K. lactis, K. fragilis (ATCC 12424), K. bulgaricus (ATCC 16045), K. wickeramii (ATCC 24178), K. waltii (ATCC 56500), K. drosophilarum (ATCC 24178), K. galactosyltransferase ... 36906, K. thermotolerans, and K. marxianus; Yarrowia spp. (EP 402226); Pichia pastoris (EP 183070); Candida spp.; Trichoderma reesia (EP 244234); Neurospora crassa; Schwanniomyces spp., e.g., Schwanniomyces occidentalis; occidentalis); and filamentous fungi such as Neurospora, Penicillium, Tolypocladium, and Aspergillus hosts such as A. nidulans and A. niger.

[0127] Suitable host cells for the expression of glycosylated antibodies are derived from multicellular organisms. Examples of invertebrate cells include plant cells and insect cells. Numerous baculovirus strains and variants have been identified, as well as corresponding permissive insect host cells derived from hosts such as Spodoptera frugiperda (caterpillar), Aedes aegypti (mosquito), Aedes albopictus (mosquito), Drosophila melanogaster (fruit fly), and Bombyx mori. Various virus strains for transfection (e.g., the L-1 variant of Autographa californica NPV and the Bm-5 strain of Bombyx mori NPV) are publicly available, and such viruses may be used as viruses according to the invention herein, particularly for transfection of Spodoptera frugiperda cells.

[0128] Plant cell cultures of cotton, corn, potato, soybean, petunia, tomato, Arabidopsis, and tobacco can also be used as hosts. Cloning and expression vectors useful for producing proteins in plant cell cultures are known to those skilled in the art. See, for example, Hiatt et al., Nature (1989) 342:76-78, Owen et al. (1992) Bio / Technology 10:790-794, Artsaenko et al. (1995) The Plant J 8:745-750, and Fecker et al. (1996) Plant Mol Biol 32:979-986.

[0129] However, most interest has been in vertebrate cells, and propagation of vertebrate cells in culture (cell culture) has become a routine procedure. Examples of useful mammalian host cell lines include SV40-transformed monkey kidney CV1 lines (e.g., COS-7, ATCC CRL 1651); human embryonic kidney lines (e.g., 293 cells, or 293 cells subcloned for growth in suspension culture, Graham et al., J. Gen Virol. 36:59 (1977)); baby hamster kidney cells (e.g., BHK, ATCC CCL 10); Chinese hamster ovary cells / -DHFR (e.g., CHO, Urlaub et al., Proc. Natl. Acad. Sci. USA 77:4216 (1980)); mouse Sertoli cells (e.g., TM4, Mather, Biol. Reprod. 23:243-251 (1980)); monkey kidney cells (e.g., CVI ATCC CCL 70); African green monkey kidney cells (e.g., VERO-76, ATCC CRL 1587); human cervical carcinoma cells (e.g., HELA, ATCC CCL 2); canine kidney cells (e.g., MDCK, ATCC CCL 34); buffalo rat hepatocytes (e.g., BRL 3A, ATCC CRL 1442); human lung cells (e.g., W138, ATCC CCL 75); human hepatocytes (e.g., Hep G2, 1413 8065); mouse mammary tumor (e.g., MMT 060562, ATCC CCL-51); TRI cells (Mather et al., Annals NY Acad. Sci. (1982) 383:44-68); MRC 5 cells; FS4 cells; and human hepatoma lines (e.g., Hep G2).

[0130] In a further embodiment, the invention provides a process for producing an antibody of the invention, said process comprising culturing a host cell of the invention under conditions permissive for expression of an antibody of the invention, and recovering the antibody produced from the culture.

[0131] As used herein, the term "culturing" refers to the in vitro maintenance, differentiation, growth, proliferation, and / or propagation of cells under appropriate conditions in a medium. Cells are grown and maintained in a cell growth medium at an appropriate temperature and gas mixture. Culture conditions vary widely depending on the cell type. Typical growth conditions are a temperature of about 37°C, a CO2 concentration of about 5%, and a humidity of about 95%. Growth medium recipes can vary, for example, in pH, concentration of the carbon source (e.g., glucose), the nature and concentration of growth factors, and the presence of other nutrients (e.g., amino acids or vitamins). Growth factors used in supplemented media are often derived from serum from animal blood (e.g., fetal bovine serum (FBS), calf serum (FCS), horse serum, and porcine serum). Cells can be grown in suspension culture or as adherent cultures. Cell lines also exist that have been modified to survive in suspension culture and thus can grow to higher densities than in adherent conditions.

[0132] The term "expression" includes all steps involved in producing an antibody of the present invention, including, but not limited to, transcription, post-transcriptional modification, translation, folding, post-translational modification, targeting to a specific intracellular or extracellular location, and secretion. The term "recovery" refers to a series of processes intended to isolate an antibody from cell culture. The "recovery" or "purification" process separates protein and non-protein components of the cell culture, ultimately separating the desired antibody from all other polypeptides and proteins. Separation steps typically exploit differences in protein size, physicochemical properties, binding affinity, and biological activity. Preparative purification aims to produce relatively large amounts of purified protein for subsequent use, while analytical purification produces relatively small amounts of protein for various research or analytical purposes.

[0133] When using recombinant techniques, antibodies can be produced intracellularly in the periplasmic space or directly secreted into the culture medium. If the antibody is produced intracellularly, as a first step, particulate debris of the host cell or lysed fragments is removed, for example, by centrifugation or ultrafiltration. The antibody of the present invention can be produced in bacteria, such as E. coli. After expression, the construct can be isolated from the bacterial cell paste in a soluble fraction and purified, for example, via affinity chromatography and / or size exclusion. Final purification can be carried out similarly to the purification process for antibodies expressed in mammalian cells and secreted into the culture medium. Carter et al. (Biotechnology (NY) 1992 Feb;10(2):163-7) describe a procedure for isolating antibodies secreted into the periplasmic space of E. coli.

[0134] Where the antibody is secreted into the medium, supernatants from such expression systems are generally first concentrated using a commercially available protein concentration filter, e.g., an ultrafiltration unit.

[0135] Antibodies of the present invention prepared from host cells can be recovered or purified using, for example, hydroxyapatite chromatography, gel electrophoresis, dialysis, and affinity chromatography. Depending on the antibody to be recovered, other protein purification techniques may also be used, such as fractionation on an ion exchange column, mixed-mode ion exchange, HIC, ethanol precipitation, size exclusion chromatography, reverse-phase HPLC, silica chromatography, heparin Sepharose chromatography, anion or cation exchange resin chromatography (e.g., polyaspartic acid column), immunoaffinity (e.g., protein A / G / L) chromatography, chromatofocusing, SDS-PAGE, ultracentrifugation, and ammonium sulfate precipitation. In any of the above steps, protease inhibitors may be included to inhibit proteolysis, and antibiotics may be included to prevent the growth of contaminants.

[0136] The present invention further provides compositions or formulations comprising the antibodies of the present invention or antibodies produced according to the processes of the present invention. The compositions are preferably diagnostic compositions. As used herein, the term "diagnostic composition" refers to a composition suitable for use in a diagnostic kit or detection system. One possible diagnostic composition of the present invention comprises one or more antibodies of the present invention, preferably in an amount useful for detecting MUC17 in a sample. The diagnostic composition may further comprise an appropriate formulation of one or more carriers, stabilizers, excipients, diluents, solubilizers, surfactants, emulsifiers, preservatives, and / or adjuvants. Diagnostic compositions of the present invention include, but are not limited to, liquid compositions, frozen compositions, and lyophilized compositions.

[0137] The composition may include a carrier, e.g., a diagnostically acceptable carrier. Generally, as used herein, "diagnotically acceptable carrier" refers to all aqueous and non-aqueous solutions, sterile solutions, solvents, buffers (e.g., phosphate-buffered saline (PBS) solutions), water, suspensions, emulsions (e.g., oil / water emulsions), various wetting agents, liposomes, dispersion media, and coatings that are compatible with diagnostic use. The use of such media and agents in diagnostic compositions is well known in the art, and compositions containing such carriers can be formulated by well-known conventional methods.

[0138] Certain embodiments provide diagnostic compositions comprising an antibody of the invention and one or more additional excipients, such as those illustratively described in this section and elsewhere herein. Excipients may be used in the invention for a variety of purposes, such as adjusting the physical, chemical, or biological properties of the formulation (e.g., adjusting viscosity), and / or may be used in the processes of the invention to improve efficacy and / or stabilize such formulations and processes against degradation and spoilage due to, for example, stresses encountered during and after manufacturing, shipping, storage, preparation for use, and administration. Excipients should generally be used at their lowest effective concentration.

[0139] In certain embodiments, diagnostic compositions may contain formulation materials to modify, maintain, or preserve certain characteristics of the composition, such as pH, osmolality, viscosity, clarity, color, isotonicity, odor, sterility, stability, dissolution or release rate, adsorption, or permeation (see Remington's Pharmaceutical Sciences, 18th Edition, 1990, Mack Publishing Company). In such embodiments, suitable formulation materials may include, but are not limited to: ·amino acid Antimicrobial agents such as antibacterial and antifungal agents Antioxidants Buffers, buffer systems, and buffering agents used to maintain the composition at or slightly below physiological pH, typically within a pH range of about 5 to about 8 or 9. Non-aqueous solvents, vegetable oils, and injectable organic esters Aqueous carriers such as water, alcoholic / aqueous solutions, emulsions, or suspensions, e.g., saline and buffered media Biodegradable polymers such as polyester Bulking agent Chelating agents Isotonic and absorption retarding agents Complexing agents Fillers ·carbohydrates Preferably, a (low molecular weight) protein, polypeptide or proteinaceous carrier of human origin Coloring agents and flavoring agents Sulfur-containing reducing agent Diluents ·emulsifier Hydrophilic polymer Salt-forming counterions Preservatives Metal complexes Solvents and co-solvents Sugars and sugar alcohols Suspension agents Surfactants or wetting agents Stability enhancer Tonicity enhancer Parenteral delivery vehicle Intravenous delivery vehicle.

[0140] It is common knowledge that various components of a diagnostic composition may have different effects, for example, amino acids may serve as buffers, stabilizers, and / or antioxidants; mannitol may serve as a bulking agent and / or tonicity enhancer; sodium chloride may serve as a delivery vehicle and / or tonicity enhancer, etc.

[0141] According to a further aspect, the present invention provides a detection system comprising: a) a first monoclonal antibody (or derivative thereof) that binds to MUC17, and b) optionally a second monoclonal antibody (or derivative thereof) that binds to MUC17, wherein binding of the first monoclonal antibody (or derivative thereof) to MUC17 occurs in the presence of the second monoclonal antibody (or derivative thereof) that binds to MUC17.

[0142] The present invention also provides a detection system comprising: a) a first monoclonal antibody (or derivative thereof) that binds to MUC17, and b) optionally a second monoclonal antibody (or derivative thereof) that binds to MUC17, wherein binding of the second monoclonal antibody (or derivative thereof) to MUC17 occurs in the presence of the first monoclonal antibody (or derivative thereof) that is bound to MUC17.

[0143] The present invention also provides a detection system comprising: a) a first monoclonal antibody (or derivative thereof) that binds to MUC17, and b) optionally a second monoclonal antibody (or derivative thereof) that binds to MUC17, wherein binding of the first monoclonal antibody (or derivative thereof) to MUC17 occurs in the presence of the second monoclonal antibody (or derivative thereof) that binds to MUC17, and binding of the second monoclonal antibody (or derivative thereof) to MUC17 occurs in the presence of the first monoclonal antibody (or derivative thereof) that binds to MUC17.

[0144] A "detection system" is a kit or tool (or diagnostic kit / tool) containing reagents for performing an analytical assay. In the context of the present invention, the assay detects and / or quantifies the presence of MUC17 in a sample (usually a liquid sample). The detection system includes an antibody that binds to MUC17. Typically, the detection system involves the use of a solid support (e.g., a microtiter plate or membrane) that serves as a surface for immobilizing either the antigen to be detected (e.g., in the case of a "direct ELISA"), or a (monoclonal) antibody that binds to MUC17 (the "capture antibody") or a "secondary antibody" (e.g., an anti-Fc antibody) that binds to the antibody that binds MUC17 (the capture antibody). Generally, the immobilization occurs nonspecifically (via adsorption to the surface) or specifically (via capture by an antibody, such as a secondary antibody). The detection system may further comprise a (monoclonal) detection antibody that binds to MUC17 (optionally conjugated to an enzyme, detectable label, or reporter group), and optionally a second antibody (e.g., an anti-Fc antibody) that binds to the detection antibody and is also conjugated to an enzyme, detectable label, or reporter group.

[0145] A very well-known detection system is the ELISA assay, which can be used for the purposes of the present invention. A "sandwich" ELISA is used to detect a sample antigen or to quantify an unknown amount of the antigen. The process can include the following: a surface is prepared to which a known amount of a so-called "capture antibody" is bound. This binding can occur directly through adsorption of the capture antibody to the surface, or through a second antibody (e.g., an anti-Fc antibody) that is adsorbed to the surface and binds to the capture antibody. Any nonspecific binding sites on the surface are blocked. An antigen-containing sample is applied to the surface, and the antigen is captured (bound) by the antibody. The plate is washed to remove unbound antigen. A "detection antibody" is added and binds to the antigen. The detection antibody can be conjugated (e.g., covalently linked) to an enzyme, detectable label, or reporter group. Otherwise, a second antibody conjugated to an enzyme, detectable label, or reporter group and that binds to the detection antibody (e.g., the Fc region of the detection antibody) is applied. The plate is washed to remove any unbound antibody. A chemical substrate is added that is converted (e.g., by an enzyme) to a detectable form (e.g., an optical (e.g., color or fluorescence) or electrochemical signal). The absorbance or fluorescence or electrochemical signal (e.g., current) of the plate well or surface is measured to determine the presence and / or amount of antigen.

[0146] Commonly used enzyme markers include: - OPD (o-phenylenediamine dihydrochloride) produces an amber color, which is often used as a conjugate protein to detect horseradish peroxidase (HRP) - TMB (3,3',5,5'-tetramethylbenzidine) turns blue when it detects HRP and turns yellow when it detects sulfuric acid or phosphoric acid. - ABTS (2,2'-azinobis[3-ethylbenzothiazoline-6-sulfonic acid]-diammonium salt) turns green when HRP is detected. - PNPP (p-nitrophenyl phosphate disodium salt) turns yellow when alkaline phosphatase is detected.

[0147] Traditional ELISAs typically involve a chromogenic reporter and substrate that can produce an observable color change to indicate the presence of the antigen. Newer ELISA-like technologies use fluorescent, electrochemiluminescent, and quantitative PCR reporters to generate a quantifiable signal. These novel reporters may have various advantages, such as higher sensitivity and multiplexing. In technical terms, these assays are not strictly "ELISAs" because they are not "enzyme-linked" but are instead linked to several non-enzymatic reporters. However, given the broad similarity of the general principles of these assays, these assays are often classified in the same category as ELISAs.

[0148] The detection system can be used in a qualitative format or in a quantitative format. A qualitative result provides a simple positive or negative result (yes or no) for the sample. The cutoff between positive and negative can be statistical. Often, 2-3 times the standard deviation (the error inherent in the test) is used to distinguish positive from negative samples. In a quantitative format, the optical density (OD) or electrochemical signal of the sample is compared to a standard curve, which is typically a serial dilution of a solution of known concentration of the target molecule.

[0149] The present invention also provides a detection system, wherein the first monoclonal antibody (or binding domain) of the detection system is a) comprising a VH region comprising VH-CDR1 shown in SEQ ID NO: 2, VH-CDR2 shown in SEQ ID NO: 3, and VH-CDR3 shown in SEQ ID NO: 4, and a VL region comprising VL-CDR1 shown in SEQ ID NO: 6, VL-CDR2 shown in SEQ ID NO: 7, and VL-CDR3 shown in SEQ ID NO: 8; b) binds to the same MUC17 epitope as the antibody in a) or competes with the antibody in a) for binding to MUC17; or c) binds to the same MUC17 epitope as the antibody in b) or competes with the antibody in b) for binding to MUC17.

[0150] The present invention also provides a detection system, the monoclonal antibody of which is: a) comprises a VH region contained in SEQ ID NO: 5; b) comprises a VL region contained in SEQ ID NO: 7; c) comprises a VH region contained in SEQ ID NO: 5 and a VL region contained in SEQ ID NO: 7; d) binds to the same MUC17 epitope as the antibody in c) or competes with the antibody in c) for binding to MUC17; or e) binds to the same MUC17 epitope as the antibody in d) or competes with the antibody in d) for binding to MUC17.

[0151] It is envisioned that the detection system uses a first monoclonal antibody as a capture antibody and a second monoclonal antibody as a detection antibody.

[0152] In a further aspect, the present invention provides a method for producing a pharmaceutical composition comprising: - Detect MUC17 in the sample; - Quantify MUC17 in the sample; - Diagnosing MUC17 or a disease associated with increased MUC17; - stratify patients diagnosed with MUC17 or diseases associated with increased MUC17; - monitoring the progression of MUC17 or a disease associated with increased MUC17; or - monitoring the response to treatment of MUC17 or a disease associated with increased MUC17 The present invention also provides use of the antibody of the present invention or the detection system of the present invention for the purpose of detecting a cancer.

[0153] In one embodiment, the sample is a biological sample, e.g., a human biological sample. The sample (biological sample / human biological sample) can be a serum sample, plasma sample, blood sample, bone marrow sample, or tissue sample. The sample can also be a supernatant obtained from a cell culture of bone marrow mononuclear cells or peripheral blood mononuclear cells. The sample can be obtained from a subject (e.g., a human subject) suspected of having or having (diagnosed with) MUC17 or a disease associated with increased MUC17, or a subject undergoing treatment for MUC17 or a disease associated with increased MUC17. In a specific embodiment, the sample is a tissue sample derived from a tissue suspected of being affected by neoplastic growth (i.e., cancerous).

[0154] A disease is a specific abnormal condition that adversely affects part or all of the structure or function of an organism, such as a human, and is not caused by any trauma. A disease is often interpreted as a "pathological condition" or "disorder" with specific signs and symptoms. The disease according to the present invention is associated with MUC17 or an increase in MUC17. The term "enhancement" is used in comparison to a healthy subject (i.e., a subject not having such a disease). According to one embodiment, the disease associated with MUC17 or an increase in MUC17 is a "MUC17-positive neoplasm."

[0155] A "neoplasm" is an abnormal growth of tissue, usually, but not always, forming a mass. When a mass forms, it is commonly referred to as a "tumor." In brain tumors, uncontrolled cell division means that the neoplastic mass expands in size, and in confined spaces such as the intracranial cavity, this quickly becomes problematic as the mass invades and displaces the brain, leading to compression of brain tissue, increased intracranial pressure, and parenchymal destruction. In accordance with the present invention, "neoplasm" or "tumor" also refers to conditions that would benefit from treatment with therapies directed against MUC17, particularly MUC17 expressed on the cell surface, such as MUC17-specific antibodies, including naked antibodies and antibody-drug conjugates (ADCs). This condition includes chronic and acute disorders or diseases, including those conditions that predispose a mammal to the condition (neoplasm or tumor) in question.

[0156] Neoplasms or tumors can be benign, potentially malignant (precancerous), or malignant (cancerous). Malignant neoplasms / tumors are commonly referred to as cancers. Malignant neoplasms / tumors usually invade and destroy surrounding tissues and may form metastases, i.e., spread to other parts, tissues, or organs of the body. A "primary tumor" is a tumor that grows at an anatomical site where tumor progression begins and progresses, resulting in a cancerous mass. For example, gastrointestinal tumors arise when abnormal cells form in the digestive tract. Most cancers develop at their primary site but then go on to form metastases or spread to other parts of the body (e.g., tissues and organs). This additional tumor is a secondary tumor. Most cancers continue to be called after their primary site even after they have spread to other parts of the body.

[0157] For purposes of the present invention, the terms "neoplasm," "tumor," and "cancer" may be used interchangeably and include both primary tumors / cancers and secondary tumors / cancers (or "metastases"), as well as MRD. The term "minimal residual disease" (MRD) refers to evidence of the presence of a small number of residual cancer cells remaining in a patient after cancer treatment, for example, when the patient is in remission (the patient has no symptoms or signs of disease). These very small numbers of residual cancer cells are usually undetectable by conventional means because standard tests used to evaluate or detect cancer are insufficiently sensitive to detect MRD. Recently, highly sensitive molecular biological MRD tests, such as flow cytometry, PCR, and next-generation sequencing, have become available. These tests can sometimes measure minimal levels of cancer cells in a tissue sample, such as as little as one cancer cell per million normal cells. In the context of the present invention, the terms "prevention," "treatment," or "amelioration" of a neoplasm are intended to encompass "prevention, treatment, or amelioration of MRD," regardless of whether MRD is detected.

[0158] "MUC17 or a disease associated with increased MUC17," "MUC17-positive neoplasm," or "(MUC17-positive) neoplasm" may be selected from the group including, but not limited to:

[0159] "Diagnosis" or "medical diagnosis" is the process of determining which disorder or condition explains a subject's disease symptoms and signs. Usually, during this process, one or more diagnostic procedures, such as diagnostic tests or medical tests, are performed. In medicine, the term "monitoring" refers to the observation of a disease, a condition, or one or several medical parameters over time. Monitoring can be performed by continuously measuring a specific parameter by using a medical monitor and / or by repeatedly performing medical tests. Diagnostic tests or medical tests are medical procedures performed to detect, diagnose, or monitor a disease, disease process, susceptibility, and / or to determine the course of treatment. Diagnostic tests or medical tests are related to clinical chemistry and molecular diagnostics, and the procedures are typically performed in a medical laboratory.

[0160] Medical therapy or treatment is an effort to cure or ameliorate disease. In the medical field, a common treatment involves pharmaceuticals. Pharmaceuticals (also called drugs, pharmaceuticals, or medications) are used to diagnose, cure, treat, or prevent disease. Thus, the term "treatment" refers to both therapeutic treatment and prophylactic or preventative measures.

[0161] In a further aspect, the present invention also provides a method for detecting and / or quantifying MUC17 in a sample, comprising: (a) using an antibody of the invention or using a detection system of the invention to determine the content of MUC17 in a sample; (b) measuring the amount of MUC17 determined in step (a) by: (i) a predefined value for MUC17 content; (ii) the content of MUC17 determined in a control sample; or (iii) the content of MUC17 determined in a sample obtained from the same source or subject at a previous time point and a process of comparing The present invention provides a method comprising:

[0162] For purposes of the present invention, the terms "quantity" or "content" (of MUC17) may be used interchangeably with the terms "level," "amount," or "concentration" (of MUC17). A "predefined value for MUC17 content" may be a predetermined "cutoff value." The value may indicate, for example, that a particular MUC17 content in a sample is indicative of MUC17 or a disease associated with increased MUC17, or is indicative of a MUC17-positive neoplasm. For example, if the MUC17 content in a sample is determined to be three standard deviations away from the predetermined cutoff value, the subject from which the sample was obtained is considered positive for gastrointestinal cancer (or other diseases described herein). A "control sample" is typically obtained from a source of the same nature as the sample to be analyzed. The control sample may be a sample representing "normal" MUC17 content (e.g., representing a healthy subject) (a "negative control sample"), or may be a sample representing "abnormally elevated" MUC17 content (e.g., representing a subject with a disease as defined herein) (a "positive control sample").

[0163] In a further aspect, the present invention provides a method for diagnosing MUC17 or a disease associated with increased MUC17, comprising: (a) using an antibody of the invention or using a detection system of the invention to determine the content of MUC17 in a sample; (b) measuring the amount of MUC17 determined in step (a) by: (i) a predefined cutoff value for MUC17 content that indicates the absence of such a disease, or (ii) the content of MUC17 determined in a control sample, representing the absence of such disease; and a process of comparing Including, wherein a higher content of MUC17 determined in step (a) compared to the predefined cutoff value in (i) or the content of MUC17 determined in a control sample in (ii) indicates the presence of MUC17 or a disease associated with increased MUC17.

[0164] In a further aspect, the invention provides a method for monitoring the progression of MUC17 or a disease associated with increased MUC17, or monitoring the response to treatment of MUC17 or a disease associated with increased MUC17, comprising: (a) using an antibody of the invention or using a detection system of the invention to determine the content of MUC17 at a first time point in a biological sample obtained from a subject diagnosed with such a disease; (b) using an antibody of the invention or using a detection system of the invention to determine the content of MUC17 in a biological sample obtained from the subject at a second (later) time point or after treatment; (c) comparing the amount of MUC17 determined in step (a) with the amount of MUC17 determined in step (b); Including, wherein a higher content of MUC17 determined in step (a) compared to the content of MUC17 determined in step (b) indicates that the disease is progressing, and / or a lower content of MUC17 determined in step (a) compared to the content of MUC17 determined in step (b) indicates that the disease is entering remission or that the disease is responding to treatment.

[0165] With respect to the above methods, it is envisioned that the "sample" is a biological sample, e.g., a human biological sample. The sample may be a (human) tissue sample or a (human) cell culture. A "sample," as defined above, may also be obtained from a human subject, preferably a human subject suspected of having or having (diagnosed with) MUC17 or a disease associated with increased MUC17, or a subject undergoing treatment for MUC17 or a disease associated with increased MUC17.

[0166] With respect to the above method, it is contemplated that the "disease associated with MUC17 or increased MUC17" may be a MUC17-positive neoplasm. The disease or MUC17-positive neoplasm may be selected from the group consisting of gastric cancer, esophageal cancer, gastroesophageal cancer (including gastroesophageal junction cancer), gastrointestinal cancer, and pancreatic cancer.

[0167] The present invention also contemplates the following: Item 1. A monoclonal antibody that may or may not bind to soluble MUC17 (MUC17), wherein binding of the antibody to MUC17 occurs in the presence of a second monoclonal antibody that binds to MUC17. Item 2. The monoclonal antibody according to Item 1, wherein MUC17 has the amino acid sequence set forth in SEQ ID NO: 1. Item 3. The monoclonal antibody of item 1 or 2, wherein binding of the monoclonal antibody to MUC17 occurs in the presence of a third antibody that binds to MUC17. Item 4. The monoclonal antibody according to any one of Items 1 to 3, wherein the monoclonal antibody comprises a VH region and / or a VL region of a rodent, for example, a mouse or rabbit. Item 5. Affinity (KD) for MUC17 is about ≦10 -7 M, ≤10 -8 M, ≤10 -9 M, or ≦10 -10 5. The monoclonal antibody according to any one of items 1 to 4, wherein the antibody is M. Item 6. The monoclonal antibody of claim 5, wherein the affinity is determined by a Biacore assay. Item 7. a) comprising a VH region comprising VH-CDR1 shown in SEQ ID NO: 2, VH-CDR2 shown in SEQ ID NO: 3, and VH-CDR3 shown in SEQ ID NO: 4, and a VL region comprising VL-CDR1 shown in SEQ ID NO: 6, VL-CDR2 shown in SEQ ID NO: 7, and VL-CDR3 shown in SEQ ID NO: 8; b) binds to the same MUC17 epitope as the antibody in a) or competes with the antibody in a) for binding to MUC17; c) binds to the same MUC17 epitope as the antibody in b) or competes with the antibody in b) for binding to MUC17; or d) The monoclonal antibody according to any one of items 1 to 6, which binds to the same MUC17 epitope as the antibody of c) or competes with the antibody of c) for binding to MUC17. Item 8. a) a VH region comprising an amino acid sequence that is at least 60%, 65%, or 70%, preferably at least 75% or 80%, more preferably at least 85%, 90%, 91%, 92%, 93%, 94%, and most preferably 95%, 96%, 97%, 98%, or 99% homologous to the VH region of SEQ ID NO: 5; and a VL region comprising at least 60%, 65%, or 70%, preferably at least 75% or 80%, more preferably at least 85%, 90%, 91%, 92%, 93%, 94%, and most preferably 95%, 96%, 97%, 98%, or 99% homologous to the VL region of SEQ ID NO: 9. 92%, 93%, 94%, and most preferably 95%, 96%, 97%, 98%, or 99% homologous to the VH-CDR1 of SEQ ID NO: 2, the VH-CDR2 of SEQ ID NO: 3, and the VH-CDR3 of SEQ ID NO: 4, and optionally the VL-CDR1 of SEQ ID NO: 6, the VL-CDR2 of SEQ ID NO: 7, and the VL-CDR3 of SEQ ID NO: 8. Item 9. a) comprises a VH region contained in SEQ ID NO: 5; b) comprises a VL region contained in SEQ ID NO: 9; c) comprises a VH region contained in SEQ ID NO: 5 and a VL region contained in SEQ ID NO: 9; d) binds to the same MUC17 epitope as the antibody in c) or competes with the antibody in c) for binding to MUC17; e) binds to the same MUC17 epitope as the antibody of d) or competes with the antibody of d) for binding to MUC17; or f) binds to the same MUC17 epitope as the antibody of e) or competes with the antibody of e) for binding to MUC17; Item 7. The monoclonal antibody according to item 7. Item 10. The monoclonal antibody of any one of items 6 to 9, wherein binding to the MUC17 epitope is determined via epitope mapping with chimeric or mutant MUC17 molecules, site-directed mutagenesis (e.g., alanine scanning), high-throughput shotgun mutagenesis epitope mapping, crosslinking-coupled mass spectrometry, X-ray co-crystallography, cryo-electron microscopy, and hydrogen-deuterium exchange. Item 11. The monoclonal antibody according to any one of Items 6 to 9, wherein the competition for binding to MUC17 is determined by a competitive ELISA assay, an Octet competitive assay, or a competitive assay using avidin-conjugated microparticles. Item 12. The monoclonal antibody according to any one of items 6 to 9 or item 11, wherein competition for binding to MUC17 is defined as at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% competition between the two tested antibodies. Item 13. The monoclonal antibody according to any one of Items 1 to 12, which is an IgG antibody, an IgD antibody, an IgE antibody, an IgM antibody, or an IgA antibody, preferably an IgG antibody, for example, an IgG1 antibody, an IgG2 antibody, an IgG3 antibody, or an IgG4 antibody. Item 14. The monoclonal antibody according to any one of items 1 to 13, wherein the monoclonal antibody and / or second monoclonal antibody binds to MUC17 in a biological sample, preferably a human biological sample, such as a (human) serum sample, a (human) plasma sample, a (human) blood sample, a (human) bone marrow sample, a (human) tissue sample, in particular a tissue sample from the stomach, the digestive tract, the esophagus, the gastroesophageal junction, and the pancreas. Item 15. A polynucleotide encoding the monoclonal antibody according to any one of Items 1 to 14. Item 16. A vector comprising the polynucleotide according to Item 15. Item 17. A host cell transformed or transfected with the polynucleotide according to Item 15 or the vector according to Item 16. Item 18. A process for producing the monoclonal antibody according to any one of items 1 to 14, comprising culturing the host cell according to item 17 under conditions permissive for expression of the monoclonal antibody, and recovering the produced monoclonal antibody from the culture. Item 19. A composition comprising the monoclonal antibody according to any one of Items 1 to 14 or the monoclonal antibody produced according to the process according to Item 18. Item 20. A detection system, a) a first monoclonal antibody that binds to MUC17; and b) a second monoclonal antibody that binds to MUC17; and Including, A detection system wherein the binding of a first monoclonal antibody to MUC17 occurs in the presence of a second monoclonal antibody that binds to MUC17, and / or the binding of the second monoclonal antibody to MUC17 occurs in the presence of the first monoclonal antibody that binds to MUC17. Item 21. The detection system according to Item 20, wherein MUC17 has the amino acid sequence set forth in SEQ ID NO: 1. Item 22. The detection system according to Item 20 or 21, wherein the binding of the first monoclonal antibody to MUC17 and the binding of the second monoclonal antibody to MUC17 occurs in the presence of a third antibody that binds to MUC17. Item 23. The detection system according to any one of Items 20 to 23, wherein the first monoclonal antibody and / or the second monoclonal antibody comprises a mouse VH region and / or a mouse VL region. Item 24. The first monoclonal antibody and / or the second monoclonal antibody has an affinity (KD) for MUC17 of about ≦10 -7 M, ≤10 -8 M, ≤10 -9 M, or ≦10 -10 24. The detection system according to any one of items 20 to 23, wherein M. Item 25. The first monoclonal antibody is a) a VH region comprising a VH-CDR1 shown in SEQ ID NO: 2, a VH-CDR2 shown in SEQ ID NO: 3, and a VH-CDR3 shown in SEQ ID NO: 4, and a VL region comprising a VL-CDR1 shown in SEQ ID NO: 6, a VL-CDR2 shown in SEQ ID NO: 7, and a VL-CDR3 shown in SEQ ID NO: 8; or 25. The detection system of any one of items 20 to 24, wherein b) the antibody of a) or b) binds to the same MUC17 epitope as the antibody of a) or b) or competes with the antibody of a) for binding to MUC17. Item 26. The detection system according to any one of Items 20 to 26, wherein the first monoclonal antibody and / or the second monoclonal antibody is an IgG antibody, an IgD antibody, an IgE antibody, an IgM antibody, or an IgA antibody, preferably an IgG antibody, for example, an IgG1 antibody, an IgG2 antibody, an IgG3 antibody, or an IgG4 antibody. Item 27. The detection system according to any one of Items 20 to 26, wherein the first monoclonal antibody is used as a capture antibody and the second monoclonal antibody is used as a detection antibody, or the first monoclonal antibody is used as a detection antibody and the second monoclonal antibody is used as a capture antibody. Item 28. The monoclonal antibody according to any one of Items 1 to 14 or the detection system according to any one of Items 20 to 27, - Detect MUC17 in the sample; - Quantify MUC17 in the sample; - Diagnosing MUC17 or a disease associated with increased MUC17; - stratify patients diagnosed with MUC17 or diseases associated with increased MUC17; - monitoring the progression of MUC17 or a disease associated with increased MUC17; or - monitoring response to treatment of MUC17 or diseases associated with increased MUC17 For use. Item 29. A method for detecting and / or quantifying MUC17 in a sample, comprising: (a) using the monoclonal antibody (or derivative) according to any one of items 1 to 14 or using the detection system according to any one of items 20 to 27 to determine the content of MUC17 in a sample; (b) measuring the amount of MUC17 determined in step (a) by: (i) a predefined value for MUC17 content; (ii) the content of MUC17 determined in a control sample, or (iii) the content of MUC17 determined in a sample obtained from the same source or subject at a previous time point and a process of comparing A method comprising: Item 30. A method for diagnosing MUC17 or a disease associated with increased MUC17, comprising: (a) using the monoclonal antibody according to any one of Items 1 to 14 or the detection system according to any one of Items 20 to 27 to determine the content of MUC17 in a sample, preferably in a tissue sample for IHC; and (b) measuring the content of MUC17 determined in step (a) by (i) a predefined cutoff value for MUC17 content that indicates the absence of such a disease, or (ii) the content of MUC17 determined in a control sample, representing the absence of such disease; and a process of comparing Including, wherein a higher content of MUC17 determined in step (a) compared to the predefined cutoff value in (i) or the content of MUC17 determined in a control sample in (ii) indicates the presence of MUC17 or a disease associated with increased MUC17. Item 31. A method for monitoring the progression of MUC17 or a disease associated with increased MUC17, or monitoring the response to treatment of MUC17 or a disease associated with increased MUC17, comprising: (a) using the monoclonal antibody according to any one of items 1 to 14 or the detection system according to any one of items 20 to 28 to determine the content of MUC17 at a first time point in a biological sample obtained from a subject diagnosed with such a disease; (b) using the monoclonal antibody of any one of items 1 to 14 or the detection system of any one of items 20 to 28 to determine the content of MUC17 in a biological sample obtained from the subject at a second time point or after treatment; (c) comparing the amount of MUC17 determined in step (a) with the amount of MUC17 determined in step (b); Including, a higher content of MUC17 determined in step (a) compared to the content of MUC17 determined in step (b) indicates that the disease is progressing, and / or a lower content of MUC17 determined in step (a) compared to the content of MUC17 determined in step (b) indicates that the disease is going into remission or that the disease is responding to treatment. Item 32. The use according to Item 28 or the method according to any one of Items 29 to 31, wherein the sample is a biological sample, preferably a human biological sample, such as a serum sample, a plasma sample, a blood sample, a bone marrow sample, a tissue sample, or a supernatant obtained from a cell culture of bone marrow mononuclear cells or peripheral blood mononuclear cells, preferably a tissue sample. Item 33. The use of Items 28 or 32 or the method of any one of Items 29 to 32, wherein the sample is obtained from a human subject, preferably a human subject suspected of having or having MUC17 or a disease associated with increased MUC17, or a subject undergoing treatment for MUC17 or a disease associated with increased MUC17. Item 34. The use according to any one of Items 29, 32, or 33 or the method according to any one of Items 29 to 33, wherein the disease is selected from the group consisting of gastric cancer, esophageal cancer, gastroesophageal cancer including gastroesophageal junction cancer, gastrointestinal cancer, and pancreatic cancer. Item 35. A method of treating a patient, preferably a human patient, having at least one cancer selected from the group comprising esophageal cancer, gastric cancer, gastrointestinal cancer, gastroesophageal cancer including gastroesophageal junction cancer, and / or pancreatic cancer, wherein the patient has increased expression of MUC17 on cancer cells, particularly colorectal cancer, gastric cancer, pancreatic cancer, colon adenocarcinoma, esophageal cancer, pancreatic adenocarcinoma, rectal adenocarcinoma, and gastric adenocarcinoma cells. Item 36. The method of treatment according to Item 35, wherein the increase in expression is determined in the method according to any one of Items 29 to 31, or the method comprises the use or product for use of any one of the preceding items relating to a diagnostic antibody, or a composition comprising the same, or a drug. Item 37. The method of treatment according to Item 35 or 36, comprising administering to the patient a drug, wherein the drug is selected from the group comprising small molecules, peptide drugs, antibodies and derivatives thereof, toxins, radiation therapy, and surgery. Item 38. The method of treatment of any one of items 35 to 37, wherein the agent is an antibody construct comprising at least two domains, one domain selectively binding to MUC17. Item 39. The method of treatment according to any one of items 35 to 38, wherein the agent is an antibody construct comprising at least two domains, the other domain selectively binding to CD3, to human CD3, in particular to the human CD3 epsilon chain. Item 40. The method of treatment of any one of claims 35 to 39, wherein the drug is an antibody construct further comprising a third domain comprising two polypeptide monomers, each comprising a hinge, a CH2 domain, and a CH3 domain, and the two polypeptide monomers are fused to each other via a peptide linker. Item 41. The method of treatment of any one of items 35 to 40, wherein the agent is a single-chain antibody construct. Item 42. The method of treatment of any one of items 35 to 41, wherein the agent is an antibody construct and the third domain comprises, in order from amino to carboxyl: hinge-CH2-CH3-linker-hinge-CH2-CH3. Item 43. The method of treatment of any one of items 35 to 42, wherein the agent is an antibody construct and each of the polypeptide monomers in the third domain has an amino acid sequence that is at least 90% identical to a sequence selected from the group consisting of SEQ ID NOs: 22 to 29. Item 44. The method of treatment according to any one of Items 35 to 43, wherein the agent is an antibody construct and each of the polypeptide monomers has an amino acid sequence selected from SEQ ID NOs: 22 to 29. Item 45. The method of treatment of any one of items 35 to 44, wherein the agent is an antibody construct and the CH2 domain comprises an intradomain cysteine ​​disulfide bridge. Item 46. The method of treatment of any one of Items 35 to 45, wherein the drug is an antibody construct and (i) the first domain comprises two antibody variable domains and the second domain comprises two antibody variable domains; (ii) the first domain comprises one antibody variable domain and the second domain comprises two antibody variable domains; (iii) the first domain comprises two antibody variable domains and the second domain comprises one antibody variable domain; or (iv) the first domain comprises one antibody variable domain and the second domain comprises one antibody variable domain. Item 47. The method of treatment of any one of items 35 to 46, wherein the agent is an antibody construct, and the first domain and the second domain are fused to the third domain via a peptide linker. Item 48. The method of treatment according to any one of Items 35 to 47, wherein the drug is an antibody construct, and the antibody construct comprises, in amino to carboxyl order: (a) a first domain; (b) a peptide linker, preferably having an amino acid sequence selected from the group consisting of SEQ ID NOs: 10 to 12; and (c) a second domain. Item 49. The method of treatment of any one of Items 35 to 48, wherein the drug is an antibody construct, and the antibody construct further comprises, in amino to carboxyl order: (d) a peptide linker having an amino acid sequence selected from the group consisting of SEQ ID NOs: 10, 11, 12, 17, 18, 19, and 20; (e) a first polypeptide monomer of a third domain; (f) a peptide linker having an amino acid sequence selected from the group consisting of SEQ ID NOs: 13, 14, 15, and 16; and (g) a second polypeptide monomer of a third domain. Item 50. The method of treatment of any one of items 35 to 49, wherein the agent is an antibody construct and the first domain of the antibody construct binds to an epitope within MUC17 corresponding to SEQ ID NO: 526 (aa 4171-4296 according to Uniprot Q685J3 numbering). Item 51. The method of treatment of any one of Items 35 to 50, wherein the agent is an antibody construct and the first domain of the antibody construct binds to an epitope within MUC17 corresponding to SEQ ID NO: 527 (aa 4184-4291 according to Uniprot Q685J3 numbering). Item 52. The method of treatment of any one of Items 35 to 51, wherein the agent is an antibody construct and the first domain of the antibody construct binds to an epitope within MUC17 corresponding to SEQ ID NO: 528 (aa 4131-4243 according to Uniprot Q685J3 numbering). Item 53. The method of treatment of any one of Items 35 to 52, wherein the agent is an antibody construct and the first domain of the antibody construct binds to an epitope within MUC17 corresponding to SEQ ID NO: 529 (aa 4244-4389 according to Uniprot Q685J3 numbering). Item 54. The method of treatment of any one of Items 35 to 53, wherein the agent is an antibody construct and the first domain of the antibody construct binds to an epitope within MUC17 corresponding to SEQ ID NO: 528 (aa 4131-4243 according to uniprot Q685J3 numbering) but does not bind to an epitope within MUC17 corresponding to SEQ ID NO: 529 (aa 4244-4389 according to uniprot Q685J3 numbering). Item 55. The method of treatment of any one of Items 35 to 54, wherein the agent is an antibody construct and the first domain of the antibody construct binds to an epitope within MUC17 corresponding to SEQ ID NO: 530 (aa 4171-4390 according to uniprot Q685J3 numbering) or SEQ ID NO: 531 (aa 4184-4390 according to uniprot Q685J3 numbering), but does not bind to an epitope within MUC17 corresponding to SEQ ID NO: 532 (aa 4291-4390 according to uniprot Q685J3 numbering) or an epitope within MUC17 corresponding to SEQ ID NO: 533 (aa 4341-4390 according to uniprot Q685J3 numbering). Item 56. The method of treatment of any one of items 35 to 55, wherein the drug is an antibody construct, and the ratio between cytotoxicity and binding affinity (EC50 / KD)*1000 is less than 250, the cytotoxicity is determined in NUGC-4 cells as target cells and huPBMCs as effector cells, and the binding affinity is determined by a surface plasmon resonance-based assay. Item 57. The method of treatment of any one of items 35 to 56, wherein the drug is an antibody construct, and the ratio between cytotoxicity and binding affinity (EC50 / KD)*1000 is less than 125, and the cytotoxicity is determined in NUGC-4 cells as target cells and huPBMCs as effector cells, and the binding affinity is determined by a surface plasmon resonance-based assay. Item 58. The method of treatment of any one of items 35 to 57, wherein the drug is an antibody construct, and the ratio between cytotoxicity and binding affinity (EC50 / KD)*1000 is less than 21, and the cytotoxicity is determined in NUGC-4 cells as target cells and huPBMCs as effector cells, and the binding affinity is determined by a surface plasmon resonance-based assay. Item 59. The drug is an antibody construct, and the first binding domain is: (a) CDR-H1 shown in SEQ ID NO: 31, CDR-H2 shown in SEQ ID NO: 32, and CDR-H3 shown in SEQ ID NO: 33; (b) CDR-H1 shown in SEQ ID NO: 42, CDR-H2 shown in SEQ ID NO: 43, and CDR-H3 shown in SEQ ID NO: 44; (c) CDR-H1 shown in SEQ ID NO: 53, CDR-H2 shown in SEQ ID NO: 54, and CDR-H3 shown in SEQ ID NO: 55; (d) CDR-H1 shown in SEQ ID NO: 64, CDR-H2 shown in SEQ ID NO: 66 (e) CDR-H1 set forth in SEQ ID NO: 75, CDR-H2 set forth in SEQ ID NO: 76, and CDR-H3 set forth in SEQ ID NO: 77; (f) CDR-H1 set forth in SEQ ID NO: 86, CDR-H2 set forth in SEQ ID NO: 87, and CDR-H3 set forth in SEQ ID NO: 88; (g) CDR-H1 set forth in SEQ ID NO: 97, CDR-H2 set forth in SEQ ID NO: 98, and CDR-H3 set forth in SEQ ID NO: 99; (h) CDR-H1 set forth in SEQ ID NO: 108, CDR-H2 set forth in SEQ ID NO: (i) CDR-H1 set forth in SEQ ID NO: 119, CDR-H2 set forth in SEQ ID NO: 120, and CDR-H3 set forth in SEQ ID NO: 121; (j) CDR-H1 set forth in SEQ ID NO: 130, CDR-H2 set forth in SEQ ID NO: 131, and CDR-H3 set forth in SEQ ID NO: 132; (k) CDR-H1 set forth in SEQ ID NO: 141, CDR-H2 set forth in SEQ ID NO: 142, and CDR-H3 set forth in SEQ ID NO: 143; (l) CDR-H1 set forth in SEQ ID NO: 152 (m) CDR-H1 set forth in SEQ ID NO: 163, CDR-H2 set forth in SEQ ID NO: 164, and CDR-H3 set forth in SEQ ID NO: 165; (n) CDR-H1 set forth in SEQ ID NO: 174, CDR-H2 set forth in SEQ ID NO: 175, and CDR-H3 set forth in SEQ ID NO: 176; (o) CDR-H1 set forth in SEQ ID NO: 185, CDR-H2 set forth in SEQ ID NO: 186, and CDR-H3 set forth in SEQ ID NO: 187;(p) CDR-H1 shown in SEQ ID NO: 196, CDR-H2 shown in SEQ ID NO: 197, and CDR-H3 shown in SEQ ID NO: 198; (q) CDR-H1 shown in SEQ ID NO: 207, CDR-H2 shown in SEQ ID NO: 208, and CDR-H3 shown in SEQ ID NO: 209; (r) CDR-H1 shown in SEQ ID NO: 218, CDR-H2 shown in SEQ ID NO: 219, and CDR-H3 shown in SEQ ID NO: 220; (s) CDR-H1 shown in SEQ ID NO: 229, CDR-H2 shown in SEQ ID NO: 230, and CDR-H3 shown in SEQ ID NO: 231; ( (t) CDR-H1 set forth in SEQ ID NO: 240, CDR-H2 set forth in SEQ ID NO: 241, and CDR-H3 set forth in SEQ ID NO: 242; (u) CDR-H1 set forth in SEQ ID NO: 251, CDR-H2 set forth in SEQ ID NO: 252, and CDR-H3 set forth in SEQ ID NO: 253; (v) CDR-H1 set forth in SEQ ID NO: 262, CDR-H2 set forth in SEQ ID NO: 263, and CDR-H3 set forth in SEQ ID NO: 264; (w) CDR-H1 set forth in SEQ ID NO: 273, CDR-H2 set forth in SEQ ID NO: 274, and CDR-H3 set forth in SEQ ID NO: 275; (x ) CDR-H1 set forth in SEQ ID NO: 284, CDR-H2 set forth in SEQ ID NO: 285, and CDR-H3 set forth in SEQ ID NO: 286; (y) CDR-H1 set forth in SEQ ID NO: 295, CDR-H2 set forth in SEQ ID NO: 296, and CDR-H3 set forth in SEQ ID NO: 297; (z) CDR-H1 set forth in SEQ ID NO: 306, CDR-H2 set forth in SEQ ID NO: 307, and CDR-H3 set forth in SEQ ID NO: 308; (aa) CDR-H1 set forth in SEQ ID NO: 317, CDR-H2 set forth in SEQ ID NO: 318, and CDR-H3 set forth in SEQ ID NO: 319; (a b) CDR-H1 set forth in SEQ ID NO: 328, CDR-H2 set forth in SEQ ID NO: 329, and CDR-H3 set forth in SEQ ID NO: 330; (ac) CDR-H1 set forth in SEQ ID NO: 339, CDR-H2 set forth in SEQ ID NO: 340, and CDR-H3 set forth in SEQ ID NO: 341; (ad) CDR-H1 set forth in SEQ ID NO: 350, CDR-H2 set forth in SEQ ID NO: 351, and CDR-H3 set forth in SEQ ID NO: 352; (ae) CDR-H1 set forth in SEQ ID NO: 361, CDR-H2 set forth in SEQ ID NO: 362, and CDR-H3 set forth in SEQ ID NO: 363;(af) CDR-H1 shown in SEQ ID NO: 372, CDR-H2 shown in SEQ ID NO: 373, and CDR-H3 shown in SEQ ID NO: 374; (ag) CDR-H1 shown in SEQ ID NO: 383, CDR-H2 shown in SEQ ID NO: 384, and CDR-H3 shown in SEQ ID NO: 385; (ah) CDR-H1 shown in SEQ ID NO: 394, CDR-H2 shown in SEQ ID NO: 395, and CDR-H3 shown in SEQ ID NO: 396; (ai) CDR-H1 shown in SEQ ID NO: 405, CDR-H2 shown in SEQ ID NO: 406, and CDR-H3 shown in SEQ ID NO: (aj) CDR-H1 shown in SEQ ID NO: 416, CDR-H2 shown in SEQ ID NO: 417, and CDR-H3 shown in SEQ ID NO: 418; (ak) CDR-H1 shown in SEQ ID NO: 427, CDR-H2 shown in SEQ ID NO: 428, and CDR-H3 shown in SEQ ID NO: 429; (al) CDR-H1 shown in SEQ ID NO: 438, CDR-H2 shown in SEQ ID NO: 439, and CDR-H3 shown in SEQ ID NO: 440; (am) CDR-H1 shown in SEQ ID NO: 449, CDR-H2 shown in SEQ ID NO: 450 and CDR-H2 shown in SEQ ID NO: 451; (an) CDR-H1 shown in SEQ ID NO: 460, CDR-H2 shown in SEQ ID NO: 461, and CDR-H3 shown in SEQ ID NO: 462; (ao) CDR-H1 shown in SEQ ID NO: 471, CDR-H2 shown in SEQ ID NO: 472, and CDR-H3 shown in SEQ ID NO: 473; (ap) CDR-H1 shown in SEQ ID NO: 482, CDR-H2 shown in SEQ ID NO: 483, and CDR-H3 shown in SEQ ID NO: 484; (aq) CDR-H1 shown in SEQ ID NO: 493 (ar) CDR-H1 set forth in SEQ ID NO: 504, CDR-H2 set forth in SEQ ID NO: 505, and CDR-H3 set forth in SEQ ID NO: 506; and (as) CDR-H1 set forth in SEQ ID NO: 515, CDR-H2 set forth in SEQ ID NO: 516, and CDR-H3 set forth in SEQ ID NO: 517 (preferably (c) CDR-H1 set forth in SEQ ID NO: 53, CDR-H2 set forth in SEQ ID NO: 54, and CDR-H3 set forth in SEQ ID NO: 55;The method of treatment according to any one of Items 35 to 58, comprising a VH region comprising CDR-H1, CDR-H2, and CDR-H3 selected from (n) CDR-H1 set forth in SEQ ID NO: 174, CDR-H2 set forth in SEQ ID NO: 175, and CDR-H3 set forth in SEQ ID NO: 176; (ac) CDR-H1 set forth in SEQ ID NO: 339, CDR-H2 set forth in SEQ ID NO: 340, and CDR-H3 set forth in SEQ ID NO: 341; and (aj) CDR-H1 set forth in SEQ ID NO: 416, CDR-H2 set forth in SEQ ID NO: 417, and CDR-H3 set forth in SEQ ID NO: 418. Item 60. The drug is an antibody construct, and the first binding domain is: (a) CDR-L1 shown in SEQ ID NO: 34, CDR-L2 shown in SEQ ID NO: 35, and CDR-L3 shown in SEQ ID NO: 36; (b) CDR-L1 shown in SEQ ID NO: 45, CDR-L2 shown in SEQ ID NO: 46, and CDR-L3 shown in SEQ ID NO: 47; (c) CDR-L1 shown in SEQ ID NO: 56, CDR-L2 shown in SEQ ID NO: 57, and CDR-L3 shown in SEQ ID NO: 58; (d) CDR-L1 shown in SEQ ID NO: 67, CDR-L2 shown in SEQ ID NO: 68 and CDR-L2 as set forth in SEQ ID NO: 69; (e) CDR-L1 as set forth in SEQ ID NO: 78, CDR-L2 as set forth in SEQ ID NO: 79, and CDR-L3 as set forth in SEQ ID NO: 80; (f) CDR-L1 as set forth in SEQ ID NO: 89, CDR-L2 as set forth in SEQ ID NO: 90, and CDR-L3 as set forth in SEQ ID NO: 91; (g) CDR-L1 as set forth in SEQ ID NO: 100, CDR-L2 as set forth in SEQ ID NO: 101, and CDR-L3 as set forth in SEQ ID NO: 102; (h) CDR-L1 as set forth in SEQ ID NO: 111, sequence (i) CDR-L1 shown in SEQ ID NO: 122, CDR-L2 shown in SEQ ID NO: 123, and CDR-L3 shown in SEQ ID NO: 124; (j) CDR-L1 shown in SEQ ID NO: 133, CDR-L2 shown in SEQ ID NO: 134, and CDR-L3 shown in SEQ ID NO: 135; (k) CDR-L1 shown in SEQ ID NO: 144, CDR-L2 shown in SEQ ID NO: 145, and CDR-L3 shown in SEQ ID NO: 146; (l) CDR-L1 shown in SEQ ID NO: 155 (m) CDR-L1 set forth in SEQ ID NO: 166, CDR-L2 set forth in SEQ ID NO: 167, and CDR-L3 set forth in SEQ ID NO: 168; (n) CDR-L1 set forth in SEQ ID NO: 177, CDR-L2 set forth in SEQ ID NO: 178, and CDR-L3 set forth in SEQ ID NO: 179; (o) CDR-L1 set forth in SEQ ID NO: 188, CDR-L2 set forth in SEQ ID NO: 189, and CDR-L3 set forth in SEQ ID NO: 190;(p) CDR-L1 shown in SEQ ID NO: 199, CDR-L2 shown in SEQ ID NO: 200, and CDR-L3 shown in SEQ ID NO: 201; (q) CDR-L1 shown in SEQ ID NO: 210, CDR-L2 shown in SEQ ID NO: 211, and CDR-L3 shown in SEQ ID NO: 212; (r) CDR-L1 shown in SEQ ID NO: 221, CDR-L2 shown in SEQ ID NO: 222, and CDR-L3 shown in SEQ ID NO: 223; (s) CDR-L1 shown in SEQ ID NO: 232, CDR-L2 shown in SEQ ID NO: 233, and CDR-L3 shown in SEQ ID NO: 234; ( (t) CDR-L1 set forth in SEQ ID NO: 243, CDR-L2 set forth in SEQ ID NO: 244, and CDR-L3 set forth in SEQ ID NO: 245; (u) CDR-L1 set forth in SEQ ID NO: 254, CDR-L2 set forth in SEQ ID NO: 255, and CDR-L3 set forth in SEQ ID NO: 256; (v) CDR-L1 set forth in SEQ ID NO: 265, CDR-L2 set forth in SEQ ID NO: 266, and CDR-L3 set forth in SEQ ID NO: 267; (w) CDR-L1 set forth in SEQ ID NO: 276, CDR-L2 set forth in SEQ ID NO: 277, and CDR-L3 set forth in SEQ ID NO: 278; (x ) CDR-L1 shown in SEQ ID NO: 287, CDR-L2 shown in SEQ ID NO: 288, and CDR-L3 shown in SEQ ID NO: 289; (y) CDR-L1 shown in SEQ ID NO: 298, CDR-L2 shown in SEQ ID NO: 299, and CDR-L3 shown in SEQ ID NO: 300; (z) CDR-L1 shown in SEQ ID NO: 309, CDR-L2 shown in SEQ ID NO: 310, and CDR-L3 shown in SEQ ID NO: 311; (aa) CDR-L1 shown in SEQ ID NO: 320, CDR-L2 shown in SEQ ID NO: 321, and CDR-L3 shown in SEQ ID NO: 322; (a b) CDR-L1 set forth in SEQ ID NO: 331, CDR-L2 set forth in SEQ ID NO: 332, and CDR-L3 set forth in SEQ ID NO: 333; (ac) CDR-L1 set forth in SEQ ID NO: 342, CDR-L2 set forth in SEQ ID NO: 343, and CDR-L3 set forth in SEQ ID NO: 344; (ad) CDR-L1 set forth in SEQ ID NO: 353, CDR-L2 set forth in SEQ ID NO: 354, and CDR-L3 set forth in SEQ ID NO: 355; (ae) CDR-L1 set forth in SEQ ID NO: 364, CDR-L2 set forth in SEQ ID NO: 365, and CDR-L3 set forth in SEQ ID NO: 366;(af) CDR-L1 shown in SEQ ID NO: 375, CDR-L2 shown in SEQ ID NO: 376, and CDR-L3 shown in SEQ ID NO: 377; (ag) CDR-L1 shown in SEQ ID NO: 386, CDR-L2 shown in SEQ ID NO: 387, and CDR-L3 shown in SEQ ID NO: 388; (ah) CDR-L1 shown in SEQ ID NO: 397, CDR-L2 shown in SEQ ID NO: 398, and CDR-L3 shown in SEQ ID NO: 399; (ai) CDR-L1 shown in SEQ ID NO: 408, CDR-L2 shown in SEQ ID NO: 409, and CDR-L3 shown in SEQ ID NO: (aj) CDR-L1 shown in SEQ ID NO: 419, CDR-L2 shown in SEQ ID NO: 420, and CDR-L3 shown in SEQ ID NO: 421; (ak) CDR-L1 shown in SEQ ID NO: 430, CDR-L2 shown in SEQ ID NO: 431, and CDR-L3 shown in SEQ ID NO: 432; (al) CDR-L1 shown in SEQ ID NO: 441, CDR-L2 shown in SEQ ID NO: 442, and CDR-L3 shown in SEQ ID NO: 443; (am) CDR-L1 shown in SEQ ID NO: 452, CDR-L2 shown in SEQ ID NO: 453 (an) CDR-L1 shown in SEQ ID NO: 463, CDR-L2 shown in SEQ ID NO: 464, and CDR-L3 shown in SEQ ID NO: 465; (ao) CDR-L1 shown in SEQ ID NO: 474, CDR-L2 shown in SEQ ID NO: 475, and CDR-L3 shown in SEQ ID NO: 476; (ap) CDR-L1 shown in SEQ ID NO: 485, CDR-L2 shown in SEQ ID NO: 486, and CDR-L3 shown in SEQ ID NO: 487; (aq) CDR-L1 shown in SEQ ID NO: 496 (ar) CDR-L1 set forth in SEQ ID NO: 507, CDR-L2 set forth in SEQ ID NO: 508, and CDR-L3 set forth in SEQ ID NO: 509; and (as) CDR-L1 set forth in SEQ ID NO: 518, CDR-L2 set forth in SEQ ID NO: 519, and CDR-L3 set forth in SEQ ID NO: 520 (preferably (c) CDR-L1 set forth in SEQ ID NO: 56, CDR-L2 set forth in SEQ ID NO: 57, and CDR-L3 set forth in SEQ ID NO: 58;60. The method of treatment according to any one of Items 35 to 59, comprising a VL region comprising CDR-L1, CDR-L2, and CDR-L3 selected from (n) CDR-L1 set forth in SEQ ID NO: 177, CDR-L2 set forth in SEQ ID NO: 178, and CDR-L3 set forth in SEQ ID NO: 179; (ac) CDR-L1 set forth in SEQ ID NO: 342, CDR-L2 set forth in SEQ ID NO: 343, and CDR-L3 set forth in SEQ ID NO: 344; and (aj) CDR-L1 set forth in SEQ ID NO: 419, CDR-L2 set forth in SEQ ID NO: 420, and CDR-L3 set forth in SEQ ID NO: 421. Item 61. The drug is an antibody construct, and the first binding domain is composed of: (a) a VL region set forth in SEQ ID NO: 38 and a VH region set forth in SEQ ID NO: 37; (b) a VL region set forth in SEQ ID NO: 49 and a VH region set forth in SEQ ID NO: 48; (c) a VL region set forth in SEQ ID NO: 60 and a VH region set forth in SEQ ID NO: 59; (d) a VL region set forth in SEQ ID NO: 71 and a VH region set forth in SEQ ID NO: 70; (e) a VL region set forth in SEQ ID NO: 82 and a VH region set forth in SEQ ID NO: 81; (f) a VL region set forth in SEQ ID NO: 93 and a VH region set forth in SEQ ID NO: 92. (g) the VL region set forth in SEQ ID NO: 104 and the VH region set forth in SEQ ID NO: 103; (h) the VL region set forth in SEQ ID NO: 115 and the VH region set forth in SEQ ID NO: 114; (i) the VL region set forth in SEQ ID NO: 126 and the VH region set forth in SEQ ID NO: 125; (j) the VL region set forth in SEQ ID NO: 137 and the VH region set forth in SEQ ID NO: 136; (k) the VL region set forth in SEQ ID NO: 148 and the VH region set forth in SEQ ID NO: 147; (l) the VL region set forth in SEQ ID NO: 159 and the VH region set forth in SEQ ID NO: 158; (m) the VL region set forth in SEQ ID NO: 17 (n) the VL region set forth in SEQ ID NO: 181 and the VH region set forth in SEQ ID NO: 180; (o) the VL region set forth in SEQ ID NO: 192 and the VH region set forth in SEQ ID NO: 191; (p) the VL region set forth in SEQ ID NO: 203 and the VH region set forth in SEQ ID NO: 202; (q) the VL region set forth in SEQ ID NO: 214 and the VH region set forth in SEQ ID NO: 213; (r) the VL region set forth in SEQ ID NO: 226 and the VH region set forth in SEQ ID NO: 225; (s) the VL region set forth in SEQ ID NO: 236 and the VH region set forth in SEQ ID NO: 236 (t) the VL region set forth in SEQ ID NO: 247 and the VH region set forth in SEQ ID NO: 246; (u) the VL region set forth in SEQ ID NO: 258 and the VH region set forth in SEQ ID NO: 257; (v) the VL region set forth in SEQ ID NO: 269 and the VH region set forth in SEQ ID NO: 268; (w) the VL region set forth in SEQ ID NO: 280 and the VH region set forth in SEQ ID NO: 279; (x) the VL region set forth in SEQ ID NO: 292 and the VH region set forth in SEQ ID NO: 290; (y) the VL region set forth in SEQ ID NO: 302 and the VH region set forth in SEQ ID NO: 301;(z) the VL region set forth in SEQ ID NO: 313 and the VH region set forth in SEQ ID NO: 312; (aa) the VL region set forth in SEQ ID NO: 324 and the VH region set forth in SEQ ID NO: 323; (ab) the VL region set forth in SEQ ID NO: 335 and the VH region set forth in SEQ ID NO: 334; (ac) the VL region set forth in SEQ ID NO: 346 and the VH region set forth in SEQ ID NO: 345; (ad) the VL region set forth in SEQ ID NO: 357 and the VH region set forth in SEQ ID NO: 356; (ae) the VL region set forth in SEQ ID NO: 368 and the VH region set forth in SEQ ID NO: 367; (af) the VL region set forth in SEQ ID NO: 379 and the VH region set forth in SEQ ID NO: 378; (ag) the VL region set forth in SEQ ID NO: 390 and the VH region set forth in SEQ ID NO: 389; (ah) the VL region set forth in SEQ ID NO: 401 and the VH region set forth in SEQ ID NO: 400; (ai) the VL region set forth in SEQ ID NO: 412 and the VH region set forth in SEQ ID NO: 411; (aj) the VL region set forth in SEQ ID NO: 423 and the VH region set forth in SEQ ID NO: 422; (ak) the VL region set forth in SEQ ID NO: 434 and the VH region set forth in SEQ ID NO: 433; (al) the VL region set forth in SEQ ID NO: 445 and the VH region set forth in SEQ ID NO: 444; (am) the VL region set forth in SEQ ID NO: 456 and the VH region set forth in SEQ ID NO: 455; (an) the VL region set forth in SEQ ID NO: 467 and the VH region set forth in SEQ ID NO: 466; (ao) the VL region set forth in SEQ ID NO: 478 and the VH region set forth in SEQ ID NO: 477; (ap) the VL region set forth in SEQ ID NO: 489 and the VH region set forth in SEQ ID NO: 488; (aq) the VL region set forth in SEQ ID NO: 500 and the VH region set forth in SEQ ID NO: 499; (ar) the VL region set forth in SEQ ID NO: 511 and the VH region set forth in SEQ ID NO: 510; and (as) the VL region set forth in SEQ ID NO: 522 and the VH region set forth in SEQ ID NO: 521. ; Item 62. The method of treatment according to any one of Items 35 to 61, wherein the drug is an antibody construct, and the antibody construct comprises a sequence selected from the amino acid sequences set forth in any one of SEQ ID NOs: 39, 50, 61, 72, 83, 94, 105, 116, 127, 138, 149, 160, 171, 182, 193, 204, 215, 226, 237, 248, 259, 270, 281, 292, 303, 314, 325, 336, 347, 358, 369, 380, 391, 402, 413, 424, 435, 446, 457, 468, 479, 490, 501, 512, and 523. Item 63. The drug is an antibody construct, and the antibody construct comprises, in order from amino to carboxyl: (a) SEQ ID NOs: 39, 50, 61, 72, 83, 94, 105, 116, 127, 138, 149, 160, 171, 182, 193, 204, 215, 226, 237, 248, 259, 270, 281, 292, 303, 314, 325, 336, 347, 358, 369, 380, 391, 402, 413, 424, 435, 446, 457, 468, 479, 490, 501, 512, and and 523; (b) a peptide linker having an amino acid sequence selected from the group consisting of SEQ ID NOs: 10 to 12; and (c) a second domain having an amino acid sequence selected from the group consisting of SEQ ID NOs: 23, 25, 41, 43, 59, 61, 77, 79, 95, 97, 113, 115, 131, 133, 149, 151, 167, 169, 185, or 187 of WO 2008 / 119567, or set forth in SEQ ID NO: 13. 63. The method of treatment according to any one of items 35 to 62, comprising: Item 64. The method of treatment of any one of Items 35 to 63, wherein the drug is an antibody construct, and the antibody construct further comprises, in order from amino to carboxyl: (d) a peptide linker having an amino acid sequence selected from the group consisting of SEQ ID NOs: 10, 11, 12, 17, 18, 19, and 20; (e) a first polypeptide monomer of a third domain having a polypeptide sequence selected from the group consisting of SEQ ID NOs: 22 to 29; (f) a peptide linker having an amino acid sequence selected from the group consisting of SEQ ID NOs: 13, 14, 15, and 16; and (g) a second polypeptide monomer of a third domain having a polypeptide sequence selected from the group consisting of SEQ ID NOs: 22 to 29. Item 65. Drugs are: SEQ ID NO: 40, 41, 51, 52, 62, 63, 73, 74, 84, 85, 95, 96, 106, 107, 117, 118, 128, 129, 139, 140, 150, 151, 161, 162, 172, 173, 183, 184, 194, 195, 205, 206, 216, 217, 227, 228, 238, 239, 249, 250, 260, 261, 271, 272, 282, 283, 293, 294, 304, 305, 315, 316, 326, 327, 337, 338, 348, 349, 359, 360, 361, 370, 372, 373, 374, 375, 376, 377, 378, 379, 380, 381, 382, ​​383, 384, 385, 386, 387, 388, 389, 390, 400, 401, 402, 403, 404, 405, 406, 407, 408, 409, 410, 411, 412, 413, 414, 415, 416, 417, 418, 419, 42 70, 371, 381, 382, ​​392, 393, 403, 404, 414, 415, 424, 426, 436, 437, 447, 448, 458, 459, 469, 470, 480, 481, 491, 492, 502, 503, 513, 514, 524, and 525, or having amino acids with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identity to said sequence.

[0168] The invention further relates to methods of treatment as defined in the claims and set out below.

[0169] In a first embodiment of a method of treatment according to the present invention, it is contemplated that an antibody construct is administered comprising a first domain that binds to MUC17 and a second domain that binds to an extracellular epitope of the human and Macaca CD3 epsilon chain. Within this embodiment, it is further contemplated that the antibody construct comprises a third domain comprising two polypeptide monomers, each comprising a hinge, a CH2 domain, and a CH3 domain, the two polypeptide monomers being fused to each other via a peptide linker. Within this embodiment, it is further contemplated that the antibody construct is a single-chain antibody construct. Within this embodiment, it is also contemplated that the antibody construct has a third domain comprising, in amino to carboxyl order: hinge-CH2-CH3-linker-hinge-CH2-CH3. Within this embodiment, it is further contemplated that the polypeptide monomers each have an amino acid sequence at least 90% identical to a sequence set forth in the Sequence Listing and in each claim. Within the above aspects, it is further envisaged to provide an antibody construct wherein the CH2 domain comprises an intradomain cysteine ​​disulfide bridge.

[0170] Within the above embodiments, it is also contemplated that an antibody construct is administered in which (i) the first domain comprises two antibody variable domains and the second domain comprises two antibody variable domains; (ii) the first domain comprises one antibody variable domain and the second domain comprises two antibody variable domains; (iii) the first domain comprises two antibody variable domains and the second domain comprises one antibody variable domain; or (iv) the first domain comprises one antibody variable domain and the second domain comprises one antibody variable domain. It is also contemplated that an antibody construct is administered in which the first domain and the second domain are fused to a third domain via a peptide linker. In this regard, it is particularly contemplated that the antibody construct is an antibody construct disclosed in WO 2019 / 133961, which application is incorporated herein by reference. The antibody constructs claimed in the above disclosure may be used in the methods of treatment described herein. It is further envisaged in the context of the present invention to administer a pharmaceutical composition comprising an antibody construct as defined above.

[0171] The method of treatment according to the present invention includes the prevention, alleviation, prevention of worsening or recurrence, or amelioration of a proliferative disorder, a neoplastic disorder, a cancer as defined in the claims, e.g., a gastrointestinal cancer (e.g., gastric cancer, esophageal cancer, gastroesophageal (esophageal) junction cancer, or colorectal cancer) or pancreatic cancer, and comprises administering to a subject in need thereof an antibody construct directed against MUC17 and CD3. In connection with the present invention, the administration of an antibody construct specifically targeting MUC17 in association with malignant tumor diagnosis is provided. To this end, MUC17 was first identified as a gene upregulated in gastric tumors compared to normal tissue expression. In this regard, MUC17 protein has been shown to be expressed in 40-77% of gastric tumors according to the immunohistochemistry method of the invention described herein. Furthermore, flow cytometry has demonstrated that MUC17 protein is expressed on the cell surface of gastric and esophageal cancer cell lines, as well as some pancreatic and colorectal cancer cell lines. Furthermore, such expression has previously been shown to be particularly high in gastric tumors in Chinese patients. Therefore, MUC17 has been identified as a valid target relevant to gastrointestinal cancers, i.e., cancers of the stomach, small intestine, and large intestine (colon), esophageal cancer, and pancreatic cancer. In the context of the present invention, the administered antibody constructs exhibit binding affinity, potent cytotoxic activity, and are the most stable maps to the SEA domain. The administered antibody constructs may have a cysteine ​​clamp, i.e., an intramolecular disulfide bond, within the target binder for improved stability, and may also be in a single-chain Fc (scFc) format as a half-life extension (HLE) moiety and directed against MUC17. Furthermore, scFc, i.e., HLE, antibody constructs allow for intravenous administration only once per week, once every two weeks, once every three weeks, or even once every four weeks, or even less frequently.Thus, the antibody construct used in the methods of the invention comprises a first domain that binds to MUC17, a second domain that binds to an extracellular epitope of the human and Macaca CD3 epsilon chain, and, optionally, a third domain comprising two polypeptide monomers, each comprising a hinge, a CH2 domain, and a CH3 domain, fused to one another via a peptide linker. In one embodiment, the administered antibody construct comprises all three such domains.

[0172] The term "antibody construct" refers to a molecule whose structure and / or function is based on the structure and / or function of an antibody, e.g., a full-length or complete immunoglobulin molecule. Thus, an antibody construct is capable of binding to its specific target or antigen and / or is derived from the variable heavy (VH) and / or variable light (VL) domains of an antibody or a fragment thereof. Furthermore, a domain that binds to its binding partner is herein understood as a binding domain of an antibody construct. Typically, a binding domain according to the present invention comprises the minimum structural requirements of an antibody that enable target binding. This minimum requirement can be defined, for example, by the presence of at least three light chain CDRs (i.e., CDR1, CDR2, and CDR3 of the VL region) and / or three heavy chain CDRs (i.e., CDR1, CDR2, and CDR3 of the VH region), preferably all six CDRs. An alternative approach to defining the minimal structural requirements of an antibody is to define the antibody's epitope within the structure of a specific target (a protein domain of the target protein contains an epitope region (epitope cluster)), or by reference to specific antibodies that compete with the defined antibody's epitope. Antibodies on which constructs according to the present invention are based include, for example, monoclonal antibodies, recombinant antibodies, chimeric antibodies, deimmunized antibodies, humanized antibodies, and human antibodies. The binding domain of an antibody construct administered according to the present invention may, for example, comprise CDRs from the above-referenced groups. Preferably, these CDRs are contained within the framework of an antibody light chain variable region (VL) and an antibody heavy chain variable region (VH). However, it is not necessary to include both. Fd fragments, for example, have two VH regions and often retain some of the antigen-binding function of an intact antigen-binding domain.Further examples of formats of antibody fragments, antibody variants, or binding domains include: (1) a Fab fragment, which is a monovalent fragment having the VL, VH, CL, and CH1 domains; (2) an F(ab')2 fragment, which is a bivalent fragment having two Fab fragments linked by a disulfide bridge at the hinge region; (3) an Fd fragment having two VH and CH1 domains; (4) an Fv fragment having the VL and VH domains of a single arm of an antibody; (5) a dAb fragment having a VH domain (Ward et al., (1989) Nature 341:544-546); (6) isolated complementarity-determining regions (CDRs); and (7) single-chain Fvs (scFvs), the latter of which is preferred (e.g., derived from an scFv library). Exemplary embodiments of antibody constructs according to the invention are described, for example, in WO 00 / 006605, WO 2005 / 040220, WO 2008 / 119567, WO 2010 / 037838, WO 2013 / 026837, WO 2013 / 026833, US Patent Application Publication No. 2014 / 0308285, US Patent Application Publication No. 2014 / 0302037, WO 2014 / 144722, WO 2014 / 151910, and WO 2015 / 048272.

[0173] The definition of "binding domain" or "domain that binds to" also includes fragments of full-length antibodies, such as VH, VHH, VL, (s)dAb, Fv, Fd, Fab, Fab', F(ab')2, or "r IgG" ("half antibodies"). The antibody constructs administered according to the invention may also include modified fragments of antibodies, also called antibody variants, such as scFv, di-scFv or bi(s)-scFv, scFv-Fc, scFv-zipper, scFab, Fab2, Fab3, diabodies, single-chain diabodies, tandem diabodies (Tandab's), tandem di-scFv, tandem tri-scFv, "multibodies" such as triabodies or tetrabodies, and single domain antibodies, such as nanobodies, or single variable domain antibodies, which comprise only one variable domain, which may be a VHH, VH, or VL, that specifically binds to an antigen or epitope independent of other V regions or domains. As used herein, the term "single-chain Fv," "single-chain antibody," or "scFv" refers to a single polypeptide chain antibody fragment that contains the variable regions from both the heavy and light chains but lacks the constant region. Typically, single-chain antibodies further contain a polypeptide linker between the VH and VL domains that enables them to form the desired structure to enable antigen binding. Single-chain antibodies are discussed in detail by Pluckthun in *The Pharmacology of Monoclonal Antibodies*, vol. 113, Rosenburg and Moore eds. Springer-Verlag, New York, pp. 269-315 (1994). Various methods for producing single chain antibodies are known, including those described in U.S. Pat. Nos. 4,694,778 and 5,260,203; WO 88 / 01649; Bird (1988) Science 242:423-442; Huston et al. (1988) Proc. Natl. Acad. Sci. USA 85:5879-5883; Ward et al. (1989) Nature 334:54454; Skerra et al. (1988) Science 242:1038-1041.In certain embodiments, single chain antibodies may also be bispecific antibodies, multispecific antibodies, human antibodies and / or humanized antibodies, and / or synthetic antibodies.

[0174] Furthermore, the definition of the term "antibody construct" includes monovalent, bivalent, and polyvalent / multivalent constructs, and thus bispecific constructs that specifically bind to only two antigenic structures, as well as multispecific constructs that specifically bind to more than two, for example, three, four, or more, antigenic structures through different binding domains. Furthermore, the definition of the term "antibody construct" includes molecules consisting of only one polypeptide chain, as well as molecules consisting of multiple polypeptide chains, where the chains can be identical (homodimers, homotrimers, or homooligomers) or different (heterodimers, heterotrimers, or heterooligomers). Examples of the above-identified antibodies and variants or derivatives thereof are described, inter alia, in Harlow and Lane, Antibodies a laboratory manual, CSHL Press (1988) and Using Antibodies: a laboratory manual, CSHL Press (1999), Kontermann and Duebel, Antibody Engineering, Springer, 2nd ed. 2010 and Little, Recombinant Antibodies for Immunotherapy, Cambridge University Press 2009.

[0175] The term "bispecific" as used herein refers to an antibody construct that is "at least bispecific," i.e., comprises at least a first binding domain and a second binding domain, wherein the first binding domain binds to one antigen or target (herein MUC17) and the second binding domain binds to another antigen or target (herein CD3). Thus, an antibody construct according to the present invention has specificity for at least two different antigens or targets. For example, the first domain preferably does not bind to an extracellular epitope of CD3ε of one or more species described herein. The term "target cell surface antigen" refers to an antigenic structure that is expressed by a cell and present on the cell surface so as to be accessible to the antibody constructs described herein. This can be a protein, preferably the extracellular portion of a protein, or a carbohydrate structure, preferably a carbohydrate structure of a protein such as a glycoprotein. This is preferably a tumor antigen. The term "bispecific antibody construct" according to the present invention also encompasses multispecific antibody constructs, the latter including, for example, trispecific antibody constructs comprising three binding domains, or constructs with more than three (e.g., four, five, ...) specificities.

[0176] When the antibody construct administered according to the present invention is (at least) bispecific, it does not exist in nature and is significantly different from naturally occurring products. Therefore, a "bispecific" antibody construct or immunoglobulin is an artificial hybrid antibody or immunoglobulin having at least two different binding sites with different specificities. Bispecific antibody constructs can be produced by various methods, including fusion of hybridomas or linking of Fab' fragments. See, for example, Songsivilai & Lachmann, Clin. Exp. Immunol. 79:315-321 (1990). The at least two binding domains and variable domains (VH / VL) of the antibody construct may or may not contain a peptide linker (spacer peptide). According to the present invention, the term "peptide linker" includes an amino acid sequence that connects the amino acid sequences of one (variable and / or binding) domain and the other (variable and / or binding) domain of the antibody construct of the present invention. Peptide linkers can also be used to fuse a third domain to other domains of an antibody construct. An essential technical feature of such peptide linkers is that they do not contain any polymerization activity. Suitable peptide linkers include those described in U.S. Pat. Nos. 4,751,180 and 4,935,233 or WO 88 / 09344. Peptide linkers can also be used to attach other domains, modules, or regions (such as half-life extending domains) to an antibody construct.

[0177] The antibody construct is preferably an "in vitro generated antibody construct." The term refers to an antibody construct according to the above definition in which all or a portion of the variable region (e.g., at least one CDR) is generated in a non-immune cell selection, such as in vitro phage display, protein chip, or any other method that allows testing of candidate sequences for their ability to bind to an antigen. Thus, the term preferably excludes sequences generated solely by genome rearrangement in immune cells of an animal. A "recombinant antibody" is an antibody produced by using recombinant DNA technology or genetic engineering.

[0178] As used herein, the term "monoclonal antibody" (mAb) or monoclonal antibody construct refers to an antibody obtained from a population of substantially homogeneous antibodies, i.e., individual antibodies comprising the population that are identical except for possible naturally occurring mutations and / or post-translational modifications (e.g., isomerization, amidation), which may be present in minor amounts. Monoclonal antibodies are highly specific, being directed against a single antigenic site or determinant on the antigen, in contrast to conventional (polyclonal) antibody preparations that typically include different antibodies directed against different determinants (or epitopes). In addition to their specificity, monoclonal antibodies are advantageous in that they are synthesized by the hybridoma culture and are therefore uncontaminated by other immunoglobulins. The modifier "monoclonal" indicates the character of the antibody as being obtained from a substantially homogeneous antibody population and should not be construed as requiring production of the antibody by any particular method. Any technique that yields antibodies produced by continuous cell line culture may be used for preparation of monoclonal antibodies. For example, the monoclonal antibodies to be used may be made by the hybridoma method first described by Koehler et al., Nature, 256:495 (1975), or may be made by recombinant DNA methods (see, e.g., U.S. Pat. No. 4,816,567). Additional techniques for producing human monoclonal antibodies include the trioma technique, the human B-cell hybridoma technique (Kozbor, Immunology Today 4 (1983), 72), and the EBV-hybridoma technique (Cole et al., Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, Inc. (1985), 77-96). The hybridomas can then be screened using standard methods, such as enzyme-linked immunosorbent assay (ELISA) and surface plasmon resonance analysis, e.g., Biacore™, to identify one or more hybridomas that produce an antibody that specifically binds to the designated antigen. Any form of the relevant antigen can be used as an immunogen, for example, recombinant antigen, naturally occurring form, any variant or fragment thereof, and antigenic peptides thereof.Surface plasmon resonance, employed in the Biacore system, can be used to enhance the binding efficiency of phage antibodies to epitopes on target cell surface antigens (Schier, Human Antibodies Hybridomas 7 (1996), 97-105; Malmborg, J. Immunol. Methods 183 (1995), 7-13). Another exemplary method for generating monoclonal antibodies includes screening protein expression libraries, such as phage display or ribosome display libraries. Phage display is described, for example, in U.S. Pat. No. 5,223,409 to Ladner et al.; Smith (1985) Science 228:1315-1317; Clackson et al., Nature, 352:624-628 (1991); and Marks et al., J. Mol. Biol., 222:581-597 (1991).

[0179] In addition to using display libraries, relevant antigens can be used to immunize non-human animals, such as rodents (such as mice, hamsters, rabbits, or rats). In one embodiment, the non-human animal contains at least a portion of a human immunoglobulin gene. For example, mouse strains deficient in mouse antibody production can be engineered with large fragments of the human Ig (immunoglobulin) locus. Using hybridoma technology, antigen-specific monoclonal antibodies derived from genes with the desired specificity can be produced and selected. See, e.g., XENOMOUSE™, Green et al. (1994) Nature Genetics 7:13-21, U.S. Patent Application Publication No. 2003 / 0070185, WO 96 / 34096, and WO 96 / 33735.

[0180] Monoclonal antibodies can also be obtained from non-human animals and then modified, e.g., humanized, deimmunized, chimerized, etc., using recombinant DNA techniques known in the art. Examples of modified antibody constructs include humanized variants of non-human antibodies, "affinity matured" antibodies (see, e.g., Hawkins et al. J. Mol. Biol. 254, 889-896 (1992) and Lowman et al., Biochemistry 30, 10832-10837 (1991)), and antibody mutants with altered effector functions (see, e.g., U.S. Pat. No. 5,648,260; Kontermann and Duebel (2010), supra; and Little (2009), supra).

[0181] In immunology, affinity maturation is the process by which B cells produce antibodies with increasing affinity for antigens during the immune response. Repeated exposure to the same antigen leads the host to produce antibodies with successively increasing affinities. Similar to natural prototypes, in vitro affinity maturation is based on the principle of mutation and selection. In vitro affinity maturation has been successfully used to optimize antibodies, antibody constructs, and antibody fragments. Random mutations within the CDRs are introduced using radiation, chemical mutagens, or error-prone PCR. In addition, genetic diversity can be increased by chain shuffling. Two or three rounds of mutation and selection using display methods such as phage display typically yield antibody fragments with affinities in the low nanomolar range.

[0182] A preferred type of amino acid substitution variation of an antibody construct involves substituting one or more hypervariable region residues of a parent antibody (e.g., a humanized or human antibody). Generally, the resulting variant selected for further development will have improved biological properties relative to the parent antibody structure from which it was generated. A convenient method for generating such substitution variants involves affinity maturation using phage display. Briefly, several sites (e.g., 6-7 sites) in the hypervariable region are mutated to generate all possible amino acid substitutions at each site. The antibody variants thus generated are displayed in a monovalent manner from filamentous phage particles as fusions to the M13 gene III product packaged within each particle. Phage-displayed variants are then screened for biological activity (e.g., binding affinity) as disclosed herein. To identify candidate hypervariable region sites for modification, alanine scanning mutagenesis can be performed to identify hypervariable region residues contributing significantly to antigen binding. Alternatively, or in addition, it may be beneficial to analyze a crystal structure of the antigen-antibody complex to identify contact points between the binding domain and, for example, human MUC17. Such contact and adjacent residues are candidates for substitution according to the techniques detailed herein. Once such variants are generated, the panel of variants can be subjected to screening as described herein, and antibodies with superior properties in one or more relevant assays can be selected for further development.

[0183] The monoclonal antibodies and antibody constructs administered according to the present invention particularly include "chimeric" antibodies (immunoglobulins) in which a portion of the heavy and / or light chain is identical to or homologous to corresponding sequences in antibodies derived from a particular species or belonging to a particular antibody class or subclass, while the remainder of the chain is identical to or homologous to corresponding sequences in antibodies derived from another species or belonging to another antibody class or subclass, as long as they exhibit the desired biological activity, as well as fragments of such antibodies (U.S. Pat. No. 4,816,567; Morrison et al., Proc. Natl. Acad. Sci. USA, 81:6851-6855 (1984)). Chimeric antibodies of interest include "primatized" antibodies, which contain variable domain antigen-binding sequences derived from a non-human primate (e.g., Old World monkey, ape, etc.) and human constant region sequences. Various approaches for producing chimeric antibodies have been described. See, e.g., Morrison et al., Proc. Natl. Acad. ScL USA 81:6851, 1985; Takeda et al., Nature 314:452, 1985; Cabilly et al., U.S. Pat. No. 4,816,567; Boss et al., U.S. Pat. No. 4,816,397; Tanaguchi et al., EP 0171496; EP 0173494; and GB 2177096.

[0184] Antibodies, antibody constructs, antibody fragments, or antibody variants can also be modified by specific deletion of human T-cell epitopes (a method termed "deimmunization"), for example, by the methods disclosed in WO 98 / 52976 or WO 00 / 34317. Briefly, the heavy and light chain variable domains of an antibody can be analyzed for peptides that bind to MHC class II; such peptides represent potential T-cell epitopes (as defined in WO 98 / 52976 and WO 00 / 34317). Potential T-cell epitopes can be detected using a computer modeling approach termed "peptide threading," as described in WO 98 / 52976 and WO 00 / 34317; in addition, databases of human MHC class II-binding peptides can be searched for motifs present within the VH and VL sequences. This motif binds to any of the 18 major MHC class II DR allotypes and therefore constitutes a potential T cell epitope. Potential T cell epitopes detected can be eliminated by substituting a small number of amino acid residues within the variable domains, or preferably by single amino acid substitutions. Conservative substitutions are typically made. In many, but not all, amino acids common to positions within human germline antibody sequences can be used. Human germline sequences are disclosed, for example, in Tomlinson, et al. (1992) J. Mol. Biol. 227:776-798; Cook, GP et al. (1995) Immunol. Today Vol. 16(5):237-242; and Tomlinson et al. (1995) EMBO J. 14:14:4628-4638. The VBASE directory provides a comprehensive directory of human immunoglobulin variable region sequences (compiled by Tomlinson, LA. et al. MRC Centre for Protein Engineering, Cambridge, UK), which can be used as a source of human sequences, e.g., for framework regions and CDRs.Consensus human framework regions may also be used, for example, as described in US Pat. No. 6,300,064.

[0185] A "humanized" antibody, antibody construct, variant, or fragment thereof (such as Fv, Fab, Fab', F(ab')2, or other antigen-binding sequence of an antibody) is an antibody or immunoglobulin of largely human sequence that contains minimal sequence derived from non-human immunoglobulin. In most cases, humanized antibodies are human immunoglobulins (recipient antibody) in which residues from a hypervariable region (also called a CDR) of the recipient are replaced by residues from a hypervariable region of a non-human (e.g., rodent) species (donor antibody) such as mouse, rat, hamster, or rabbit having the desired specificity, affinity, and capacity. In some instances, Fv framework region (FR) residues of the human immunoglobulin are replaced by corresponding non-human residues. Furthermore, as used herein, "humanized antibodies" may also comprise residues that are not found in either the recipient antibody or the donor antibody. These modifications are made to further refine and optimize antibody performance. A humanized antibody can also comprise at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin. For further details, see Jones et al., Nature, 321:522-525 (1986); Reichmann et al., Nature, 332:323-329 (1988); and Presta, Curr. Op. Struct. Biol., 2:593-596 (1992). Humanized antibodies or fragments thereof can be generated by replacing sequences of the Fv variable domain not directly involved in antigen binding with equivalent sequences from a human Fv variable domain. Exemplary methods for making humanized antibodies or fragments thereof are provided by Morrison (1985) Science 229:1202-1207; Oi et al. (1986) BioTechniques 4:214, and U.S. Patent Nos. 5,585,089, 5,693,761, 5,693,762, 5,859,205, and 6,407,213. These methods include isolating, manipulating, and expressing the nucleic acid sequences that encode all or part of immunoglobulin Fv variable domains from at least one of a heavy or light chain.Such nucleic acids can be obtained from hybridomas and other sources that produce antibodies against the predetermined target described above. Recombinant DNA encoding the humanized antibody molecule can then be cloned into an appropriate expression vector. Humanized antibodies can also be produced using transgenic animals, such as mice, that express human heavy and light chain genes but are incapable of expressing endogenous mouse immunoglobulin heavy and light chain genes. Winter describes an exemplary CDR-grafting method that can be used to prepare the humanized antibodies described herein (U.S. Pat. No. 5,225,539). All of the CDRs of a particular human antibody can be replaced with at least a portion of a non-human CDR, or only a portion of the CDRs can be replaced with non-human CDRs. It is only necessary to replace the number of CDRs required for binding of the humanized antibody to a predetermined antigen. Humanized antibodies can be optimized by introducing conservative substitutions, consensus sequence substitutions, germline substitutions, and / or back mutations. Such modified immunoglobulin molecules can be produced by any of several techniques known in the art (e.g., Teng et al., Proc. Natl. Acad. Sci. USA, 80:7308-7312, 1983; Kozbor et al., Immunology Today, 4:7279, 1983; Olsson et al., Meth. Enzymol., 92:3-16, 1982, and EP 239400).

[0186] The terms "human antibody," "human antibody construct," and "human binding domain" include antibodies, antibody constructs, and binding domains having antibody regions, such as variable and constant regions or domains, that substantially correspond to human germline immunoglobulin sequences known in the art, including, for example, those described by Kabat et al. (1991) supra. Human antibodies, antibody constructs, or binding domains of the invention may include amino acid residues not encoded by human germline immunoglobulin sequences (e.g., mutations introduced by random or site-specific mutagenesis in vitro or by somatic mutation in vivo), for example, within the CDRs, particularly CDR3. Human antibodies, antibody constructs, or binding domains may have at least one, two, three, four, five, or more positions substituted with an amino acid residue not encoded by a human germline immunoglobulin sequence. The definitions of human antibody, antibody construct, and binding domain as used herein also contemplate fully human antibodies that contain only non-artificial and / or genetically modified human sequences of antibodies, such as those that can be derived using techniques or systems such as Xenomouse. Preferably, a "fully human antibody" does not contain amino acid residues that are not encoded by human germline immunoglobulin.

[0187] The antibody construct administered in accordance with the present invention is an "isolated" or "substantially pure" antibody construct. "Isolated" or "substantially pure," when used to describe the antibody constructs disclosed herein, refers to an antibody construct that has been identified, separated, and / or recovered from components of its production environment. Preferably, the antibody construct is free or substantially free from association with all other components from its production environment. Contaminant components of the production environment (e.g., those arising from recombinant, transfected cells) are typically substances that would interfere with diagnostic or therapeutic uses of the polypeptide and may include enzymes, hormones, and other proteinaceous or non-proteinaceous solutes. The antibody construct may, for example, constitute at least about 5% or at least about 50% by weight of the total protein in a given sample. It is understood that an isolated protein may constitute 5% to 99.9% by weight of the total protein content, depending on the circumstances. The polypeptide may be produced at significantly higher concentrations using inducible or high-expression promoters to ensure that the polypeptide is produced at high concentration levels. The definition includes the production of antibody constructs in a wide variety of organisms and / or host cells known in the art. In a preferred embodiment, the antibody construct will be purified (1) to a degree sufficient to obtain at least 15 residues of N-terminal or internal amino acid sequence by use of a spinning cup sequenator, or (2) to homogeneity by SDS-PAGE under non-reducing or reducing conditions using Coomassie blue, or preferably silver staining. Ordinarily, however, an isolated antibody construct will be prepared by at least one purification step.

[0188] The term "binding domain" characterizes a domain that specifically binds to / interacts with / recognizes a given target epitope or a given target site on a target molecule (antigen), herein: MUC17 and CD3. The structure and function of the first binding domain (recognizing MUC17), and also preferably the structure and / or function of the second binding domain (recognizing CD3), are based on the structure and / or function of an antibody, e.g., a full-length or complete immunoglobulin molecule, and / or are derived from the variable heavy chain (VH) and / or variable light chain (VL) domains of an antibody or fragment thereof. Preferably, the first binding domain is characterized by the presence of three light chain CDRs (i.e., CDR1, CDR2, and CDR3 of the VL region) and / or three heavy chain CDRs (i.e., CDR1, CDR2, and CDR3 of the VH region). The second binding domain also preferably comprises the minimal structural requirements of an antibody that enable target binding. More preferably, the second binding domain comprises at least three light chain CDRs (i.e., CDR1, CDR2, and CDR3 of the VL region) and / or three heavy chain CDRs (i.e., CDR1, CDR2, and CDR3 of the VH region). It is envisaged that the first binding domain and / or the second binding domain are produced or obtained by phage display or library screening methods, rather than by grafting CDR sequences from an existing (monoclonal) antibody into a scaffold.

[0189] According to the present invention, the binding domain is in the form of one or more polypeptides. Such polypeptides may comprise a proteinaceous portion and a non-proteinaceous portion (a chemical linker or chemical cross-linking agent, e.g., glutaraldehyde). Proteins (including fragments thereof, preferably biologically active fragments, and peptides, usually having less than 30 amino acids) comprise two or more amino acids coupled to each other via covalent peptide bonds (resulting in a chain of amino acids).

[0190] The term "polypeptide" as used herein describes a group of molecules, typically consisting of more than 30 amino acids. Polypeptides can further form multimers, such as dimers, trimers, and higher oligomers, i.e., multimers consisting of multiple polypeptide molecules. The polypeptide molecules forming such dimers, trimers, etc. may be identical or non-identical. The corresponding higher-order structures of such multimers are consequently referred to as homo- or heterodimers, homo- or heterotrimers, etc. An example of a heteromultimer is an antibody molecule, which in its naturally occurring form consists of two identical polypeptide light chains and two identical polypeptide heavy chains. The terms "peptide," "polypeptide," and "protein" also refer to naturally modified peptides / polypeptides / proteins that have been modified, for example, by post-translational modifications such as glycosylation, acetylation, phosphorylation, etc. Furthermore, "peptides," "polypeptides," or "proteins," as referred to herein, may be chemically modified, e.g., pegylated. Such modifications are well known in the art and are described herein below.

[0191] Preferably, the binding domain that binds MUC17 and / or the binding domain that binds CD3ε are human binding domains. Antibodies and antibody constructs comprising at least one human binding domain avoid some of the problems associated with antibodies or antibody constructs with non-human variable and / or constant regions, such as those derived from rodents (e.g., mouse, rat, hamster, or rabbit). The presence of such rodent-derived proteins can result in rapid clearance of the antibody or antibody construct or can lead to an immune response against the antibody or antibody construct by the patient. To avoid the use of rodent-derived antibodies or antibody constructs, human or fully human antibodies / antibody constructs can be generated by introducing human antibody function into rodents such that the rodents produce fully human antibodies.

[0192] The ability to clone and reconstruct megabase-sized human loci in yeast artificial chromosomes (YACs) and introduce them into the mouse germline provides a powerful approach for elucidating the functional elements of very large or loosely mapped loci and for generating useful models of human disease. Furthermore, techniques such as replacing mouse loci with their human equivalents will provide unique insights into the expression and regulation of nascent human gene products, their communication with other systems, and their involvement in disease induction and progression.

[0193] An important practical application of such a strategy is the "humanization" of the mouse humoral immune system. The introduction of human immunoglobulin (Ig) loci into mice in which the endogenous Ig genes have been inactivated provides an opportunity to study the mechanisms underlying the programmed expression and assembly of antibodies and their role in B-cell development. Furthermore, such a strategy would provide an ideal source for the production of fully human monoclonal antibodies (mAbs), a key milestone in realizing the promise of antibody therapy in human diseases. Fully human antibodies or antibody constructs are expected to minimize the immunogenicity and allergic reactions inherent in mouse or mouse-derived mAbs, thereby increasing the efficacy and safety of administered antibodies / antibody constructs. The use of fully human antibodies or antibody constructs is expected to offer significant advantages in the treatment of chronic and recurrent human diseases that require repeated administration of compounds, such as inflammation, autoimmunity, and cancer. One approach toward this goal has been to engineer mouse strains deficient in mouse antibody production with large fragments of human Ig loci, with the expectation that such mice would produce a broad repertoire of human antibodies in the absence of mouse antibodies. Large human Ig fragments would preserve the broad diversity of variable genes and the appropriate regulation of antibody production and expression. By utilizing the mouse machinery for antibody diversification and selection and the lack of immune tolerance to human proteins, the human antibody repertoire recapitulated in these mouse strains should yield high-affinity antibodies against any antigen of interest, including human antigens. Using hybridoma technology, antigen-specific human mAbs with desired specificities could be readily produced and selected. This general strategy was demonstrated in connection with the generation of the first XenoMouse mouse strains (see Green et al., Nature Genetics 7:13-21 (1994)). XenoMouse strains were engineered with YACs containing germline configuration fragments of the human heavy chain and kappa light chain loci, 245 kb and 190 kb in size, respectively, that contained the core sequences of the variable and constant regions.This human Ig-containing YAC has proven compatible with the mouse system for both antibody rearrangement and expression and was able to replace inactivated mouse Ig genes. This was demonstrated by the ability to induce B cell development to produce an adult-like human repertoire of fully human antibodies and to generate antigen-specific human mAbs. These results also suggested that the introduction of a large portion of the human Ig locus, containing multiple V genes, additional regulatory elements, and human Ig constant regions, could recapitulate the virtually complete repertoire characteristic of the human humoral response to infection and immunization. Recently, extending the work of Green et al., the introduction of megabase-sized germline-configuration YAC fragments of each human heavy chain locus and kappa light chain locus resulted in the introduction of approximately 80% of the human antibody repertoire. See Mendez et al., Nature Genetics 15:146-156 (1997) and U.S. Patent Application No. 08 / 759,620.The production of XenoMouse animals is further described in U.S. Patent Application Nos. 07 / 466008, 07 / 610,515, 07 / 919,297, 07 / 922,649, 08 / 031,801, 08 / 112,848, 08 / 234,145, 08 / 376,279, 08 / 430,938, 08 / 464,584, 08 / 464,582, 08 / 463,191, 08 / 462,837 ... This is discussed and accurately outlined in U.S. Patent Application Nos. 08 / 486,853, 08 / 486,857, 08 / 486,859, 08 / 462,513, 08 / 724,752, and 08 / 759,620; and U.S. Patent Nos. 6,162,963; 6,150,584; 6,114,598; 6,075,181, and 5,939,598, as well as Japanese Patent Nos. 3068180, 3068506, and 3068507. See also Mendez et al. Nature Genetics 15:146-156 (1997) and Green and Jakobovits J. Exp. Med. 188:483-495 (1998), EP 0463151 B1, WO 94 / 02602, WO 96 / 34096, WO 98 / 24893, WO 00 / 76310, and WO 03 / 47336.

[0194] In another approach, other companies, including GenPharm International, Inc., have utilized a "minilocus" approach. In the minilocus approach, an exogenous Ig locus is mimicked by including individual genes from the Ig locus. Thus, one or more VH genes, one or more DH genes, one or more JH genes, a mu constant region, and a second constant region (preferably a gamma constant region) are formed in a construct that is inserted into an animal. This approach is described in U.S. Pat. No. 5,545,807 to Surani et al., and in U.S. Pat. Nos. 5,545,806; 5,625,825; 5,625,126; 5,633,425; 5,661,016; 5,770,429; 5,789,650; 5,814,318; and 5,870,429 to Lonberg and Kay, respectively. Nos. 7,397; 5,874,299; and 6,255,458 to Krimpenfort and Berns, U.S. Pat. Nos. 5,591,669 and 6,023,010 to Berns et al., U.S. Pat. Nos. 5,612,205; 5,721,367; and 5,789,215 to Choi and Dunn, and U.S. Pat. No. 5,643,763 to GenPharm and U.S. Patent Application Nos. 07 / 574,748, 07 / 575,962, 07 / 810,279, 07 / 853,408, 07 / 904,068, 07 / 990,860, 08 / 053,131, 08 / 096,762, 08 / 155,301, 08 / 161,739, 08 / 165,699, and 08 / 209,741 to International.See EP 0546073B1, WO 92 / 03918, WO 92 / 22645, WO 92 / 22647, WO 92 / 22670, WO 93 / 12227, WO 94 / 00569, WO 94 / 25585, WO 96 / 14436, WO 97 / 13852, and WO 98 / 24884, and U.S. Pat. No. 5,981,175. See also Taylor et al. (1992) and (1994), Chen et al. (1993), Tuaillon et al. (1993) and (1995), Choi et al. (1993), Lonberg et al. (1994), and Fishwild et al. (1996).

[0195] Kirin has also demonstrated the production of human antibodies from mice into which large chromosome fragments or entire chromosomes have been introduced by microcell fusion. See EP 773288 and EP 843961. Xenerex Biosciences is developing a technology for the potential production of human antibodies. In this technology, SCID mice are reconstituted with human lymphocytes, such as B cells and / or T cells. The mice can then be immunized with an antigen to generate an immune response against that antigen. See U.S. Pat. Nos. 5,476,996; 5,698,767; and 5,958,765.

[0196] Human anti-mouse antibody (HAMA) responses have led industry to tailor chimeric or otherwise humanized antibodies. However, it is expected that certain human anti-chimeric antibody (HACA) responses will be observed, particularly with chronic or multiple-dose antibody use. Therefore, it would be desirable to provide an antibody construct comprising a human binding domain for MUC17 and a human binding domain for CD3ε to eliminate the concerns and / or impact of HAMA or HACA responses.

[0197] The terms "(selectively) bind to", "(specifically) bind to", "(specifically) recognize", "(specifically) be directed against" and "(specifically) react with" mean, according to the present invention, that a binding domain interacts or specifically interacts with a given epitope or a given target site on a target molecule (antigen), here MUC17 and CD3ε, respectively.

[0198] The term "epitope" refers to a site on an antigen to which a binding domain, such as an antibody or immunoglobulin, or a derivative, fragment, or variant of an antibody or immunoglobulin, specifically binds. Because "epitopes" are antigenic, the term epitope is sometimes also referred to herein as an "antigenic structure" or "antigenic determinant." Thus, the binding domain is the "antigen interaction site." The binding / interaction is also understood to define "specific recognition." An "epitope" can be formed by both contiguous or non-contiguous amino acids juxtaposed by tertiary folding of a protein. A "linear epitope" is an epitope in which the primary amino acid sequence constitutes the recognized epitope. A linear epitope typically contains at least three or at least four, more commonly at least five, at least six, or at least seven, e.g., about 8 to about 10, amino acids in a unique sequence. A "conformational epitope," in contrast to a linear epitope, is an epitope in which the primary sequence of amino acids comprising the epitope is not the only defining element of the recognized epitope (e.g., an epitope in which the primary sequence of amino acids is not necessarily recognized by a binding domain). Typically, a conformational epitope comprises an increased number of amino acids compared to a linear epitope. With regard to the recognition of a conformational epitope, the binding domain recognizes the three-dimensional structure of an antigen, preferably a peptide or protein, or a fragment thereof (in the context of the present invention, the antigenic structure for one of the binding domains is contained within the target cell surface antigen protein). For example, when a protein molecule folds to form a three-dimensional structure, certain amino acids and / or polypeptide backbones forming the conformational epitope are juxtaposed, thereby enabling an antibody to recognize the epitope. Methods of determining the conformation of epitopes include, but are not limited to, X-ray crystallography, two-dimensional nuclear magnetic resonance (2D-NMR) spectroscopy, and site-directed spin labeling and electron paramagnetic resonance (EPR) spectroscopy.The method of epitope mapping is described below: When a region (a contiguous stretch of amino acids) in the human MUC17 protein is exchanged or substituted with the corresponding region of nonhuman and nonprimate MUC17 (e.g., mouse MUC17, but also chicken, rat, hamster, rabbit, etc.), reduced binding of the binding domain is expected, as long as the binding domain is not cross-reactive with the nonhuman, nonprimate MUC17 used. This reduction is preferably at least 10%, 20%, 30%, 40%, or 50%; more preferably at least 60%, 70%, or 80%, and most preferably 90%, 95%, or even 100% relative to the binding of each region in the human MUC17 protein, assuming binding to each region in the human MUC17 protein is 100%. It is envisioned that the above-described human MUC17 / non-human MUC17 chimeras will be expressed in CHO cells. It is also envisioned that human MUC17 / non-human MUC17 chimeras may be fused to the transmembrane and / or cytoplasmic domains of different membrane-associated proteins, such as EpCAM.

[0199] In an alternative or additional method of epitope mapping, several truncations of the human MUC17 extracellular domain can be generated to determine the specific region recognized by the binding domain. In the truncations, different extracellular MUC17 domains / subdomains or regions are deleted stepwise, starting from the N-terminus. It is contemplated that truncated MUC17 can be expressed in CHO cells. It is also contemplated that truncated MUC17 can be fused to the transmembrane and / or cytoplasmic domains of different membrane-associated proteins, such as EpCAM. It is also contemplated that truncated MUC17 can include a signal peptide domain at the N-terminus, such as a signal peptide derived from the mouse IgG heavy chain signal peptide. Furthermore, it is contemplated that truncated MUC17 can include a v5 domain at the N-terminus (following the signal peptide), which can confirm correct expression on the cell surface. A truncated MUC17 that no longer includes the MUC17 region recognized by the binding domain is expected to result in reduced or lost binding. The reduction in binding is preferably at least 10%, 20%, 30%, 40%, or 50%; more preferably at least 60%, 70%, 80%, and most preferably 90%, 95%, or even 100%, where binding to the entire human MUC17 protein (or its extracellular region or domain) is taken as 100%.

[0200] A further method for determining the contribution of specific residues of MUC17 to recognition by an antibody construct or binding domain is alanine scanning, in which each residue to be analyzed is substituted with alanine, e.g., via site-directed mutagenesis (see, e.g., Morrison KL & Weiss GA. Cur Opin Chem Biol. 2001 Jun;5(3):302-7). Alanine is used because of its non-bulky, chemically inert methyl functional group, which still mimics the secondary structure criteria of many other amino acids. Occasionally, bulky amino acids such as valine or leucine can be used when it is desired to preserve the size of the mutated residue. Alanine scanning is a mature technique that has been used for a long time.

[0201] The interaction between a binding domain and an epitope or an epitope-containing region means that the binding domain exhibits substantial affinity for the epitope / epitope-containing region on a particular protein or antigen (herein, MUC17 and CD3), and generally does not exhibit significant reactivity with proteins or antigens other than MUC17 or CD3. "Substantial affinity" refers to a binding domain with an affinity of about 10 -6 M(KD) or stronger. Preferably, the binding affinity is about 10 -12 ~10 -8 M, 10 -12 ~10 -9 M, 10 -12 ~10 -10 M, 10 -11 ~10 -8 M, preferably about 10 -11 ~10 -9 Binding is considered specific when M is M. Whether a binding domain specifically reacts with or binds to a target can be easily tested, inter alia, by comparing the reaction of the binding domain with the target protein or antigen to the reaction of the binding domain with proteins or antigens other than MUC17 or CD3. Preferably, the binding domains of the present invention do not essentially or substantially bind to proteins or antigens other than MUC17 or CD3 (i.e., the first binding domain cannot bind to proteins other than MUC17, and the second binding domain cannot bind to proteins other than CD3). An expected feature of the antibody constructs of the present invention is that they have superior affinity characteristics compared to other HLE formats. Such superior affinity consequently suggests an extended in vivo half-life. The longer half-life of the antibody constructs of the present invention can reduce the duration and frequency of administration, which typically contributes to improved patient compliance. This is particularly important because the antibody constructs of the present invention are particularly beneficial for highly debilitated or even multi-disease cancer patients.

[0202] The terms "does not essentially / substantially bind" or "cannot bind" mean that the binding domains of the invention do not bind to proteins or antigens other than MUC17 or CD3, i.e., do not exhibit more than 30%, preferably more than 20%, more preferably more than 10%, and particularly preferably more than 9%, 8%, 7%, 6%, or 5% reactivity with proteins or antigens other than MUC17 or CD3, when binding to MUC17 or CD3, respectively, is taken as 100%.

[0203] Specific binding is believed to be mediated by specific motifs within the amino acid sequences of the binding domain and the antigen. Thus, binding is achieved as a result of their primary, secondary, and / or tertiary structure, as well as secondary modifications of said structure. Specific interaction of the antigen-interaction site with its specific antigen can result in simple binding of said site to the antigen. Furthermore, specific interaction of the antigen-interaction site with its specific antigen can alternatively or additionally result in the initiation of a signal, for example, due to the induction of a conformational change in the antigen, oligomerization of the antigen, etc.

[0204] The term "variable" refers to the portion of an antibody or immunoglobulin domain (i.e., the "variable domain") that exhibits variability in sequence and is responsible for determining the specificity and binding affinity of a particular antibody. The variable heavy chain (VH) and variable light chain (VL) pair together to form a single antigen-binding site. The variability is not uniformly distributed throughout the variable domain of an antibody, but is concentrated within subdomains of each of the heavy and light chain variable regions. These subdomains are called "hypervariable regions" or "complementarity-determining regions" (CDRs). The more conserved (i.e., non-hypervariable) portions of the variable domain are called "framework" regions (FRMs or FRs), which provide a scaffold for the six CDRs that form the antigen-binding surface in three-dimensional space. Naturally occurring heavy and light chain variable domains each contain four FRM regions (FR1, FR2, FR3, and FR4) that largely adopt a β-sheet configuration, connected by three hypervariable regions that form loops connecting, and occasionally forming part of, the β-sheet structure. The hypervariable regions in each chain are held together in close proximity by the FRMs and, with the hypervariable regions from the other chain, contribute to the formation of the antigen-binding site (see Kabat et al., supra).

[0205] The term "CDR" and its plural "CDRs" refer to complementarity-determining regions, three of which (CDR-L1, CDR-L2, and CDR-L3) constitute the binding properties of the light chain variable region, and three of which (CDR-H1, CDR-H2, and CDR-H3) constitute the binding properties of the heavy chain variable region. CDRs contain most of the residues responsible for the antibody's specific interactions with the antigen and thus contribute to the functional activity of the antibody molecule; CDRs are the primary determinants of antigen specificity. The precise definition of the boundaries and lengths of CDRs follows various classification and numbering systems. Thus, CDRs may be referred to by Kabat, Chothia, contact, or any other boundary definition, including the numbering systems described herein. Although the boundaries differ, each of these systems has some overlap in the portions that constitute the so-called "hypervariable regions" within the variable sequences. Thus, CDR definitions according to these systems may differ in length and boundary regions relative to the adjacent framework regions. See, for example, Kabat (an approach based on interspecies sequence variability), Chothia (an approach based on crystallographic studies of antigen-antibody complexes), and / or MacCallum (Kabat et al., supra; Chothia et al., J. Mol. Biol., 1987, 196:901-917; and MacCallum et al., J. Mol. Biol., 1996, 262:732). Yet another standard for characterizing antigen-binding sites is the AbM definition used by Oxford Molecular's AbM antibody modeling software. See, for example, Protein Sequence and Structure Analysis of Antibody Variable Domains. In: Antibody Engineering Lab Manual (Eds.: Duebel, S. and Kontermann, R., Springer-Verlag, Heidelberg). Two residue identification techniques can be combined to define hybrid CDRs, as long as they define overlapping but not identical regions. However, numbering according to the so-called Kabat system is preferred. Typically, the CDRs form loop structures that can be classified as canonical structures.The term "canonical structure" refers to the main chain conformation adopted by an antigen-binding (CDR) loop. Comparative structural studies have found that five of the six antigen-binding loops have only a limited repertoire of available conformations. Each canonical structure can be characterized by the torsion angles of the polypeptide backbone. Thus, corresponding loops between antibodies can have very similar three-dimensional structures, despite the high amino acid sequence variability in most parts of the loop (Chothia and Lesk, J. Mol. Biol., 1987, 196:901; Chothia et al., Nature, 1989, 342:877; Martin and Thornton, J. Mol. Biol., 1996, 263:800). Furthermore, there is a relationship between the loop conformation adopted and the surrounding amino acid sequence. The conformation of a particular canonical class is determined by the length of the loop and the amino acid residues present at key positions within the loop and within the conserved framework (i.e., outside the loop), and therefore assignment to a particular canonical class can be made based on the presence of these key amino acid residues.

[0206] The term "canonical structure" can also include considerations regarding the linear sequence of an antibody, for example, as classified by Kabat (Kabat et al., supra). The Kabat numbering scheme is a widely adopted standard for numbering the amino acid residues of antibody variable domains in a consistent manner and, as noted elsewhere herein, is the preferred scheme used in the present invention. Additional structural considerations can also be used to determine the canonical structure of an antibody. For example, differences not fully reflected by the Kabat numbering can be accounted for by the numbering system of Chothia et al. and / or can be revealed by other techniques, such as crystallography and two- or three-dimensional computer modeling. Thus, a given antibody sequence is placed into a canonical class, which may, among other things, allow for the identification of an appropriate chassis sequence (e.g., based on the desire to include various canonical structures in a library). The Kabat numbering of antibody amino acid sequences and the structural considerations described by Chothia et al. (supra), as well as their significance in interpreting canonical aspects of antibody structure, are explained in the literature. The subunit structures and three-dimensional configurations of various classes of immunoglobulins are well known in the art. For a review of antibody structure, see Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory, eds. Harlow et al., 1988.

[0207] The CDR3 of the light chain and, in particular, the CDR3 of the heavy chain may constitute the most important determinant for antigen binding within the light chain variable region and the heavy chain variable region. In some antibody constructs, the heavy chain CDR3 appears to constitute the main contact area between the antigen and the antibody. An in vitro selection scheme that changes only the CDR3 can be used to change the binding properties of the antibody or to determine which residues contribute to antigen binding. Therefore, the CDR3 is typically the greatest source of molecular diversity within the antibody binding site. For example, H3 can be as few as 2 amino acid residues or more than 26 amino acids.

[0208] In a classical full-length antibody or immunoglobulin, each light (L) chain is linked to a heavy (H) chain by one covalent disulfide bond, while the two H chains are linked to each other by one or more disulfide bonds, depending on the H chain isotype. The CH domain closest to the VH is usually referred to as CH1. The constant ("C") domains are not directly involved in antigen binding but exhibit various effector functions, such as antibody-dependent, cell-mediated cytotoxicity, and complement activation. The Fc region of an antibody is contained within the heavy chain constant domain and can, for example, interact with Fc receptors located on the cell surface.

[0209] The sequences of antibody genes after assembly and somatic mutation are highly diverse, and the diverse genes are 10 It is estimated that each gene encodes a different antibody molecule (Immunoglobulin Genes, 2 nd (ed., eds. Jonio et al., Academic Press, San Diego, CA, 1995). Thus, the immune system provides a repertoire of immunoglobulins. The term "repertoire" refers to at least one nucleotide sequence derived, in whole or in part, from at least one sequence encoding at least one immunoglobulin. The sequences can be generated by in vivo rearrangement of V, D, and J segments of heavy chains and V and J segments of light chains. Alternatively, the sequences can be generated by cells undergoing rearrangement, e.g., in response to in vitro stimulation. Alternatively, some or all of the sequences can be obtained by DNA splicing, nucleotide synthesis, mutagenesis, and other methods (see, e.g., U.S. Pat. No. 5,565,332). A repertoire can include only one sequence or multiple sequences, including those within a genetically diverse collection.

[0210] The term "Fc portion" or "Fc monomer" in the context of the present invention refers to a polypeptide comprising at least one domain having the function of a CH2 domain and at least one domain having the function of a CH3 domain of an immunoglobulin molecule. As is evident from the term "Fc monomer," a polypeptide comprising these CH domains is a "polypeptide monomer." An Fc monomer may be a polypeptide comprising at least a fragment of an immunoglobulin constant region, excluding the first constant region immunoglobulin domain (CH1) of the heavy chain, but retaining at least a functional portion of one CH2 domain and one functional portion of one CH3 domain, where the CH2 domain is amino-terminal to the CH3 domain. In a preferred embodiment of this definition, an Fc monomer may be a polypeptide constant region comprising a portion of an Ig-Fc hinge region, a CH2 region, and a CH3 region, where the hinge region is amino-terminal to the CH2 domain. The hinge region of the present invention is assumed to promote dimerization. Such Fc polypeptide molecules can be obtained, for example, but not limited to, by papain digestion of an immunoglobulin region (which, of course, produces a dimer of two Fc polypeptides). In another aspect of this definition, an Fc monomer can be a polypeptide region comprising a portion of a CH2 region and a CH3 region. Such Fc polypeptide molecules can be obtained, for example, but not limited to, by pepsin digestion of an immunoglobulin molecule. In one embodiment, the polypeptide sequence of the Fc monomer is substantially similar to the Fc polypeptide sequences of an IgG1 Fc region, an IgG2 Fc region, an IgG3 Fc region, an IgG4 Fc region, an IgM Fc region, an IgA Fc region, an IgD Fc region, and an IgE Fc region (see, e.g., Padlan, Molecular Immunology, 31(3), 169-217 (1993)). Because some variation exists between immunoglobulins, and simply for clarity, the Fc monomer refers to the two heavy chain constant region immunoglobulin domains at the end of IgA, IgD, and IgG, and the three heavy chain constant region immunoglobulin domains at the end of IgE and IgM.

[0211] As described above, an Fc monomer may also comprise a flexible hinge N-terminal to these domains. For IgA and IgM, the Fc monomer may comprise a J chain. For IgG, the Fc portion comprises immunoglobulin domains CH2 and CH3, and a hinge between the first two domains and CH2. Although the boundaries of the Fc portion may vary, an example of a human IgG heavy chain Fc portion comprising functional hinge, CH2, and CH3 domains can be defined as including, for example, residue D231 (corresponding to D234 in Table 2 below) of the hinge domain to P476 and L476 (for IgG4) at the carboxyl terminus of the CH3 domain, respectively (numbering according to Kabat). Two Fc portions or Fc monomers fused to each other via a peptide linker define the third domain of the antibody construct of the invention, which may also be defined as an scFc domain. The scFc domains disclosed herein, each of the Fc monomers fused to one another, are envisioned to be comprised only in the third domain of the antibody construct.

[0212] [Table 2]

[0213] The locations and sequences of the IgG CH2 and IgG CD3 domains can be identified by similarity using the Kabat numbering shown in Table 3.

[0214] [Table 3]

[0215] In one embodiment of the present invention, the amino acid residues highlighted in bold within the CH3 domain of the first or both Fc monomers are deleted.

[0216] The peptide linker fusing the polypeptide monomers of the third domain ("Fc portion" or "Fc monomer") to one another preferably comprises at least 25 amino acid residues (25, 26, 27, 28, 29, 30, etc.). More preferably, the peptide linker comprises at least 30 amino acid residues (30, 31, 32, 33, 34, 35, etc.). It is also preferred that the linker comprises a maximum of 40 amino acid residues, more preferably a maximum of 35 amino acid residues, and most preferably exactly 30 amino acid residues.

[0217] When a linker is used to fuse a first domain to a second domain, or to fuse a first or second domain to a third domain, the linker is preferably of sufficient length and sequence to ensure that the first and second domains retain their distinct binding specificities independently of each other. For peptide linkers connecting at least two binding domains (or two variable domains) in an antibody construct, peptide linkers containing only a few amino acid residues, for example, 12 or fewer, are preferred. Thus, peptide linkers of 12, 11, 10, 9, 8, 7, 6, or 5 amino acid residues are preferred. Peptide linkers with fewer than five amino acids are contemplated, containing 4, 3, 2, or 1 amino acid, with Gly-rich linkers being preferred. A preferred embodiment of a peptide linker for fusing the first and second domains is shown in SEQ ID NO: 10. A preferred linker embodiment of a peptide linker for fusing the second and third domains is a (Gly)4-linker, also referred to as a G4-linker. The characteristics of the peptide linker, including not promoting secondary structures, are known in the art and are described, for example, in Dall'Acqua et al. (Biochem. (1998) 37, 9266-9273), Cheadle et al. (Mol Immunol (1992) 29, 21-30), and Raag and Whitlow (FASEB (1995) 9(1), 73-80). Furthermore, peptide linkers that do not promote any secondary structures are preferred. The linkage of the domains to each other can be achieved, for example, by genetic engineering, as described in the Examples. Methods for preparing fused and operably linked bispecific single-chain constructs and expressing them in mammalian cells or bacteria are well known in the art (e.g., WO 99 / 54440 or Sambrook et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, 2001).

[0218] According to a particularly preferred embodiment, the first and second domains of the antibody construct of the present invention are "bispecific single-chain antibody constructs," more preferably bispecific "single-chain Fvs" (scFvs). Although the two domains of an Fv fragment, VL and VH, are encoded by separate genes, they can be joined by a synthetic linker (as described hereinabove) that allows them to be produced as a single protein chain using recombinant methods in which the VL and VH regions pair to form a monovalent molecule (see, e.g., Huston et al. (1988) Proc. Natl. Acad. Sci USA 85:5879-5883). These antibody fragments can be obtained using conventional techniques known to those skilled in the art, and the fragments can be evaluated for function in the same manner as full-length or whole antibodies. Thus, a single-chain variable fragment (scFv) is a fusion protein of the variable regions of immunoglobulin heavy (VH) and light (VL) chains linked by a short linker peptide, typically about 10 to about 25 amino acids, preferably about 15 to 20 amino acids. The linker is typically glycine-rich for flexibility and serine- or threonine-rich for solubility, and can link the N-terminus of VH to the C-terminus of VL, or vice versa. This protein retains the specificity of the original immunoglobulin despite the removal of the constant region and the introduction of the linker.

[0219] Bispecific single-chain antibody constructs are known in the art and are described in WO 99 / 54440, Mack, J. Immunol. (1997), 158, 3965-3970, Mack, PNAS, (1995), 92, 7021-7025, Kufer, Cancer Immunol. Immunother., (1997), 45, 193-197, Loeffler, Blood, (2000), 95, 6, 2098-2103, Bruehl, Immunol., (2001), 166, 2420-2426, Kipriyanov, J. Mol. Biol., (1999), 293, 41-56. Techniques described for the production of single chain antibodies (see, inter alia, U.S. Pat. No. 4,946,778; Kontermann and Duebel (2010), supra; and Little (2009), supra) can be adapted to produce single chain antibody constructs that specifically recognize a target of choice.

[0220] Bivalent (also called divalent) or bispecific single-chain variable fragments (bi-scFv or di-scFv with format (scFv)2) can be engineered by linking two scFv molecules (e.g., using a linker as described herein above). If the two scFv molecules have the same binding specificity, the resulting (scFv)2 molecule is preferably called bivalent (i.e., has two valencies for the same target epitope). If the two scFv molecules have different binding specificities, the resulting (scFv)2 molecule is preferably called bispecific. Linking can be done by producing a single peptide chain with two VH and two VL regions, resulting in a tandem scFv (see, e.g., Kufer P. et al., (2004) Trends in Biotechnology 22(5):238-244). Another possibility is to create scFv molecules with a linker peptide that is too short (e.g., about 5 amino acids) to allow the two variable regions to fold together, thereby allowing the scFvs to dimerize, a type known as a diabody (see, e.g., Hollinger, Philipp et al., (July 1993) PNAS 90(14):6444-8).

[0221] The first, second, or first and second domains may all constitute a single domain antibody, a variable domain or at least the CDRs of a single domain antibody. Single domain antibodies contain only one (monomeric) antibody variable domain that is capable of selectively binding to a specific antigen, independent of other V regions or domains. The first single domain antibodies were engineered from heavy chain antibodies found in camels, and consist of V H Cartilaginous fish also have heavy chain antibodies (IgNAR), from which V fragments are derived. NARSingle domain antibodies, called fragments, can be obtained. An alternative approach is to split the dimeric variable domain of a common immunoglobulin, e.g., human or rodent, into monomers to obtain VH or VL as single domain Abs. Currently, most research on single domain antibodies is based on the heavy chain variable region, but nanobodies derived from light chains have also been shown to specifically bind to target epitopes. Examples of single domain antibodies are called sdAbs, nanobodies, or single variable domain antibodies. Therefore, a (single domain mAb)2 is a V H , V L , V H H and V NAR A monoclonal antibody construct is a monoclonal antibody construct composed of (at least) two single domain monoclonal antibodies independently selected from the group comprising: (a) an "scFv-single domain mAb" and (b) an "scFv-single domain mAb"; and (c) an "scFv-single domain mAb"; a ...

[0222] Whether an antibody construct competes for binding with another given antibody construct can be measured by a competitive assay, such as a competitive ELISA or a cell-based competitive assay. Avidin-conjugated microparticles (beads) can also be used. Similar to an avidin-coated ELISA plate, each of these beads can be used as a substrate when reacted with biotinylated proteins, on which the assay can be performed. Antigen is coated on the beads, followed by pre-coating with the first antibody. A second antibody is added, and any additional binding is determined. Possible means for reading include flow cytometry.

[0223] Cytotoxicity mediated by an antibody construct can be measured by various methods. Effector cells can be, for example, stimulated enriched (human) CD8-positive T cells or unstimulated (human) peripheral blood mononuclear cells (PBMCs). If the target cells are of macaque origin or express or are transfected with macaque MUC17 bound by the first domain, the effector cells should also be of macaque origin, such as a macaque T cell line, e.g., 4119LnPx. The target cells should express MUC17, e.g., human or macaque MUC17 (at least the extracellular domain of MUC17). The target cells can be a cell line (e.g., CHO) that is stably or transiently transfected with MUC17, e.g., human or macaque MUC17. Typically, EC 50 Values ​​are expected to decrease as target cell lines express higher levels of MUC17 on their cell surface. The effector to target cell (E:T) ratio is typically approximately 10:1, but can vary. The cytotoxic activity of MUC17 bispecific antibody constructs is 51 Cytotoxicity can be measured by Cr release assay (incubation time of about 18 hours) or FACS-based cytotoxicity assay (incubation time of about 48 hours). Modification of the incubation time (cytotoxic response) of the assay is also possible. Other methods for measuring cytotoxicity are well known to those skilled in the art and include MTT or MTS assays, ATP-based assays including bioluminescence assays, sulforhodamine B (SRB) assays, WST assays, clonogenic assays, and ECIS techniques.

[0224] The cytotoxic activity mediated by the MUC17xCD3 antibody construct is preferably measured by a cell-based cytotoxicity assay. 51 Cytotoxic activity can be measured by EC 50 The EC values ​​are expressed as half-maximal effective concentrations (the concentration of an antibody construct that induces a cytotoxic response halfway between baseline and maximum). Preferably, the EC values ​​are 0.05 for the MUC17xCD3 antibody construct. 50Values ​​are ≦5000 pM or ≦4000 pM, more preferably ≦3000 pM or ≦2000 pM, even more preferably ≦1000 pM or ≦500 pM, even more preferably ≦400 pM or ≦300 pM, even more preferably ≦200 pM, even more preferably ≦100 pM, even more preferably ≦50 pM, even more preferably ≦20 pM or ≦10 pM, and most preferably ≦5 pM. Preferably, the MUC17×CD3 antibody construct does not induce / mediate lysis, or essentially does not induce / mediate lysis, of MUC17-negative cells, such as CHO cells. The terms "does not induce lysis," "does not essentially induce lysis," "does not mediate lysis," or "does not essentially mediate lysis" mean that the antibody constructs of the invention do not induce or mediate lysis of more than 30%, preferably more than 20%, more preferably more than 10%, and particularly preferably more than 9%, 8%, 7%, 6%, or 5% of MUC17-negative cells, where lysis of a MUC17-positive human cell line is taken as 100%. This typically applies for antibody construct concentrations of up to 500 nM. Those skilled in the art will know how to measure cell lysis without further ado.

[0225] The first and / or second (or any additional) binding domains of the antibody constructs of the invention are preferably cross-species specific for members of the mammalian order of primates. Cross-species specific CD3 binding domains are described, for example, in WO 2008 / 119567. According to one embodiment, in addition to binding to human MUC17 and human CD3, the first and / or second binding domains will also bind to MUC17 / CD3 of primates, including, but not limited to, New World primates (such as marmosets (Callithrix jacchus), cotton-top tamarins (Saguinus Oedipus), or squirrel monkeys (Saimiri sciureus)), Old World primates (such as baboons and macaques), gibbons, and non-human hominins.

[0226] The term "pharmaceutical composition" as used herein relates to a composition suitable for administration to a patient, preferably a human patient. Particularly preferred pharmaceutical compositions of the present invention comprise one or more antibody constructs of the present invention, preferably in a therapeutically effective amount. Preferably, the pharmaceutical composition further comprises one or more (pharmaceutically effective) carriers, stabilizers, excipients, diluents, solubilizers, surfactants, emulsifiers, preservatives, and / or suitable formulations of adjuvants. Acceptable components of the composition are preferably non-toxic to recipients at the dosages and concentrations employed. Pharmaceutical compositions of the present invention include, but are not limited to, liquid compositions, frozen compositions, and lyophilized compositions. The compositions may comprise a pharmaceutically acceptable carrier. Generally, as used herein, "pharmaceutically acceptable carrier" refers to any and all aqueous and non-aqueous solutions, sterile solutions, solvents, buffers, e.g., phosphate-buffered saline (PBS) solutions, water, suspensions, emulsions such as oil / water emulsions, various types of wetting agents, liposomes, dispersion media, and coatings that are compatible with pharmaceutical administration, particularly parenteral administration. The use of such media and agents in pharmaceutical compositions is well known in the art, and compositions containing such carriers can be formulated by well-known conventional methods. In certain embodiments, pharmaceutical compositions can contain formulating materials intended to modify, sustain, or preserve, for example, the pH, osmolality, viscosity, clarity, color, isotonicity, odor, sterility, stability, dissolution or release rate, adsorption, or penetration of the composition (see REMINGTON'S PHARMACEUTICAL SCIENCES, 18th Edition, (AR Genrmo, ed.), 1990, Mack Publishing Company). In such embodiments, suitable formulating materials can include, but are not limited to, the following: amino acids, such as glycine, alanine, glutamine, asparagine, threonine, proline, 2-phenylalanine (including charged amino acids, preferably lysine, lysine acetate, arginine, glutamate, and / or histidine); ·Antibacterial drugs, such as antibacterial and antifungal agents; Antioxidants such as ascorbic acid, methionine, sodium sulfite, or sodium bisulfite; buffers, buffer systems, and buffering agents used to maintain the composition at physiological pH or slightly lower, preferably at a lower pH of 4.0-6.5; examples of buffers include boric acid, bicarbonate, Tris-HCl, citric acid, phosphoric acid, or other organic acids, succinic acid, phosphate, and histidine; for example, Tris buffer at about pH 7.0-8.5; non-aqueous solvents, such as propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable organic esters such as ethyl oleate; Aqueous carriers, including water, alcoholic / aqueous solutions, emulsions, or suspensions (including saline and buffered media); ·Biodegradable polymers such as polyester; · Bulking agents such as mannitol or glycine; · Chelating agents such as ethylenediaminetetraacetic acid (EDTA); ·Isotonic and absorption retarding agents; Complexing agents such as caffeine, polyvinylpyrrolidone, beta-cyclodextrin, or hydroxypropyl-beta-cyclodextrin; Fillers; Monosaccharides; disaccharides; and other carbohydrates (such as glucose, mannose, or dextrins); the carbohydrates may be non-reducing sugars, preferably trehalose, sucrose, octasulfate, sorbitol, or xylitol; (low molecular weight) proteins, polypeptides or proteinaceous carriers, preferably of human origin, such as human or bovine serum albumin, gelatin or immunoglobulins; · coloring and flavoring agents; sulfur-containing reducing agents, such as glutathione, thioctic acid, sodium thioglycolate, thioglycerol, [alpha]-monothioglycerol, and sodium thiosulfate; · Diluents; ·emulsifier; · Hydrophilic polymers such as polyvinylpyrrolidone; · Salt-forming counterions such as sodium; Preservatives, such as antimicrobials, antioxidants, chelating agents, and inert gases; examples include benzalkonium chloride, benzoic acid, salicylic acid, thimerosal, phenethyl alcohol, methylparaben, propylparaben, chlorhexidine, sorbic acid, or hydrogen peroxide; · Metal complexes such as Zn-protein complexes; · Solvents and co-solvents (such as glycerin, propylene glycol, or polyethylene glycol); sugars and sugar alcohols, for example trehalose, sucrose, octasulfate, mannitol, sorbitol or xylitol, stachyose, mannose, sorbose, xylose, ribose, myoinisitose, galactose, lactitol, ribitol, myoinisitol, galactitol, glycerol, cyclitols (for example inositol), polyethylene glycol; and polyhydric sugar alcohols; · suspending agents; surfactants or wetting agents, such as pluronics, PEG, sorbitan esters, polysorbates, e.g., polysorbate 20, polysorbate, Triton, tromethamine, lecithin, cholesterol, tyloxapol; surfactants can be detergents, preferably with a molecular weight of >1.2 KD, and / or polyethers, preferably with a molecular weight of >3 KD; non-limiting examples of preferred detergents include Tween 20, Tween 40, Tween 60, Tween 80, and Tween 85; non-limiting examples of preferred polyethers include PEG 3000, PEG 3350, PEG 4000, and PEG 5000; ·Stability enhancers such as sucrose or sorbitol; isotonicity enhancing agents, for example alkali metal halides, preferably sodium chloride or potassium chloride, mannitol, sorbitol; Parenteral delivery vehicles, including sodium chloride solution, Ringer's dextrose, dextrose and sodium chloride, lactated Ringer's solution, or fixed oils; Intravenous delivery vehicles, including fluid and nutrient replenishers, electrolyte replenishers (such as those based on Ringer's dextrose).

[0227] It is contemplated that, in addition to the antibody construct defined herein, the composition may contain additional biologically active agents, depending on the intended use of the composition. Such agents may be drugs known in the art, such as drugs acting on the gastrointestinal system, drugs acting as cytostatics, drugs preventing hyperuricemia, drugs inhibiting immune responses (e.g., corticosteroids), drugs modulating inflammatory responses, drugs acting on the circulatory system, and / or cytokines. It is also contemplated that the antibody construct of the present invention may be used in combination therapy, i.e., in combination with another anti-cancer drug. In certain embodiments, the optimal pharmaceutical composition will be determined by one of skill in the art depending, for example, on the intended route of administration, delivery format, and desired dosage. See, e.g., REMINGTON'S PHARMACEUTICAL SCIENCES, supra. In certain embodiments, such compositions may affect the physical state, stability, in vivo release rate, and in vitro clearance rate of the antibody construct of the present invention. In certain embodiments, the primary vehicle or carrier in a pharmaceutical composition may be either aqueous or non-aqueous in nature. For example, a suitable vehicle or carrier may be water for injection, saline solution, or artificial cerebrospinal fluid, optionally supplemented with other ingredients common in compositions for parenteral administration. Neutral buffered saline or saline mixed with serum albumin are further exemplary vehicles. In certain embodiments, the antibody constructs of the compositions of the present invention may be prepared for storage by combining selected compositions having a desired degree of purity with optional formulating agents (REMINGTON'S PHARMACEUTICAL SCIENCES, supra) in the form of a lyophilized cake or aqueous solution. Furthermore, in certain embodiments, the antibody constructs of the present invention may be formulated as a lyophilizate using appropriate excipients such as sucrose.

[0228] When parenteral administration is intended, the therapeutic composition used in the present invention may be provided in the form of a pyrogen-free, parenterally acceptable aqueous solution containing the desired antibody construct of the present invention in a pharmaceutically acceptable vehicle. A particularly suitable vehicle for parenteral injection is sterile distilled water, in which the antibody construct of the present invention is formulated as a sterile, isotonic solution, properly preserved. In certain embodiments, preparations may include formulating the desired molecule with agents capable of achieving controlled or sustained release of the product, such as injectable microspheres, bioerodible particles, polymeric compounds (such as polylactic acid or polyglycolic acid), beads, or liposomes, which may be delivered via depot injection. In certain embodiments, hyaluronic acid, which has the effect of enhancing duration in the circulation, may be used. In certain embodiments, the desired antibody construct may be introduced using an implantable drug delivery device.

[0229] Additional pharmaceutical compositions will be apparent to those skilled in the art, including formulations comprising the antibody constructs of the present invention in sustained- or controlled-delivery / release formulations. Techniques for formulating various other sustained- or controlled-delivery means, such as liposome carriers, bioerodible microparticles or porous beads, and depot injections, are also known to those skilled in the art. See, for example, International Application PCT / US93 / 00829, which describes controlled-release porous polymer microparticles for delivery of pharmaceutical compositions. Sustained-release preparations may comprise semipermeable polymer matrices in the form of shaped articles, e.g., films, or microcapsules. Sustained-release matrices can include polyesters, hydrogels, polylactides (disclosed in U.S. Pat. No. 3,773,919 and EP 058481), copolymers of L-glutamic acid and gamma-ethyl-L-glutamate (Sidman et al., 1983, Biopolymers 2:547-556), poly(2-hydroxyethyl-methacrylate) (Langer et al., 1981, J. Biomed. Mater. Res. 15:167-277 and Langer, 1982, Chem. Tech. 12:98-105), ethylene vinyl acetate (Langer et al., 1981, supra), or poly-D(-)-3-hydroxybutyrate (EP 133,988). Sustained-release compositions can also include liposomes, which can be prepared by any of several methods known in the art. See, e.g., Eppstein et al., 1985, Proc. Natl. Acad. Sci. USA 82:3688-3692; EP-A-036,676; EP-A-088,046, and EP-A-143,949.

[0230] The antibody constructs may also be encapsulated in microcapsules (e.g., hydroxymethylcellulose or gelatin microcapsules and poly(methyl methacrylate) microcapsules), colloidal drug delivery systems (e.g., liposomes, albumin microspheres, microemulsions, nanoparticles, and nanocapsules), or macroemulsions prepared, for example, by coacervation techniques or by interfacial polymerization. Such techniques are disclosed in Remington's Pharmaceutical Sciences, 16th edition, Oslo, A. Ed. (1980).

[0231] Pharmaceutical compositions used for in vivo administration are typically provided as sterile preparations. Sterilization can be achieved by filtration through sterile filtration membranes. If the composition is lyophilized, sterilization using this method can be performed before or after lyophilization and reconstitution. Compositions for parenteral administration can be stored in lyophilized form or in a solution. Parenteral compositions are generally placed into a container with a sterile access port, for example, an intravenous solution bag or vial with a stopper that can be pierced by a hypodermic injection needle.

[0232] Another embodiment includes the self-buffering antibody constructs of the formulations of the invention that may be used as pharmaceutical compositions, as described in International Patent Application WO 06138181 A2 (International Application PCT / US2006 / 022599). Various descriptions are available for protein stabilization and formulation materials and methods useful in this regard, see, for example, Arakawa et al., "Solvent interactions in pharmaceutical formulations," Pharm Res. 8(3):285-91 (1991); Kendrick et al., "Physical stabilization of proteins in aqueous solution," in: RATIONAL DESIGN OF STABLE PROTEIN FORMULATIONS: THEORY AND PRACTICE, Carpenter and Manning, eds. Pharmaceutical Biotechnology. 13:61-84 (2002); and Randolph et al., "Surfactant-protein interactions," Pharm Biotechnol. 13:159-75 (2002), particularly the sections concerning excipients and processes for self-buffering protein formulations according to the present invention, particularly those relating to protein pharmaceuticals and processes for veterinary and / or human medical use.

[0233] Salts may be used in certain embodiments to, for example, adjust the ionic strength and / or tonicity of a formulation and / or improve the solubility and / or physical stability of a protein or other component of a composition. As is well known, ions can stabilize proteins in their native state by binding to charged residues on the protein's surface and by shielding charged and polar groups in the protein, reducing the strength of their electrostatic, attractive, and repulsive interactions. Ions can also stabilize proteins in their denatured state, particularly by binding to the protein's denatured peptide bond (--CONH). Furthermore, ionic interactions with charged and polar groups in proteins can prevent or reduce protein aggregation and insolubilization by reducing intermolecular electrostatic interactions. Ionic species have significantly different effects on proteins. Several rankings for categorizing ions and their effects on proteins have been developed and can be used in formulating pharmaceutical compositions. One example is the Hofmeister series, which ranks ionic solutes and polar nonionic solutes by their effect on the conformational stability of proteins in solution. Stabilizing solutes are called "kosmotropics." Destabilizing solutes are called "chaotropics." Kosmotropes are commonly used at such high concentrations (e.g., >1 molar ammonium sulfate) that they cause proteins to precipitate ("salt out") from solution. Chaotropes are commonly used to denature and / or solubilize ("salt in") proteins. The relative effectiveness of an ion for "salting in" and "salting out" defines the ion's position in the Hofmeister series.

[0234] Free amino acids can be used as bulking agents, stabilizers, and antioxidants in antibody construct formulations according to various embodiments, as well as for other standard applications. Lysine, proline, serine, and alanine can be used to stabilize proteins in the formulation. Glycine is useful for lyophilization to ensure proper cake structure and properties. Arginine can be useful in inhibiting protein aggregation in both liquid and lyophilized formulations. Methionine is useful as an antioxidant.

[0235] Polyols include sugars, such as mannitol, sucrose, and sorbitol, and polyhydric alcohols, such as glycerol and propylene glycol, and, for purposes of discussion herein, polyethylene glycol (PEG) and related substances. Polyols are kosmotropic. Polyols are useful stabilizers for protecting proteins from physical and chemical degradation processes in both liquid and lyophilized formulations. Polyols are also useful for adjusting the tonicity of the formulation. Among polyols useful in select embodiments of the present invention, mannitol is commonly used to ensure the structural stability of the cake in lyophilized formulations. Mannitol ensures the structural stability of the cake. Mannitol is commonly used in conjunction with a lyoprotectant, such as sucrose. Sorbitol and sucrose are preferred agents for adjusting isotonicity and as stabilizers for protection from freeze-thaw stress during transportation or during bulk preparation in the manufacturing process. Reducing sugars (containing free aldehyde or ketone groups), such as glucose and lactose, can glycate surface lysine and arginine residues. Therefore, reducing sugars are generally not among the preferred polyols. In addition, sugars that form such reactive species, such as sucrose, are also not among the preferred polyols because they are hydrolyzed under acidic conditions into fructose and glucose, resulting in glycation. PEG is useful for stabilizing proteins and as a cryoprotectant, and can be used in this regard.

[0236] Embodiments of the antibody construct formulation further include a surfactant. Protein molecules can be susceptible to adsorption onto surfaces, as well as denaturation and resulting aggregation at air-liquid, solid-liquid, and liquid-liquid interfaces. This effect is approximately inversely proportional to protein concentration. These adverse interactions are typically exacerbated by physical agitation, such as that encountered during product transportation and handling. Surfactants are routinely used to prevent, minimize, or reduce surface adsorption. In this regard, surfactants useful in the present invention include polysorbate 20, polysorbate 80, other fatty acid esters of sorbitan polyethoxylate, and poloxamer 188. Surfactants are also commonly used to control protein conformational stability. In this regard, the use of surfactants is protein-specific, as any given surfactant will typically stabilize some proteins and destabilize others.

[0237] Polysorbates are susceptible to oxidative degradation and often contain sufficient peroxide content, when provided, to cause oxidation of protein residue side chains, particularly methionine. Consequently, polysorbates should be used with caution and, when used, at the lowest effective concentration. In this regard, polysorbates exemplify the principle that excipients should be used at the lowest effective concentration.

[0238] Embodiments of the antibody construct formulation further include one or more antioxidants. Harmful oxidation of proteins in pharmaceutical formulations can be prevented to some extent by maintaining appropriate levels of ambient oxygen and temperature and by avoiding exposure to light. Antioxidant excipients can also be used to prevent oxidative degradation of proteins. Antioxidants useful in this regard include reducing agents, oxygen / free radical scavengers, and chelating agents. Antioxidants used in therapeutic protein formulations according to the present invention are preferably water-soluble and maintain activity throughout the product's shelf life. In this regard, EDTA is a preferred antioxidant according to the present invention. Antioxidants can damage proteins. For example, reducing agents, such as glutathione, can particularly disrupt intramolecular disulfide bonds. Therefore, the antioxidant is selected to, among other things, eliminate or substantially reduce the possibility of damaging the proteins in the formulation.

[0239] The formulation may also contain metal ions that are protein cofactors and essential for forming protein coordination complexes, such as zinc, which is essential for forming certain insulin suspensions. Metal ions may also inhibit some processes that degrade proteins. However, metal ions also catalyze the physical and chemical processes that degrade proteins. Magnesium ions (10-120 mM) can be used to inhibit the isomerization of aspartic acid to isoaspartic acid. Ca +2 ions (up to 100 mM) can increase the stability of human deoxyribonuclease. +2 , Mn +2 , and Zn +2 can destabilize rhDNase. +2 and Sr +2 can stabilize factor VIII, which is +2 , Mn +2 and Zn +2 , Cu +2 and Fe +2 The aggregation can be destabilized by Al +3 It can be increased by ions.

[0240] Embodiments of the formulation may further include one or more preservatives. Preservatives are necessary when developing multi-dose parenteral formulations involving multiple extractions from the same container. Their primary function is to inhibit microbial growth and ensure product sterility throughout the drug product's shelf life or usage period. Commonly used preservatives include benzyl alcohol, phenol, and m-cresol. While preservatives have a long history of use with small molecule parenteral drugs, developing protein formulations containing preservatives can be challenging. Preservatives almost always have a destabilizing effect on proteins (aggregation), which is a major factor limiting their use in multi-dose protein formulations. To date, most protein drugs have been formulated for single-use only. However, the possibility of multi-dose formulations offers added benefits of patient convenience and increased marketability. Human growth hormone (hGH) is a good example, where the development of preserved formulations has led to the commercialization of more convenient multi-use injection pens. At least four such pen devices containing preserved formulations of hGH are currently available on the market. Norditropin (liquid, Novo Nordisk), Nutropin AQ (liquid, Genentech), and Genotropin (lyophilized-dual chamber cartridge, Pharmacia & Upjohn) contain phenol, while Somatrope (Eli Lilly) is formulated with m-cresol. Several aspects need to be considered during the formulation and development of a preservative. The effective preservative concentration in the drug product must be optimized. This requires testing a given preservative in a range of dosage forms over a concentration range that confers antimicrobial efficacy without compromising protein stability.

[0241] As might be expected, developing a liquid formulation containing a preservative is more challenging than a lyophilized formulation. Freeze-dried products can be lyophilized without the preservative and reconstituted with a preservative-containing diluent at the time of use. This reduces the time the preservative is in contact with the protein, significantly minimizing the associated stability risks. For liquid formulations, the preservative's effectiveness and stability should be maintained throughout the product's shelf life (approximately 18-24 months). It is important to note that the effectiveness of the preservative must be demonstrated in the final formulation containing the active drug and all excipient components.

[0242] The antibody constructs disclosed herein can also be formulated as immunoliposomes. A "liposome" is a small vesicle composed of various types of lipids, phospholipids, and / or surfactants that is useful for drug delivery to mammals. The components of a liposome are generally arranged in a bilayer formation, similar to the lipid arrangement of biological membranes. Liposomes containing antibody constructs are prepared by methods known in the art, e.g., as described in Epstein et al., Proc. Natl. Acad. Sci. USA, 82:3688 (1985); Hwang et al., Proc. Natl. Acad. Sci. USA, 77:4030 (1980); U.S. Pat. Nos. 4,485,045 and 4,544,545; and WO 97 / 38731. Liposomes with enhanced circulation time are disclosed in U.S. Pat. No. 5,013,556. Particularly useful liposomes can be generated by the reverse-phase evaporation method with a lipid composition comprising phosphatidylcholine, cholesterol, and PEG-derivatized phosphatidylethanolamine (PEG-PE). Liposomes are extruded through filters of defined pore size to yield liposomes with the desired diameter. Fab' fragments of the antibody constructs of the present invention can be conjugated to liposomes via a disulfide-interchange reaction as described by Martin et al. J. Biol. Chem. 257:286-288 (1982). Optionally, a chemotherapeutic agent is contained within the liposome. See Gabizon et al. J. National Cancer Inst. 81(19)1484 (1989).

[0243] Once the pharmaceutical composition has been formulated, it may be stored in sterile vials as a solution, suspension, gel, emulsion, solid, crystal, or as a dehydrated or lyophilized powder. Such formulations may be stored in a ready-to-use form or in a form (e.g., lyophilized) that is reconstituted prior to administration.

[0244] The biological activity of the pharmaceutical compositions defined herein can be determined, for example, by cytotoxicity assays as described in the Examples below, in WO 99 / 54440, or in Schlereth et al. (Cancer Immunol. Immunother. 20 (2005), 1-12). As used herein, "efficacy" or "in vivo efficacy" refers to the response to therapy with the pharmaceutical compositions of the present invention, for example, using standardized NCI response criteria. The success or in vivo efficacy of therapy using the pharmaceutical compositions of the present invention refers to the effectiveness of the composition for its intended purpose, i.e., its ability to cause its desired effect, i.e., the depletion of pathological cells, e.g., tumor cells. In vivo efficacy can be monitored by established standard methods for each disease entity, including, but not limited to, white blood cell counts, differential counts, fluorescence-activated cell sorting, and bone marrow aspiration. Additionally, various disease-specific clinical chemistry parameters and other established standard methods can be used.Additionally, computed tomography, x-ray, and nuclear magnetic resonance imaging (e.g., response assessment based on the National Cancer Institute criteria [Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, Lister TA, Vose J, Grillo-Lopez A, Hagenbeek A, Cabanillas F, Klippensten D, Hiddemann W, Castellino R, Harris NL, Armitage JO, Carter W, Hoppe R, Canellos GP. Report of an international workshop to standardize response criteria for non-Hodgkins lymphomas. NCI Sponsored International Working Group. J Clin Oncol. 1999]. Apr;17(4):1244]), positron emission tomography scanning, white blood cell count, differential, fluorescence activated cell sorting, bone marrow aspiration, lymph node biopsy / histology, and various lymphoma-specific clinical chemistry parameters (e.g., lactate dehydrogenase), as well as other established standard methods may be used.

[0245] Another major challenge in the development of drugs, such as the pharmaceutical compositions of the present invention, is the predictable modulation of pharmacokinetic properties. To this end, the pharmacokinetic profile of a candidate drug can be established, i.e., a profile of pharmacokinetic parameters that affect the ability of a particular drug to treat a given condition. Pharmacokinetic parameters of a drug that affect the ability of a drug to treat a particular disease entity include, but are not limited to, half-life, volume of distribution, hepatic first-pass metabolism, and degree of serum binding. The efficacy of a given drug can be influenced by each of the above parameters. A presumed feature of the antibody constructs of the present invention provided by a specific FC format is that the antibody constructs include, for example, differences in pharmacokinetic behavior. The half-life extended targeting antibody constructs of the present invention preferably exhibit a surprisingly increased in vivo residence time compared to "canonical" non-HLE versions of the antibody construct. "Half-life" refers to the time it takes for 50% of an administered drug to be eliminated by biological processes, such as metabolism, excretion, etc. "Hepatic first-pass metabolism" refers to the tendency of a drug to be metabolized immediately upon first contact with the liver, i.e., during its first passage through the liver. "Volume of distribution" refers to the degree of retention of a drug throughout various compartments of the body, such as intracellular and extracellular spaces, tissues and organs, and the distribution of the drug within those compartments. "Extent of serum binding" refers to the tendency of a drug to interact with and bind to serum proteins, such as albumin, resulting in a reduction or elimination of the drug's biological activity.

[0246] Pharmacokinetic parameters also include bioavailability, lag time (Tlag), Tmax, absorption rate, more onset, and / or Cmax for a given amount of drug administered. "Bioavailability" refers to the amount of drug in the blood compartment. "Lag time" refers to the delay between administration of a drug and when the drug can be detected and measured in blood or plasma. "Tmax" refers to the time after administration to reach the maximum blood concentration of the drug, and "Cmax" refers to the blood concentration maximally attainable for a given drug. The time to reach the blood or tissue concentration of the drug required for a biological effect is affected by all of these parameters. Pharmacokinetic parameters of antibody constructs exhibiting interspecies specificity that can be determined in preclinical animal studies in non-chimpanzee primates, as outlined above, are defined, for example, in the publication by Schlereth et al. (Cancer Immunol. Immunother. 20 (2005), 1-12).

[0247] In a preferred embodiment, the pharmaceutical composition is stable for at least 4 weeks at about -20°C. As is evident from the accompanying examples, the quality of the antibody constructs of the present invention versus the corresponding state of the art antibody constructs can be tested using a variety of systems. The tests are understood to be in accordance with the "ICH Harmonized Tripartite Guideline: Stability Testing of Biotechnological / Biological Products Q5C and Specifications: Test Procedures and Acceptance Criteria for Biotechnological / Biological Products Q6B," and are selected to provide a stability-indicating profile that allows reliable detection of changes in product identity, purity, and potency. It is well accepted that the term "purity" is a relative term. Due to glycosylation, deamidation, or other heterogeneous effects, the absolute purity of a biotechnological / biological product typically must be assessed by multiple methods, and the derived purity value is method-dependent. For stability testing purposes, purity tests should be tailored to the determination of degradation products.

[0248] The quality of pharmaceutical compositions comprising the antibody constructs of the present invention can be assessed, for example, by analyzing the content of soluble aggregates (HMWS by size exclusion) in solution. Stability for at least 4 weeks at about -20°C is characterized by a content of less than 1.5% HMWS, preferably less than 1% HMWS.

[0249] The formulations described herein are useful as pharmaceutical compositions for treating, ameliorating, and / or preventing the pathological medical conditions described herein in patients in need thereof. The term "treatment" refers to both therapeutic treatment and prophylactic or preventative measures. Treatment includes the administration or administration of a formulation to the body, isolated tissue, or cells of a patient with a disease / disorder, a symptom of a disease / disorder, or a predisposition to a disease / disorder, with the intent to cure, remedy, alleviate, relieve, alter, correct, improve, reverse, or affect the disease, symptom of a disease, or predisposition to a disease.

[0250] The term "amelioration," as used herein, refers to any improvement in the disease state of a patient having a disease as defined herein below, by administration of an antibody construct to a subject in need thereof. Such improvement may be seen as a slowing or halting of the progression of the patient's disease. The term "prevention," as used herein, refers to the avoidance of the onset or recurrence of a tumor, or cancer, or metastatic cancer, as defined herein below, in a patient having such a disease, by administration of an antibody construct to a subject in need thereof.

[0251] The term "disease" refers to any condition that would benefit from treatment with the antibody constructs or pharmaceutical compositions described herein, including chronic and acute disorders or diseases, including those conditions that predispose a mammal to the disease in question.

[0252] A "neoplasm" is an abnormal growth of tissue, usually, but not necessarily, forming a mass. When it forms a mass, it is commonly referred to as a "tumor." A neoplasm or tumor can be benign, potentially malignant (pre-cancerous), or malignant. A malignant neoplasm is commonly called a cancer. Malignant neoplasms usually invade and destroy surrounding tissue and can form metastases, i.e., spread to other parts, tissues, or organs of the body. Thus, the term "metastatic cancer" includes metastasis to tissues or organs other than that of the primary tumor. Lymphomas and leukemias are lymphatic neoplasms. For purposes of the present invention, lymphomas and leukemias are also encompassed by the terms "tumor" or "cancer."

[0253] The term "subject in need" or "in need of treatment" includes those already with the disorder as well as those in which the disorder is to be prevented. A subject in need or "patient" includes human and other mammalian subjects receiving either prophylactic or therapeutic treatment.

[0254] The antibody constructs of the present invention will generally be designed for a particular route and method of administration, a particular dosage and frequency, and a particular treatment of a particular disease, particularly in the areas of bioavailability and duration. The materials of the composition are preferably formulated in concentrations that are acceptable to the site of administration.

[0255] Thus, formulations and compositions according to the present invention may be designed for delivery by any suitable route of administration. ·Topical route (e.g., on the skin, inhalation, nose, eyes, pinna / ear, vagina, mucous membranes); Enteral routes (e.g., oral, gastrointestinal, sublingual, sublabial, buccal, rectal); and Parenteral routes (e.g., intravenous, intraarterial, intraosseous, intramuscular, intracerebral, intraventricular, epidural, intrathecal, subcutaneous, intraperitoneal, extraamniotic, intraarticular, intracardiac, intradermal, intralesional, intrauterine, intravesical, intravitreal, transdermal, intranasal, transmucosal, intrasynovial, intraluminal) These include, but are not limited to:

[0256] The pharmaceutical compositions and antibody constructs are particularly useful for parenteral administration, e.g., subcutaneous or intravenous delivery, e.g., by injection, e.g., bolus injection, or by infusion, e.g., continuous infusion. The pharmaceutical composition can be administered using a medical device. Examples of medical devices for administering pharmaceutical compositions are described in U.S. Pat. Nos. 4,475,196; 4,439,196; 4,447,224; 4,447,233; 4,486,194; 4,487,603; 4,596,556; 4,790,824; 4,941,880; 5,064,413; 5,312,335; 5,312,335; 5,383,851; and 5,399,163.

[0257] If the pharmaceutical composition is lyophilized, the lyophilized material is first reconstituted in an appropriate liquid prior to administration, for example, bacteriostatic water for injection (BWFI), saline, phosphate buffered saline (PBS), or the same formulation in which the protein was present prior to lyophilization.

[0258] The composition can be administered to a subject at an appropriate dose, which can be determined, for example, by a dose-escalation study in which the antibody constructs of the present invention exhibiting cross-species specificity described herein are administered to non-chimpanzee primates, such as macaques, in increasing doses. As mentioned above, the antibody constructs of the present invention exhibiting cross-species specificity described herein have the advantage that they can be used in the same form in preclinical studies in non-chimpanzee primates and as drugs in humans. The dosing regimen will be determined by the attending physician based on clinical factors. As is well known in the medical arts, the dosage for any one patient depends on many factors, including the patient's size, body surface area, age, the specific compound being administered, sex, time and route of administration, general health, and other drugs being administered simultaneously.

[0259] The term "effective dose" or "effective administration amount" is defined as an amount sufficient to achieve or at least partially achieve a desired effect. The term "therapeutically effective dose" is defined as an amount sufficient to cure or at least partially arrest a disease and its complications in a patient already suffering from the disease. The amount or dosage effective for this use will depend on the condition (indication) being treated, the antibody construct being delivered, the nature and purpose of the treatment, the severity of the disease, previous treatments, the patient's medical history and response to the treatment, the route of administration, the patient's size (weight, body surface area, or organ size) and / or condition (age and general health), and the general status of the patient's own immune system. The appropriate dosage can be administered to the patient in a single administration or multiple administrations and can be adjusted according to the judgment of the attending physician to obtain the optimal therapeutic effect. Typical dosages can range from about 0.1 μg / kg up to about 30 mg / kg or more, depending on the factors mentioned above. In certain embodiments, dosages may range from 1.0 μg / kg up to about 20 mg / kg, and in some cases from 10 μg / kg up to about 10 mg / kg, or from 100 μg / kg up to about 5 mg / kg. A therapeutically effective amount of an antibody construct of the invention preferably reduces the severity of disease symptoms, increases the frequency or duration of symptom-free periods, or prevents functional impairment or disability resulting from disease affliction. For treating diseases correlated with MUC17 expression as described hereinabove, a therapeutically effective amount of an antibody construct of the invention, herein: an anti-MUC17 / anti-CD3 antibody construct, preferably inhibits cell growth or tumor growth by at least about 20%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, or at least about 90% compared to untreated patients. The ability of a compound to inhibit tumor growth can be assessed in animal models predictive of efficacy.

[0260] The pharmaceutical composition can be administered as a single treatment or, if necessary, in combination with additional treatments, such as anti-cancer therapies, including other proteinaceous and non-proteinaceous drugs, which may be administered simultaneously with the composition comprising the antibody construct defined herein, or may be administered separately at chronologically defined intervals and dosages before or after administration of said antibody construct.

[0261] As used herein, the term "effective and non-toxic dose" refers to a tolerated dose of an antibody construct that is high enough to cause depletion of pathological cells, tumor elimination, tumor regression, or disease stabilization without causing or essentially causing significant toxic effects. Such an effective and non-toxic dose can be determined, for example, by dose-escalation studies described in the art, and should be below the dose that induces serious adverse side events (dose-limiting toxicity, DLT). As used herein, the term "toxicity" refers to the toxic effects of a drug that manifest as adverse events or serious adverse events. Such side events may refer to a lack of systemic drug tolerance and / or a lack of local tolerance after administration. Toxicity may also include teratogenic or carcinogenic effects caused by the drug.

[0262] As used herein, the terms "safety," "in vivo safety," or "tolerability" are defined as the administration of a drug that does not induce serious adverse events immediately after administration (local tolerance) and during longer periods of drug use. "Safety," "in vivo safety," or "tolerability" can be assessed, for example, during treatment and periodically during follow-up. Measurements include clinical evaluations, such as organ findings and screening for laboratory abnormalities. Clinical evaluations can be performed, and deviations from normal findings can be recorded / coded according to NCI-CTC and / or MedDRA standards. Organ findings can include criteria such as allergy / immunology, blood / bone marrow, cardiac arrhythmias, and coagulation, as set forth in the Common Terminology Criteria for Adverse Events v3.0 (CTCAE). Laboratory parameters that can be tested include, for example, hematology, clinical chemistry, coagulation profiles, and urinalysis and investigations of other body fluids, such as serum, plasma, lymph, or spinal fluid. Thus, safety can be assessed by physical examination, imaging techniques (i.e. ultrasound, x-ray, CT scan, magnetic resonance imaging (MRI), other measurements by technical devices (i.e. electrocardiogram), vital signs, for example, by measuring laboratory parameters and recording adverse events. For example, in the uses and methods according to the present invention, adverse events in non-chimpanzee primates can be examined by histopathological and / or histochemical methods.

[0263] The above terms are also referred to, for example, in Preclinical safety evaluation of biotechnology-derived pharmaceuticals S6 of July 16, 1997; ICH Harmonized Tripartite Guideline; ICH Steering Committee meeting.

[0264] The invention further provides diagnostic kits comprising an antibody of the invention or an antibody produced according to the process of the invention.

[0265] In the context of the present invention, the term "kit" refers to two or more components (one of which corresponds to an antibody construct of the present invention) packaged together in a container, vessel, or other arrangement. A kit can therefore be described as a set of products and / or implements sufficient to accomplish a particular purpose that can be sold individually.

[0266] The kit may comprise one or more containers (e.g., vials, ampoules, containers, syringes, bottles, bags) of any suitable shape, size, and material (preferably waterproof, e.g., plastic or glass) containing the antibody construct or pharmaceutical composition of the invention in a dosage amount suitable for administration (see above). The kit may further contain instructions for use (e.g., in the form of a leaflet or instruction manual), a means for administering the antibody construct of the invention, e.g., a syringe, pump, or infuser, a means for reconstituting the antibody construct of the invention, and / or a means for diluting the antibody construct of the invention.

[0267] The present invention also provides kits for single-dose administration units. The kits of the present invention may also contain a first container containing a dried / lyophilized antibody construct and a second container containing an aqueous formulation. In certain embodiments of the present invention, kits are provided that contain single-chamber and multi-chamber pre-filled syringes (e.g., liquid syringes and lyosyringes).

[0268] As used herein, the singular forms "a," "an," and "the" include plural references unless the context clearly dictates otherwise. Thus, for example, reference to a "reagent" includes one or more of such various reagents, and reference to a "method" includes reference to equivalent steps and methods known to those of skill in the art that may be modified or substituted for the method described herein.

[0269] Unless otherwise indicated, the term "at least" preceding a series of elements is to be understood to refer to every element in the series. Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. Such equivalents are intended to be encompassed by this invention.

[0270] The term "and / or", wherever used herein, includes the meanings "and", "or" and "any other combination of the elements connected by said term".

[0271] As used herein, the term "about" or "approximately" means within ±20%, preferably within ±15%, more preferably within ±10%, and most preferably within ±5% of a given value or range. It also includes specific values, for example, "about 50" includes the value "50."

[0272] Throughout this specification and the claims, unless the context otherwise requires, the word "comprise," and variations such as "comprises" and "comprising," will be understood to imply the inclusion of the stated integer or step, or group of integers or steps, but not the exclusion of any other integers or steps, or group of integers or steps. As used herein, the term "comprising" may be interchanged with the terms "containing" or "including," or, as sometimes used herein, the term "having."

[0273] As used herein, "consisting of" excludes any element, step, or ingredient not specified in the claim element. As used herein, "consisting essentially of" does not exclude materials or steps that do not materially affect the basic and novel characteristics of the claim.

[0274] In each instance herein, any of the terms "comprising," "consisting essentially of," and "consisting of" may be replaced with either of the other two terms.

[0275] The above description and the following examples provide exemplary arrangements, but the present invention is not limited to the particular methodology, techniques, protocols, materials, reagents, substances, etc. described herein, as these may vary. The terminology used herein is for the purpose of describing particular embodiments only and is not intended to limit the scope of the invention, which is defined solely by the claims. Aspects of the invention are provided in the independent claims. Some optional features of the invention are provided in the dependent claims.

[0276] All publications and patents (including all patents, patent applications, scientific publications, manufacturer's specifications, manuals, etc.) cited throughout the text of this specification, whether prior or infra, are hereby incorporated by reference in their entirety. Nothing herein should be construed as an admission that the present invention is not entitled to antedate any disclosure by virtue of prior invention. To the extent that material incorporated by reference contradicts or is inconsistent with the present specification, the present specification will take precedence over any such material.

[0277] A better understanding of the present invention and its advantages will be obtained from the following examples, which are provided for illustrative purposes only and are not intended, and should not be construed, to limit the scope of the invention in any way.

[0278] [Table 4]

[0279] [Table 5]

[0280] [Table 6]

[0281] [Table 7]

[0282] [Table 8]

[0283] [Table 9]

[0284] [Table 10]

[0285] [Table 11]

[0286] [Table 12]

[0287]

Table 13

[0288]

Table 14

[0289]

Table 15

[0290] Table 16

[0291] Table 17

[0292] Table 18

[0293] Table 19

[0294] Table 20

[0295] Table 21

[0296] Table 22

[0297] Table 23

[0298] Table 24

[0299] Table 25

[0300] Table 26

[0301] Table 27

[0302] Table 28

[0303] Table 29

[0304]

Table 30

[0305] Table 31

[0306] Table 32

[0307] Table 33

[0308] Table 34

[0309] Table 35

[0310] Table 36

[0311] Table 37

[0312] Table 38

[0313] Table 39

[0314] Table 40

[0315] Table 41

[0316] Table 42

[0317] Table 43

[0318] Table 44

[0319] Table 45

[0320] Table 46

[0321] Table 47

[0322] Table 48

[0323] Table 49

[0324] Table 50

[0325] Table 51

[0326] Table 52

[0327] Table 53

[0328] Table 54

[0329] [Table 55]

[0330] [Table 56] [Example]

[0331] Generation of anti-human MUC17 IHC reagents—immunization and hybridoma generation We generated hybridomas that selectively identify anti-human MUC17 by immunohistochemistry. The antibodies thus generated recognize the membrane ...

Claims

1. An antibody that binds to human MUC17 as shown in SEQ ID NO: 1, which binds to cell surface-associated MUC17 protein and comprises heavy chain CDR1, CDR2 and CDR3 as shown in SEQ ID NOs: 2, 3 and 4, and light chain CDR1, CDR2 and CDR3 as shown in SEQ ID NOs: 6, 7 and 8.

2. The antibody of claim 1 , wherein the antibody comprises a VH region and / or a VL region contained in SEQ ID NO: 5 and / or 9.

3. The antibody of claim 1 or 2, wherein the antibody is a monoclonal antibody.

4. 4. The antibody of any one of claims 1 to 3, wherein the antibody specifically binds to human and cynomolgus monkey MUC17 when used in vitro in immunohistochemistry assays, to MUC17-expressing cells in fluorescence-activated cell sorting assays, and to fixed and permeabilized MUC17-expressing cells.

5. The antibody of claim 4, wherein the antibody does not bind to a secreted form of huMUC17.

6. The antibody according to any one of claims 1 to 5, which is an IgG antibody, an IgD antibody, an IgE antibody, an IgM antibody, or an IgA antibody.

7. The antibody of claim 6, which is an IgG antibody selected from an IgG1 antibody, an IgG2 antibody, an IgG3 antibody, or an IgG4 antibody.

8. A polynucleotide encoding the antibody of any one of claims 1 to 7.

9. A vector comprising the polynucleotide of claim 8.

10. A host cell transformed or transfected with a polynucleotide according to claim 8 or a vector according to claim 9.

11. 11. A process for producing an antibody according to any one of claims 1 to 7, comprising culturing a host cell according to claim 10 under conditions permissive for expression of said antibody, and recovering the produced antibody from the culture.

12. A composition comprising the antibody of any one of claims 1 to 7.

13. A detection tool comprising an antibody according to any one of claims 1 to 7 or a composition according to claim 12.

14. A composition for diagnosing a MUC17-positive neoplasm, comprising an antibody according to any one of claims 1 to 7.

15. A composition for detecting the neoplastic growth of a MUC17-positive neoplasm, comprising an antibody according to any one of claims 1 to 7.

16. 16. The composition of claim 15, wherein said detecting comprises determining the amount of MUC17 expression in a sample from a patient suspected of having cancer.

17. 17. The composition of claim 16, wherein the detecting further comprises determining the amount of MUC17 expression in a negative control sample.

18. 18. The composition of claim 17, wherein the detecting further comprises determining the amount of MUC17 expression in a positive control sample.

19. The composition of any one of claims 16 to 18, wherein the detecting further comprises comparing the expression levels of MUC17 between the samples.

20. The composition of claim 19, wherein the expression levels in the negative control and / or positive control are derived from stored data in at least one negative control sample and / or at least one positive control sample obtained in a method for detecting neoplastic growth comprising determining the amount of expression of MUC17.

21. The composition of claim 20, wherein the expression levels in the negative control sample and / or the positive control sample are derived from stored data comprising average expression levels of multiple negative control samples and / or multiple positive control samples obtained in a method for detecting neoplastic growth comprising determining the amount of expression of MUC17.

22. The composition of any one of claims 16 to 21, wherein the sample is a solid tissue sample or a liquid tissue sample.

23. 1. A method for detecting and / or quantifying MUC17 expression in a sample, comprising: (a) using an antibody according to claims 1 to 7 or a detection tool according to claim 13 to determine the expression level of MUC17 in a sample; (b) determining the expression level of MUC17 in step (a); (i) a predefined value for MUC17 expression level; (ii) the expression level of MUC17 determined in a control sample; or (iii) the expression level of MUC17 determined in a sample obtained from the same source or subject at an earlier time point. and a process of comparing A method comprising:

24. 1. A method for providing data for diagnosing a MUC17-positive neoplasm, comprising: (a) using an antibody as defined in any one of claims 1 to 7 or a composition as defined in any one of claims 12 and 14 to 22, or using a detection tool as defined in claim 13, to determine the expression level of MUC17 in a sample; (b) determining the expression level of MUC17 in step (a); (i) a predefined cutoff value for MUC17 expression that indicates the absence of a MUC17-positive neoplasm; or (ii) the expression level of MUC17 determined in a negative control sample representing the absence of MUC17-positive neoplasms; and a process of comparing Including, wherein a higher expression level of MUC17 determined in step (a) compared to the predefined cutoff value in (i) or the expression level of MUC17 determined in the negative control sample in (ii) indicates the presence of a MUC17-positive neoplasm.

25. 1. A method of monitoring the progression of a MUC17-positive neoplasm or monitoring the response of a MUC17-positive neoplasm to treatment, comprising: (a) using an antibody as defined in any one of claims 1 to 7 or a detection tool as defined in claim 13 to determine the expression level of MUC17 at a first time point in a sample obtained from a subject diagnosed with a MUC17-positive neoplasm; (b) using an antibody as defined in any one of claims 1 to 7 or a detection tool as defined in claim 13 to determine the expression level of MUC17 in a sample obtained from said subject at a second time point or after treatment; (c) comparing the amount of MUC17 expression determined in step (a) with the amount of MUC17 expression determined in step (b); Including, A method wherein a higher expression level of MUC17 determined in step (a) compared to the expression level of MUC17 determined in step (b) indicates that the MUC17-positive neoplasm is progressing, and / or a lower expression level of MUC17 determined in step (a) compared to the expression level of MUC17 determined in step (b) indicates that the MUC17-positive neoplasm is in remission or is responding to the treatment.

26. The composition according to any one of claims 16 to 22, wherein the sample is a biological sample.

27. 27. The composition of claim 26, wherein the sample is a human biological sample.

28. 28. The composition of claim 27, wherein the sample is a tissue sample or a sample containing cultured cells.

29. The composition of any one of claims 16 to 22, wherein the sample is obtained from a human subject.

30. 30. The composition of claim 29, wherein the sample is obtained from a human subject suspected of having or having a MUC17-positive neoplasm, or a subject undergoing treatment for a MUC17-positive neoplasm.

31. 23. The composition of any one of claims 14 to 22, wherein the MUC17-positive neoplasm is selected from the group comprising esophageal cancer, gastric cancer, gastrointestinal cancer, gastroesophageal cancer including gastroesophageal junction cancer, and pancreatic cancer.

32. The method according to any one of claims 23 to 25, wherein the sample is a biological sample.

33. 33. The method of claim 32, wherein the sample is a human biological sample.

34. 34. The method of claim 32 or 33, wherein the sample is a tissue sample or a sample containing cultured cells.

35. The method of any one of claims 23 to 25, wherein the sample is obtained from a human subject.

36. 36. The method of claim 35, wherein the sample is obtained from a human subject suspected of having or having a MUC17-positive neoplasm, or a subject undergoing treatment for a MUC17-positive neoplasm.

37. 26. The method of any one of claims 24 or 25, wherein the MUC17-positive neoplasm is selected from the group comprising esophageal cancer, gastric cancer, gastrointestinal cancer, gastroesophageal cancer including gastroesophageal junction cancer, and pancreatic cancer.

38. A diagnostic kit comprising an antibody or composition and / or a detection tool according to any one of claims 1 to 7, 12, 13 or 16 to 22.

Images